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The enzyme steroid 5a-reductase catalyses the reduction of A4"5 double bonds in a
variety of steroid substrates. Preliminary evidence has suggested that 5a-reduction of
glucocorticoids is increased in obesity, consistent with the observation that in the
face of an enhanced Cortisol secretion rate, plasma Cortisol levels are not consistently
elevated in obesity. The implications of enhanced 5a-reduction of glucocorticoids
for glucocorticoid receptor activation are unclear. 5a-Reduced metabolites of other
steroids e.g. testosterone and aldosterone have significant affinity for the parent
hormone receptor, therefore we hypothesised that 5a-reduced glucocorticoids are
glucocorticoid agonists.
In obese versus lean Zucker rats, hepatic 5a-reductase type 1 mRNA expression and
protein levels were increased. They also had increased activity of hepatic 5(3-
reductase activity. By contrast, 3oc-hydroxysteroid dehydrogenase mRNA expression
was unchanged in obesity. Greater inactivation of corticosterone by A-ring
reductases in liver may decrease local corticosterone concentrations in these sites,
and increase the metabolic clearance rate of glucocorticoids, thus increasing drive to
the hypothalamic-pituitary-adrenal axis (HPA).
To investigate whether 5a-reduced metabolites of corticosterone are glucocorticoid
receptor agonists, competition binding studies were carried out. In displacing tritiated
dexamethasone from binding sites in hepatocytes from male lean Zucker rats,
corticosterone and 5a-tetrahydrocorticosterone (5aTHB) had similar affinities which
were greater than 5a-dihydrocorticosterone (5ctDHB) and 5(3-reduced metabolites.
Binding of corticosterone and 5aDHB binding was impaired in obesity whereas
5aTHB binding was unaltered suggesting that 5aTHB may modulate GR activation
in obesity.
Activation of glucocorticoid receptors was assessed following transient transfection
into HeLa cells with an MMTV-luciferase reporter. By comparison with
1
corticosterone, 5aTHB was active and additive. 5(3-Reduced metabolites did not
activate glucocorticoid receptors. In addition, in H4IIE cells which express
endogenous glucocorticoid receptors, 5aTHB induced tyrosine aminotransferase
mRNA expression albeit to a lesser extent than corticosterone. 5aTHB was also
found to possess glucocorticoid activity in vivo as suppression of plasma ACTH was
demonstrated in adrenalectomised lean Zucker rats following i.p. administration of
corticosterone or 5aTHB.
We conclude that hepatic A-ring reduction is enhanced in the obese Zucker rat
producing increased concentrations of 5aTHB which can bind and activate
glucocorticoid receptors. Transcription of glucocorticoid regulated genes in tissues
which express 5a-reductases will thus be influenced by intracellular levels of both
corticosterone and its 5a-reduced metabolites. Manipulation of this enzyme may




List of Figures ix




Chapter One, Introduction 1
1.1 Glucocorticoids 2
1.1.1 Steroid Hormone Structure 2
1.1.2. Glucocorticoid Biosynthesis 2
1.1.3 Glucocorticoid Secretion 5
1.1.4 Glucocorticoid Action 7
1.1.5 The Glucocorticoid Receptor 7
1.1.5.1 Background 7
1.1.5.2 Mechanism of glucocorticoid receptor action 9
1.1.5.2.1 Ligand binding and dissociation from heat shock
proteins 9
1.1.5.2.2 Phosphorylation and nuclear translocation 9
1.1.5.2.3 Dimerisation and DNA binding 10
1.1.5.2.4 Transactivation 10
1.1.5.2.5 Transrepression 11
1.1.5.3 Other Glucocorticoid binding sites 11
1.1.6 Glucocorticoid Effects 13
1.1.6.1 Effects on metabolism 13
1.1.6.2 Effects on the cardiovascular system 14
1.1.6.3 Effects on the immune system 15
1.1.6.4 Effects on the central nervous system 15
1.1.6.5 Effects on growth and development 16
m
1.1.7 Metabolism of Glucocorticoids 17
1.2 A-ring Reductases 19
1.2.1 5a-Reductase 19
1.2.1.1 History of 5a-reductase 19
1.2.1.2 Identification of two distinct isozymes 20
1.2.1.3 The role of 5a-reductase types 1 and 2 22
1.2.1.4 Regulation of 5a-reductase 24
1.2.2 5(3-Reductase and 3a-Hydroxysteroid Dehydrogenase 26
1.2.3 ll(3-hydroxysteroid dehydrogenase type 1 28
1.3 The role of glucocorticoids in obesity 30
1.4 Aims of this thesis 33
Chapter Two, Materials and Methods 34
2.1 Materials 35
2.2 Buffers and Solutions 35
2.3 Animal Maintenance 39
2.3.1 Surgery 39
2.4 Maintenance of cell lines 39
2.5 Enzymology 40
2.5.1 Preparation of tissue homogenates 40
2.5.2 Sub-cellular fractionation of liver 40
2.5.3 Protein Estimation 41
2.5.4 In vitro assay of 5a-reductase activity 41
2.5.5 In vitro assay of 5(3-reductase activity 44
2.5.6 High - Performance Liquid Chromatography 47
2.5.6.1 Preliminary work 47
2.5.6.2 HPLC conditions for in vitro 5(3-reductase assay 54
2.6 Gas chromatography / mass spectrometry 54
2.6.1 Extraction of steroids 54
2.6.1.1 Extraction from cell medium 54
2.6.1.2 Extraction from tissues 55
2.6.2 Gas chromatography / mass spectrometry 55
iv
2.7 RT-PCR 55
2.7.1 Tissue Preparation 56
2.7.1.1 Intact Tissues 56
2.7.2 RNA Extraction 56
2.7.2.1 Homogenisation 56
2.7.2.2 Phase Separation 56
2.7.2.3 RNA Precipitation 57
2.7.2.4 RNA Wash 57
2.7.2.5 RNA Resuspension 57
2.7.2.6 RNA Quantification 57
2.7.3 Reverse Transcriptase Reaction 58
2.7.4 PCR Reactions 58
2.8 Real-Time PCR 59
2.8.1 Tissue Preparation 59
2.8.2 RNA extraction and quantification 59
2.8.3 Real-Time PCR reactions 59
2.9 Northern Analysis of mRNA 60
2.9.1 Extraction of RNA 60
2.9.2 RNA electrophoresis and capillary transfer 60
2.9.3 Hybridisation to 32p-labelled cDNA 61
2.10 Preparation of 32P and 35S labelled cDNA probes 63
2.10.1 DNA ligation 63
2.10.2 Bacterial Transformation 63
2.10.3 Screening of clones 63
2.10.4 Plasmid DNA preparation 64
2.10.5 Restriction enzyme digestion of plasmid and purification 65
of fragment
2.11 35S In situ Hybridisation 66
2.11.1 Slide preparation 66
2.11.2 Tissue section preparation 66
2.11.3 Fixation protocol 67
2.11.4 Probe templates for in situ hybridisation 67
v
2.11.5 Synthesis of 35S-UTP labeled ribo-probes 67
2.11.6 Pre-hybridisation and hybridisation steps 68
2.11.7 RNase treatment and washes 68
2.11.8 Visualisation of hybridisation 69
2.12 Glucocorticoid receptor binding assays 69
2.12.1 Tissue handling 69
2.12.1.1 Cytosol preparation 69
2.12.1.2 Microsome preparation 70
2.12.1.3 Hepatocyte preparation 70
2.12.2 Binding assays 70
2.13 Transient transfection studies 71
2.13.1 Transient transfections 71
2.13.2 Luciferase assays 72
2.13.3 P-galactosidase assays 72
2.13.4 Data analysis 73
2.14 Examination of glucocorticoid effects on angiogenesis 73
2.15 Plasma assays 73
2.15.1 Adrenocorticotropin (ACTH) radioimmunoassay 73
2.15.2 Corticosterone radioimmunoassay 74
2.16 Statistics 74
Chapter Three, Localisation of A-ring Reductases 75
3.1 Introduction 76
3.2 Methods 77
3.2.1 A-ring reductase Expression Studies 77
3.2.1.1 RT-PCR 77
3.2.1.2 In Situ Hybridisation 77
3.2.2 Bioactivity assays 77
3.2.3 5a - and 5P-Reductase activity in liver 77
3.3 Results 78
3.3.1 Detection of A-ring reductase expression by RT-PCR 78
3.3.2 Localisation of A-ring reductase mRNA expression 78
vi
by in-situ hybridisation
3.3.3 5a-Reductase activity 78
3.3.4 5p-Reductase activity 79
3.4 Discussion 89
3.4.1 Bioactivity assays 89
3.4.2 Isozyme expression 91




4.2.1 Assay of glucocorticoid receptor binding activity 96
4.2.2 Glucocorticoid receptor activation in cell lines 96
4.2.3 Metabolic transformation of steroids 97
4.2.4 Ex vivo glucocorticoid activity 97
4.2.5 In vivo glucocorticoid activity 97
4.2.6 Statistics 98
4.3 Results 99
4.3.1 Glucocorticoid receptor binding in isolated hepatocytes 99
4.3.2 Glucocorticoid receptor binding in cytosol 99
4.3.3 Glucocorticoid receptor binding in microsomes 99
4.3.4 Activation of glucocorticoid receptors in transfected HeLa cells 100
4.3.5 Induction of tyrosine aminotransferase mRNA in H4IIE cells 100
4.3.6 Metabolic transformation of steroids 101
4.3.7 Inhibition of angiogenesis ex vivo 101
4.3.8 Suppression of plasma ACTH in vivo 101
4.3.9 Effect of 5aTHB on hepatic TAT and PEPCK 102
4.4 Discussion 116
Chapter Five, A-Ring Reductases in Obesity 124
5.1 Introduction 125
5.2 Methods 128
5.2.1 A-ring reductase expression studies 128
vii
5.2.1.1 RT-PCR 128
5.2.1.2 Real-Time PCR 128
5.2.1.3 Northern blots 128
5.2.1.4 Western blots 128
5.2.1.5 In-situ hybridisation 129
5.2.2 5(3-Reductase Activity Studies 129
5.2.3 Glucocorticoid binding experiments 129
5.2.4 Statistics 129
5.3 Results 130
5.3.1 A-ring reductase expression 130
5.3.2 A-ring reductase activity 130
5.3.3 Glucocorticoid receptor binding 130
5.4 Discussion 141
Chapter 6, Conclusions 145
6.1 5a-reduced glucocorticoids and the glucocorticoid receptor 146
6.2 A-ring reductases in obesity 146
6.3 Physiological relevance of alterations in 5a-reductase 147
6.4 Future studies 147
6.5 Summary 150
References 151
Publications from this thesis 185
viii
List of Figures
Figure 1.1 The basic steroid ring structure 3
Figure 1.2 Biosynthesis of glucocorticoids in the adrenal cortex 4
Figure 1.3 The Hypothalamic-Pituitary-Adrenal axis of the Rat 6
Figure 1.4 Model of Glucocorticoid Receptor activity 12
Figure 1.5 Glucocorticoid metabolism 18
Figure 2.1 Flow diagram for the subcellular fractionation of rat liver 42
Figure 2.2 Protein assay standard curve 46
Figure 2.3 Separation of 5a- and 5(3-dihydro-metabolites of corticosterone 51
by HPLC
Figure 2.4 Separation of 5a- and 5(3-tetrahydro-metabolites of corticosterone 52
by HPLC
Figure 2.5 Separation of 5a- and 5[3-tetrahydro-metabolites of corticosterone 53
with (3-cyclodextrin
Figure 3.1 Expression of 5a-reductase type 1, 5(3-reductase and 3a-HSD 80
mRNA in rat liver
Figure 3.2 Absence of expression of 5a-reductase type 2 in rat liver 81
Figure 3.3 Expression of 5a-reductase type 1 and 3a-HSD mRNA in 82
omental and subcutaneous adipose tissue.
Figure 3.4 Expression of 5a-reductase type 1, 5(3-reductase and 83
3a-hydroxysteroid dehydrogenase in H4IIE cells but not in HeLa cells.
Figure 3.5 Expression of 5a-reductase Type 1 and 5a-reductase Type lb 84
mRNA in rat liver
Figure 3.6 A-ring Reductase mRNA Expression in Rat Liver 85
Figure 3.7 Periportal 5a-reductase type 1 distribution 86
Figure 3.8 Identification of 5a - and 5(3 -reduced tetrahydro-metabolites 87
of corticosterone measured by GCMS.
ix
Figure 3.9 Chromatogram of 5(3-reductase activity in liver cytosol 88
Figure 4.1 Glucocorticoid receptor binding in isolated hepatocytes from 103
male lean Zucker rats
Figure 4.2 Glucocorticoid binding in isolated hepatocytes, cytosol and 104
microsomes from liver of male lean Zucker rats
Figure 4.3 Effects of corticosterone metabolites in HeLa cells transfected 106
with human GR and a luciferase reporter
Figure 4.4 Effects of corticosterone metabolites in HeLa cells transfected 107
with human GR and a luciferase reporter
Figure 4.5 Effects of corticosterone metabolites in HeLa cells transfected 108
with human GR and a luciferase reporter
Figure 4.6 Induction of tyrosine aminotransferase (TAT) mRNA by 109
corticosterone metabolites in H4TTE liver-derived cell line
Figure 4.7 Induction of tyrosine aminotransferase (TAT) mRNA by 110
corticosterone metabolites in H4TTE liver-derived cell line
Figure 4.8 Inhibition of angiogenesis by corticosterone and 5aTHB 111
Figure 4.9 Inhibition of angiogenesis by 5aTHB 112
Figure 4.10 Suppression of plasma ACTH by B and 5aTHB in vivo 113
Figure 4.11 Absence of induction of phosphoenolpyruvate carboxykinase 114
(PEPCK) mRNA by corticosterone and 5aTHB in rat liver.
Figure 4.12 Absence of induction of tyrosine aminotransferase (TAT) mRNA 115
by corticosterone and 5aTHB in rat liver
Figure 5.1 Expression of 5a-reductase type 1 and 5a-reductase type lb in 132
rat liver
Figure 5.2 Hepatic 5a-reductase type 1 mRNA and protein expression 133
Figure 5.3 Western blot analysis of liver microsomes from lean and 134
obese Zucker rats.
Figure 5.4 5a-Reductase mRNA expression in lean and obese Zucker 135
Rat Liver
x
Figure 5.5 5a-Reductase type 1 mRNA expression in lean and obese 136
Zucker rat subcutaneous and omental adipose tissue
Figure 5.6 5(3-reductase (a) activity and (b) mRNA expression 137
Figure 5.7 3a-HSD mRNA expression 138
Figure 5.8 Binding coefficients of glucocorticoids in isolated hepatocytes 139
Figure 6.1 Proposed mechanism for the role of 5a-reductase in obesity 149
xi
List of Tables
Table 1.1 Enzymes involved in glucocorticoid biosynthesis 5
Table 1.2 Summary of properties of 5a-reductase isozymes of rat, mouse 23
and human
Table 2.1 Cell lines summary table 40
Table 2.2 Determination of 5a-reductase and 5(3-reductase bioactivity 45
Table 2.3 Initial retention times for separation of corticosterone and its 49
metabolites
Table 2.4 Specific primers and PCR conditions 62
Table 2.5 Characteristics of probe generation for in-situ hybridisation 67
Table 4.1 Binding affinities of glucocorticoids in isolated rat hepatocytes, 105
liver cytosol and microsomes
Table 5.1 Binding co-efficients (Kd, nM) of glucocorticoids in hepatocytes 140



















































Maximal binding capacity (quantity of ligand
required to saturate receptor)






CNS Central nervous system
CRH Corticotrophin-releasing hormone
dATP deoxyadenosine triphosphate
















GABA Gamma-amino butyric acid
GCMS Gas Chromatography Mass Spectrometry
GH Growth hormone
GLUT-4 Glucose Transporter 4
GR Glucocorticoid receptor
GRE Glucocorticoid response element





HPLC High Performance Liquid Chromatography
Hsp Heat-shock protein
xiv
IGF-1 Insulin-like growth factor-1
kb kilobases
Kj Dissociation constant (concentration of ligand
required to achieve half maximal binding of
receptor)
kDa kiloDaltons




LSD Least square difference
LTR-Luc Long terminal repeat-Luciferase
MDRl-type P-gp Multi-drug resistance 1-type P-glycoprotein
met methionine
MMTV Mouse mammary tumour virus
MOPS 3-(N-Morpholino) propanesulfonic acid
mRNA Messenger RNA
MR Mineralocorticoid receptor
NADPH Reduced form of nicotinamide adenine
dinucleotide phosphate
NF-kB Nuclear factor kB
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PEPCK Phospoenolpyruvate carboxykinase
POMC Propionomelanocortin





SDS Sodium dodecyl sulphate
SEM Standard error of the mean
xv
SPA Scintillation proximity assay
SSC Saline-sodium citrate
TAT Tyrosine aminotransferase
TBE Tris boric acid EDTA
TE Tris EDTA









I declare that this thesis was written by me and that the data presented within it is a
result of my own work, except the procedures listed below .
Surgical procedures were carried out by Dr Chris Kenyon of the Endocrinology Unit,
School of Molecular and Clinical Medicine, University of Edinburgh.
5a-reductase type 1 Western blot was carried out by Dr Dawn Livingstone of the
Endocrinology Unit, School of Molecular and Clinical Medicine, University of
Edinburgh.
GCMS analysis of samples was carried out by Ms Alison Ayres of the
Endocrinology Unit, School of Molecular and Clinical Medicine, University of
Edinburgh.
I declare that this work has not been submitted for any other degree.
Kerry J Mclnnes, Edinburgh,
xvii
Acknowledgements
Throughout my PhD studies I have received valuable assistance from so many
sources that it is hard to acknowledge everyone who has helped. Therefore I would
like to thank the entire Endocrinology Unit for their input. I am also very grateful to
the CVRI and the Wellcome Trust for their generous support.
I would like to say a big thankyou to my supervisors Ruth Andrew and Brian Walker
for their encouragement and enthusiasm throughout my studies. Further thanks are
due especially to Dawn Livingstone and Chris Kenyon who have both spent a great
deal of time giving me valuable advice.
Thanks also goes to the other Wellcome trust students in particular, Helen Munn for
driving me to the lab in the "Wellcome Trust Fun Bus" and for introducing me to the
delights of banana and bacon pizza, and to David O'Regan for providing much
entertainment and Prosecco when it was needed!
Last but not least, a very big thankyou to all of my very good friends and family





The following introductory chapter describes glucocorticoid physiology, with
particular emphasis on glucocorticoid metabolism and the role of A-ring reductases.
Evidence for the role of glucocorticoids in obesity is discussed and finally, a list of
the aims of this thesis is presented.
1.1 Glucocorticoids
Glucocorticoids (corticosterone in rodents and Cortisol in humans) were initially
named to reflect their effects on carbohydrate metabolism. However, it is now well
understood that these hormones are essential for survival and exert an influence on
most systems of the body including the immune system, fluid and electrolyte
homeostasis and the physiological response to stress.
1.1.1 Steroid Hormone Structure
Glucocorticoids are part of the steroid hormone family, each member of which
contains structural modifications of the common precursor molecule, cholesterol.
The chemical structure of steroid hormones is based on that of cholesterol, consisting
of three cyclohexane rings and one cyclopentane ring (Figure 1.1). Each steroid
hormone is given its unique properties by the substitution of chemical groups at
various positions on the backbone molecule.
1.1.2 Glucocorticoid Biosynthesis
Glucocorticoid synthesis from cholesterol occurs in the zona fasciculata of the
adrenal cortex, with a smaller contribution of the zona reticularis. Steroid hormone
biosynthesis is catalysed by members of the cytochrome P450 oxidative enzyme
family which are located in the membranes of the mitochondria and endoplasmic
reticulum (ER) (Table 1.1), and characterised by their absorbance maximum of
450nm (Miller 1988). The sequence of reactions involved in glucocorticoid
biosynthesis is shown in Figure 1.2.
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Figure 1.1: The basic steroid ring structure
The four carbon rings are identified by letters and the individual carbon
atoms by numbers. Chemical groups are designated by the number of the
carbon to which they are attached.
3
Figure 1.2: Biosynthesis of Glucocorticoids in the Adrenal Cortex
Glucocorticoid biosynthesis from cholesterol in the adrenal cortex is catalysed by
CYP oxidative enzymes. The sequence of reactions involved in glucocorticoid
biosynthesis is shown, with specific enzyme names indicated in boxes.
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General Name Specific Name Intracellular Location
Cholesterol side-chain cleavage CYP11A1 Inner mitochondrial memb.
3(3-Hydroxysteroid dehydrogenase 3|3-HSDII Endoplasmic reticulum
*(17a-Hydroxy 1 ase) (CYP17) (Endoplasmic reticulum)
21-Hydroxylase CYP21A2 Endoplasmic reticulum
liP-Hydroxylase CYP11B1 Inner mitochondria] memb.
Table 1.1: Enzymes Involved in Glucocorticoid Biosynthesis
* Does not occur in rat or mouse adrenal.
1.1.3 Glucocorticoid secretion
Glucocorticoid synthesis and release from the adrenal cortex is controlled by
hormonal interactions between the hypothalamus, pituitary gland and the adrenal
gland (known as the hypothalamic-pituitary-adrenal (HPA) axis), and can in turn be
influenced by both neural and chemical stimuli. Stimulation of the hypothalamus
(e.g. by stress) results in the release of corticotrophin releasing hormone (CRH)
(Vale et al. 1981) and arginine vasopressin (AVP) (Lamberts et al. 1984; Engler et
al. 1989) into the hypothalamic-hypophyseal portal capillary system. Stimulation of
CRH receptors on corticotrophs of the anterior pituitary results in the rapid release of
adrenocorticotrophic hormone (ACTH) into the systemic circulation (Horrocks et al.
1990). ACTH is synthesised from the polypeptide pro-opiomelanocortin (POMC)
and acts via plasma membrane receptors (melanocortin-2-receptors) on adrenal cells,
to stimulate steroidogenesis and hence, the secretion of glucocorticoids.
Glucocorticoids themselves provide a negative feedback loop to regulate their own
secretion. They suppress ACTH secretion at the level of the hypothalamus by
inhibiting CRH release, and at the level of the pituitary by inhibiting POMC
transcription and ACTH synthesis. This feedback loop acts to maintain
physiological plasma glucocorticoid levels (De Kloet 1991). The HPA axis of the rat
is summarised in Figure 1.3.
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Figure 1.3: The Hypothalamic-Pituitary -Adrenal Axis of the Rat
Corticosterone is secreted by the adrenal cortex in response to the secretion
of ACTH by the anterior pituitary, secretion of which is triggered by CRH
and AVP release by the PVN of the hypothalamus. Corticosterone has a
negative feedback effect upon its own secretion at the hypothalamus and
pituitary, and also influences the activity of the neuronal projections to the
hypothalamus from higher brain centres.
Key: + up-regulation, -down regulation
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In addition to the stimulated release of glucocorticoids described above, there is also
a diurnal variation in glucocorticoid secretion. Glucocorticoid secretion follows the
pattern of plasma ACTH and there is a major increase in activity before awakening.
Thereafter, the release of ACTH and glucocorticoids generally occurs only for brief
episodes. After each episode, plasma glucocorticoid levels increase enough to
suppress further ACTH release and then fall to reach the set-point of negative
feedback control. This diurnal pattern comprising of pulses of ACTH/ glucocorticoid
secretion control circulating glucocorticoid levels in the plasma (Horrocks et al.
1990; Chrousos & Gold 1998).
1.1.4 Glucocorticoid Action
Circulating glucocorticoids (corticosterone and Cortisol) are predominantly bound to
corticosteroid-binding globulin (CBG) and albumin, with only 5-10% freely
circulating in the plasma (Hammond et al. 1990). The lipophilic nature of these
hormones allows them to pass freely through the cell membrane. However, only free
steroid can diffuse across cell membranes to bind to the intracellular glucocorticoid
receptor. Glucocorticoid-binding proteins therefore act to buffer free corticosterone
concentrations. However, these proteins can become saturated at high physiological
glucocorticoid concentrations, amplifying fluctuations in free steroid levels
throughout the period of diurnal variation.
1.1.5 The Glucocorticoid Receptor
1.1.5.1 Background
Endogenous glucocorticoids and their synthetic derivatives act via the glucocorticoid
receptor (GR). GR is a member of the nuclear hormone receptor superfamily of
ligand-activated transcription factors and mediates transactivation of target genes by
binding sequence specific recognition elements in their promoter region.
When the human GR cDNA was first cloned in 1985 (Hollenberg et al. 1985;
Weinberger et al. 1985) two GR gene splicing products were identified and termed
GRa and GR(3. The human GRa and GR(3 mRNA both contain exons 1-8, but
7
contain different versions of exon 9 as a result of alternative splicing. GRa is
ubiquitously expressed and is recognised as the classical GR (Hollenberg et al.
1985). Most of our understanding of GR physiology comes from the study of this
isoform. GRa shows high affinity for dexamethasone, modest affinity for Cortisol
and corticosterone and low affinity for aldosterone, deoxycorticosterone and the sex
steroids. The GR(3 isoform, which differs only in the last 15 amino acids, does not
bind active glucocorticoids and is transcriptionally inactive on glucocorticoid-
response element -containing enhancers (Vottero & Chrousos 1999). GR(3 was long
dismissed as a cloning artefact however it is expressed at varying levels in a range of
tissues (Oakley et al. 1996; Oakley et al. 1997). Evidence suggests that GR(3 acts as
a ligand-independent negative regulator of glucocorticoid action by forming GRa/(3
heterodimers that are incapable of binding co-activators as a GRa homodimer would
(Bamberger et al. 1995; Oakley et al. 1999). However, other groups have not
detected this dominant negative inhibitory effect of GR(3 (Hecht et al. 1997; de
Lange et al. 1999).
Various GR isoforms are also produced by alternative translation initiation. The
major protein product termed GR-A with an apparent molecular mass of 94 kDa
represents translation from the first initiator AUG codon. The next downstream start
codon (met 27 in humans or met 28 in rodents) results in production of a 91 kDa GR
termed GR-B. The shorter GR-B species is nearly twice as efficient in glucocorticoid
response element-mediated transactivation as the longer GR-A (Yudt & Cidlowski
2001). The biological significance of this alternative initiation remains unclear.
However, the distinct biological activities of these isoforms suggest that they may
play a role in the diversity of glucocorticoid response.
The homologous structural organisation of the nuclear receptors is well known. The
DNA binding domain (DBD) is centrally located, flanked on the carboxy-terminal by
an approximately 250-amino acid ligand-binding domain (LBD) and by a variably
sized non-homologous amino-terminal domain (Beato et al. 1995).
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1.1.5.2 Mechanism of glucocorticoid receptor action
1.1.5.2.1 Ligand binding and dissociation from heat shock proteins
In the absence of ligand, GR resides in the cytosol in association with several other
proteins including hsp90 from which it dissociates upon ligand binding (Pratt & Toft
1997). Hsp90 associates with the ligand-binding domain of the receptor and
maintains the receptor in a conformation that can bind steroid but is transcriptionally
inactive (Cadepond et al. 1991). Other chaperone proteins including hsp40 and hsp70
are required for formation of a stable GR-hsp90 complex (Pratt & Dittmar 1998).
The crystal structure of the human GR LBD bound to dexamethasone and a
coactivator motif derived from the transcriptional intermediary factor 2 has been
recently elucidated (Bledsoe et al. 2002). The overall structure of the GR LBD is
similar to other nuclear receptor LBDs with 1 la-helixes and four (3-strands that are
folded to create a hydrophobic pocket for the ligand. There are several features
unique to the GR LBD including a distinct dimerisation interface that involves the
formation of a central hydrophobic intermolecular (3-sheet (Bledsoe et al. 2002). The
crystal structure also reveals an additional charge clamp that determines the binding
selectivity of a coactivator and a distinct ligand binding pocket that explains the
selectivity of GR for endogenous steroid hormones (Bledsoe et al. 2002).
1.1.5.2.2 Phosphorylation and nuclear translocation
The glucocorticoid receptor is phosphorylated in the absence of ligand and becomes
hyperphosphorylated after agonist-binding but not after binding of an antagonist
(Orti et al. 1989). The phosphorylated GR subsequently translocates to the nucleus.
However, receptor phosphorylation is not necessary for nuclear translocation since a
mouse GR lacking all phosphorylation sites still undergoes nuclear translocation
upon ligand activation (Webster et al. 1997). Two domains of GR have been
implicated in nuclear translocation. The first (NL1) is localised in the C-terminal part
of the DBD and is 100% conserved between human and rat GR (Picard & Yamamoto
1987). The LBD inhibits the function of NL1 and this inhibition can be abolished by
ligand binding (Cadepond et al. 1992). The exact location of the second nuclear
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localisation signal is (NL2) is unknown but has been mapped to the LBD (Picard &
Yamamoto 1987).
1.1.5.2.3 Dimerisation and DNA binding
Upon ligand binding the GR can form homodimers. This process appears to involve
the DNA binding domain (DBD) which consists of two protein loops co-ordinated by
a zinc ion, resulting in two zinc fingers which are both followed by an amphipathic
a-helix. GR can then bind specific DNA sequences called glucocorticoid-responsive
elements (GRE) of target genes to initiate transcription. Several amino acids in the
DNA binding domain interact with the DNA to keep GR in the major groove of the
DNA a-helix (Luisi et al. 1991).
1.1.5.2.4 Transactivation
It is not fully understood how binding of GR to GREs leads to transcription
initiation. The basic transcription machinery which consists of RNA polymerase II
and other general transcription factors such as TATA box-binding protein must be
recruited to the promoter (Beato et al. 1989). In addition the transcriptional activity
of the GR depends on coactivators that facilitate recruitment of the basal
transcription machinery or remodel chromatin (Collingwood et al. 1999; Jenkins et
al. 2001). Optimal transactivation of target genes is dependent on the presence of two
domains, x-1 and t-2. The function of x-1 is hormone-independent whereas hormone
binding is required for the activity of x-2 (Hollenberg & Evans 1988). A summary of
the events involved in the activity of GR is described in Figure 1.4.
More recent studies investigating the mouse mammary tumour virus long terminal
repeat (MMTV-LTR) which contains several GREs have shown that transcriptional
activation by GR requires DNA binding, disruption of local chromatin structure and
assembly of the initiation complex at a TATA box (Hebbar & Archer 2003).
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1.1.5.2.5 Transrepression
GR is also able to transrepress the expression of specific target genes by at least three
mechanisms. Firstly, it can bind to DNA sequences called negative GREs in the
promoter region of target genes (Caims et al. 1993). Secondly, GR can bind to DNA
elements that consist of a non-overlapping GRE and a binding site for a different
transcription factor (known as composite GREs) (Pearce & Yamamoto 1993). A
third mechanism occurs without binding to DNA. GR inhibits AP-1, the collagenase
promoter by direct protein-protein interactions (Jonat et al. 1990). In addition GR
can repress the activity of NF-kB by physically interacting with the p65/RelA
subunit (Ray & Prefontaine 1994) More recent studies have also shown that GR can
inhibit p65-induced transcription by interfering with histone acetylation and
phosphorylation of RNA polymerase II (Ito et al. 2001).
1.1.5.3 Other Glucocorticoid binding sites
Glucocorticoids can bind to a site other than the cytosolic GR. Low affinity
glucocorticoid binding sites ("LAGS") have been demonstrated in the microsomal
fraction (Ambellan et al. 1981) and nuclear envelope (Roszak et al. 1990).
Glucocorticoids may also be able to act upon membrane bound receptors.
Glucocorticoid binding sites have been described in rat neuronal membranes
(Liposits & Bohn 1993), rat liver plasma membranes (Allera et al. 1980; Lackner et
al. 1998) and human leukemic cells (Gametchu et al. 1999). The physiological
relevance of these binding sites remains unclear, but they may be involved in rapid
non-genomic actions of glucocorticoids (Borski 2000)
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Figure 1.4: Model of glucocorticoid Receptor activity
Free hormone dissociates from the circulating transport protein (CBG), diffuses into
the cytosol, and binds to inactive GR. This activates the receptor by causing
dissociation of the heat-shock protein complex (HSP). The receptor dimerises and is
translocated into the nucleus. Here the activated receptor binds to glucocorticoid-
response elements in the promoter region of target genes, and recruits other elements
of the transcriptional apparatus of the cell. Transcribed mRNA is translated into
protein products by ribosomes in the cytosol.
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1.1.6 Glucocorticoid Effects
The roles of glucocorticoid hormones in various physiological systems were initially
identified from clinical observations of the consequences of adrenal disease.
Glucocorticoid excess (e.g. in Cushing's syndrome) is characterised by redistribution
and accumulation of fat in more central depots, impaired glucose tolerance,
hypertension, muscle weakness and increased susceptibility to injury (Cushing
1912). In contrast, glucocorticoid insufficiency (e.g. in Addison's disease) is
characterised by weight loss, loss of appetite and postural hypotension (Addison
1855). Further insight into the effect of glucocorticoids was aided by the advent of
the steroid biosynthesis inhibitor, metyrapone and the glucocorticoid receptor
antagonist, mifepristone (RU486).
1.1.6.1 Effects on metabolism
The metabolic effects of glucocorticoids are essentially anabolic in the liver and
catabolic in muscle and adipose tissue, the overall effect of which is to increase
blood glucose levels. Glucocorticoids increase hepatic glucose production by
stimulating the synthesis of enzymes essential in hepatic gluconeogenesis (e.g.
phosphoenolpyruvate carboxykinase (PEPCK) (Friedman et al. 1997) and glucose-6-
phospatase (G6Pase) (Yoshiuchi et al. 1998). In addition, glucocorticoids mobilise
substrates for hepatic gluconeogenesis by stimulating release of amino acids from
skeletal muscle and fatty acids and glycerol from adipose tissue (Exton 1979).
Glucocorticoids also inhibit glucose uptake by peripheral tissues by decreasing
transport of the GLUT4 transporter to the cell membrane (Weinstein et al. 1995), and
stimulate glycogen storage by activating glycogen synthase and inhibiting glycogen
phosphorylation (Stalmans & Laloux 1979).
Glucocorticoids promote differentiation of pre-adipocytes to mature adipocytes
(Hauner et al. 1987). Glucocorticoids receptors have been found in isolated
adipocytes (Bronnegard et al. 1990) and stromal cells (Zhao et al. 1995) and they
induce several gene products including lipoprotein lipase and glycerol-3-phosphate
dehydrogenase (Fried et al. 1993). The end result is differentiation of adipose
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stromal cells into adipocytes (Hauner et al. 1989; Bronnegard et al. 1995) and
accumulation of lipid. Site-specific alterations in fat accumulation via
glucocorticoid-mediated activation of lipoprotein lipase and hormone-sensitive lipase
can result in obesity in glucocorticoid excess and may be a result of specific up-
regulation of GR (Bronnegard et al. 1990).
These various effects of glucocorticoids on metabolism contribute to the
maintenance of blood glucose during food deprivation and the mobilisation of extra
glucose during stress. These protective effects come at a cost of decreased protein
and fat.
1.1.6.2 Effects on the cardiovascular system
Glucocorticoids are needed to maintain normal vascular integrity and responsiveness
and to maintain the volume of body fluids. Although the exact mechanisms involved
in glucocorticoid-mediated regulation of blood pressure have not been fully
elucidated, their effects in the cardiovascular system are wide ranging.
Glucocorticoids regulate cardiac output by maintaining contractility and work
performance of the heart. In addition, glucocorticoids also play an important role in
the regulation of fluid and electrolyte balance. These hormones can directly
influence sodium handling (Montrella-Waybill et al. 1991), and are essential for the
regulation of angiotensinogen production from the liver, AVP production from the
hypothalamus and atrial naturetic peptide (ANP) production from cardiac myocytes -
each of which can influence sodium/ water handling in the kidney.
Glucocorticoids are therefore essential for the maintenance of normal blood pressure
and alterations in circulating glucocorticoid concentrations can cause hypertension
(e.g. in Cushing's syndrome) and hypotension (e.g. in Addison's disease). The
mechanisms of glucocorticoid-induced hypertension include increased systemic
vascular resistance, increased extracellular volume and increased cardiac
contractility. Cushing's disease is associated with an enhanced sensitivity to the
pressor effects of angiotensin II and noradrenaline and a decrease in the levels of
vasodilator prostaglandins (Sartura et al. 1986). Observations in mice with a
14
transgenic deletion of the 11(3HSD2 gene (Kotelevtsev et al. 1999) have confirmed
the role of glucocorticoids in the control of blood pressure and vascular function.
11(3HSD2 acts in aldosterone target tissues to protect mineralocorticoid receptors
from inappropriate activation by glucocorticoids (Edwards et al. 1988). The
11(3HSD2 knockout mice are hypertensive and have enhanced vasoconstrictor
responses to noradrenaline and 5-hydroxytryptamine and impaired nitric oxide
mediated endothelium dependent vasodilatation (Hadoke et al. 1999).
1.1.6.3 Effects on the immune system
The reactions to various injuries and foreign substances involve multiple anti¬
inflammatory and immune responses. Glucocorticoids have profound inhibitory
effects on both the early and the late manifestations of inflammation and have
therefore been exploited clinically in the treatment of inflammation and autoimmune
disease and prevention of rejection of transplanted organs. The anti-inflammatory
effects of the glucocorticoids are due to actions on blood vessels, inflammatory cells
and inflammatory mediators (Barnes & Adcock 1993).
Glucocorticoids alter the trafficking of cells of the immune system (T- and B-cells,
neutrophils, monocytes and granulocytes) resulting in suppression of local
inflammatory responses (Dale et al. 1975). Glucocorticoids are also able to induce
lymphocyte apoptosis (Nazareth et al. 1991) and inhibit T-cell cytokine synthesis
(Cupps et al. 1985), therefore indirectly inhibiting B-cell and macrophage activation
and proliferation (Rinehart et al. 1982). Glucocorticoids suppress the synthesis of
several key substances that mediate the inflammatory response including the
prostaglandins and can stimulate synthesis of others that are anti-inflammatory
including lipocortins (Goulding & Godolphin 1990).
1.1.6.4 Effects on the central nervous system
Several cell types of the central nervous system (CNS) contain glucocorticoid
receptors, including neurones, astrocytes, glial cells and oligodendrocytes. Clinical
observations have indicated that glucocorticoids influence cognition, mood,
reception of sensory stimuli and sleep patterns by modulating neuronal activity
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(McEwen et al. 1986). Chronic exposure to glucocorticoids induces neurotoxicity,
hypothetically resulting in decreased hippocampal volume and therefore decreased
memory function (Sapolsky et al. 1985). Psychological disturbances are common in
Cushing's disease presenting as initial euphoria but subsequent depression or manic
behaviour (Loosen et al. 1992). Patients with severe primary depression have an
impaired suppression of plasma Cortisol following dexamethasone administration
which may return to normal after treatment of the depression. Administration of
exogenous glucocorticoids is also known to decrease the duration of rapid eye
movement sleep (Kreiger 1972). With glucocorticoid deficiency, the senses of taste,
hearing and smell are accentuated. The exact mechanisms involved in
glucocorticoid-mediated changes in behaviour are unclear.
The non-genomic effects of glucocorticoids are readily apparent in the CNS. These
responses (e.g. neuronal hyperpolarisation and suppression of spontaneous electrical
activity) are too rapid to be mediated by classical transcriptional effects on target
genes, therefore a direct membrane effect is more likely (Orchinik et al. 1991).
1.1.6.5 Effects on growth and development
At physiological levels, glucocorticoids are necessary for skeletal growth and are
important for the maturation of various foetal organs. They are essential for foetal
lung development, including the synthesis of pulmonary surfactant and are used
clinically to stimulate lung maturation in premature babies (Ballard 1987).
Glucocorticoids are also involved in the maturation of intestinal enzymes.
Glucocorticoid excess is associated with osteopenia (decreased new bone formation
and bone resorption) (Weinstein et al. 1998) and with impaired calcium and
phosphate absorption in the intestine and kidney (Laake 1960; Hahn et al. 1979). The
combination of these events results in osteoporosis (Reid 2000). Additionally,
glucocorticoids have deleterious effects on connective tissue caused by inhibition of
fibroblast proliferation and extracellular matrix synthesis (Pratt & Aronow 1966).
Excessive glucocorticoid exposure of the foetus in utero is also disadvantageous,
resulting in retardation of foetal growth (Reinisch et al. 1978) which can
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'programme' an increased risk of cardiovascular disease in later life. Perinatal
manipulation of glucocorticoid exposure in rats has been shown to permanently alter
GR expression in the brain, HPA axis responses (Meaney et al. 1994), gluconeogenic
enzymes, glucose tolerance and blood pressure (Nyirenda et al. 1998).
1.1.7 Metabolism of glucocorticoids
The metabolism of glucocorticoids involves reduction, oxidation, hydroxylation and
conjugation, and the metabolic pathway of corticosterone is shown in Figure 1.5. The
pathway involves the interconversion of corticosterone (B) (Cortisol in humans) with
its inactive 11-keto metabolite, 11-dehydrocorticosterone (A) (cortisone in humans)
by the isozymes of llp-hydroxysteroid dehydrogenase (lipHSD). The subsequent
metabolism of corticosterone and 11-dehydrocorticosterone follow similar paths. The
rate-limiting step of glucocorticoid metabolism is the reduction of the A4'5 double
bond in the A-ring of the steroid structure (the biology of these enzymes is discussed
in detail in section 1.2). 5a- and 5p-reductase can both act on corticosterone whereas
11-dehydrocorticosterone is metabolised by 5(3-reductase only. These enzymes
produce two dihydro-stereoisomers, differing only in the orientation of the additional
hydrogen atom at carbon 5. These dihydro-metabolites are then rapidly reduced
further by 3a-hydroxysteroid dehydrogenase (3a-HSD) to yield tetrahydro-
metabolites, the most abundant urinary glucocorticoid metabolites. Additional
reduction by 20a- and 20|3-hydroxysteroid dehydrogenases produces cortols and
cortolones, which are finally oxidised by 21-oxidase to produce cortolic and
cortolonic acids. Glucocorticoids and their metabolites are poorly water-soluble,
therefore, conjugation to glucuronic acid or sulphates in the liver increases their
water-solubility and decreases their binding to proteins therefore aiding excretion.
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Corticosterone (B) 11-dehydrocorticosterone
Figure 1.5: Glucocorticoid metabolism
Glucocorticoid metabolism involves reduction, oxidation, hydroxylation,
and conjugation, catalysed by the enzymes in the boxes. Both 5a- and 5(3-
reduction of corticosterone can occur but 11-dehydrocorticosterone is only
acted on by 5(3-reductase.
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1.2 A-ring reductases
The focus of this thesis is the metabolism of glucocorticoids by A-ring reductases,
and their physiology is described in this section
1.2.1 5a-Reductase
1.2.1.1 History of 5a-reductase
A 5a-reductase enzyme was initially characterised in the 1950's in rat liver slices
based on its ability to convert deoxycorticosterone to 5a-reduced metabolites
(Schneider & Horstmann 1951; Schneider 1952). Subsequent work showed that this
enzyme was present in the microsomal fraction and that it utilised reduced pyridine
nucleotide (NADPH) as a co-factor (Forchielli & Dorfman 1956; McGuire &
Tomkins 1960; McGuire et al. 1960). 5a-Reductase catalyses the reduction of A4'5
double bonds in a variety of steroid substrates and is thought to have both catabolic
and anabolic roles in steroid hormone metabolism. 5a-Reduction of steroids renders
their 3-oxo groups more susceptible to reduction by 3a- hydroxysteroid
dehydrogenases (3a-HSDs) and to subsequent sulfation and glucuronylation. The
latter modifications reduce the affinity of the steroid for binding proteins, make it
more hydrophilic, and facilitate its excretion in the urine.
5a-Reductase was thought to participate in the catabolism of steroids and research in
the 1960's showed that 5a-reductase would not catalyse the reverse reaction
(dehydrogenation) of reduced steroids (Wilson 1975). More attention was focused on
5a-reductase when it was documented that dihydrotestosterone, the 5a- reduced
metabolite of testosterone, was a more potent androgen than testosterone in bioassays
with prostate and that it could bind preferentially to the androgen receptor (Siiteri &
Wilson 1974). Definitive evidence for the key role of 5a-reductase came from
developmental and genetic studies that showed that this reaction is crucial for
formation of the normal male phenotype during embryogenesis (Siiteri & Wilson
1974) and that absence of steroid 5a-reductase activity underlies a rare form of male
pseudohermaphroditism, originally termed pseudovaginal perineoscrotal
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hypospadias, in which masculinisation of the developing genitalia is incomplete due
to inadequate conversion of testosterone to 5aDHT (Walsh et al. 1974; Imperato-
McGinley et al. 1974).
1.2.1.2. Identification of two distinct isozymes
It was originally assumed that several steroid 5a-reductase isozymes must exist, each
of which preferentially using a different steroid substrate (McGuire & Tomkins
1960). In agreement with this notion, steroid 5a-reductase activities with different
kinetic properties and pH optima were demonstrated in human tissues and one of
these activities was absent in patients with steroid 5a-reductase deficiency (Moore et
al. 1975). Further insight into the existence of multiple enzymes was hampered by
the extreme insolubility of the protein (Moore & Wilson 1972) and many attempts
were made to purify 5a-reductase from both rat and human sources.
Expression cloning studies allowed the full length cDNA encoding the rat liver 5a-
reductase to be isolated from a xenopus library and was subsequently used to identify
a human homologue (Andersson & Russell 1990). The human cDNA and its encoded
enzyme however exhibited several puzzling features that strongly suggested the
existence of a second 5a-reductase gene. 1) The cDNA product was only weakly
inhibited by finasteride, a powerful inhibitor of 5a-reductase activity in the prostate,
2) the cDNA produced a 5a-reductase with an alkaline pH optimum compared to the
predominant acidic pH optimum enzyme activity of prostate and 3) mutations were
not detected in the coding region of the cDNA isolated from patients with 5a-
reductase deficiency (Jenkins et al. 1992).
A second cDNA was subsequently cloned in cultured human cells (Andersson et al.
1991). The two human isozymes designated type 1 and type 2 are approximately
46% identical in sequence (Russell & Wilson 1994). The type 1 isozymes had a
broad pH optima that spans the alkaline range (pH 6-8.5) (Normington & Russell
1992) while the type 2 isozyme had a narrow acidic pH optima centred around 5.0
(Andersson et al. 1991).
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A rat homologue of the second human 5a-reductase has also been cloned and again
in this species, the second cDNA encodes a different protein that catalyses the same
biochemical reaction as that encoded by the first cDNA (Normington & Russell
1992). 5a-Reductases have also been studied in the mouse and two isozymes have
been found which are similar to the rat enzymes and not the human isozymes
(Mahendroo et al. 1996). The type 2 isozymes of rat and human are more closely
related to each other (77% sequence identity) than they are to their type 1
counterparts (<50% sequence identity) and both have an acidic pH optima in contrast
to the neutral to basic pH optima of the type 1 isozymes (Normington & Russell
1992). However there are differences in tissue expression of isozymes between
species and in their sensitivity to the 4-azasteroid inhibitors.
The rat and human type 1 isozymes differ with respect to their sensitivity to 4-
azasteroids in that the human type 1 isozyme is not sensitive to inhibition by these
compounds (Thigpen & Russell 1992). This appears to be due to a difference
between species in a four amino-acid segment encoded within exon 1 that are
thought to define a portion of the substrate-binding domain (Thigpen & Russell
1992). The rat type 2 isozyme is inhibited potently by 4-azasteroid inhibitors with a
Ki of 0.46 ± 0.21 nM compared to the rat type 1 isozyme (Ki ; 5.8 ± 0.6 nM )
(Normington & Russell 1992).
The human 5a-reductase type 1 isozyme is expressed in liver (Thigpen et al. 1993),
the skin (Harris et al. 1992; Imperato-McGinley et al. 1992; Thigpen et al. 1993) and
kidney (Quinkler et al. 2003). 5a-Reductase type 2 predominates in the prostate but
is also expressed in the skin and liver (Normington & Russell 1992; Thigpen et al.
1993). In the rat, the type 1 enzyme is expressed in both the liver and prostate
(Andersson et al. 1989) and the type 2 isozyme predominates in male reproductive
tissues such as the testis, vas deferens and epidydymis but is not expressed in the
liver. In contrast to the situation in human prostate, both isozymes are expressed in
the rat ventral prostate with basal epithelial cells expressing the type 1 enzyme and
stromal cells expressing the type 2 isozyme (Berman & Russell 1993). A summary
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of the properties of the 5a-reductase isozymes of rat and human is shown in Table
1.2.
5a-Reductase type 1 is constitutively expressed in the rat CNS at all stages of brain
development and is similar in males and females. The gene expression of the type 2
isozyme is different with expression almost exclusively in late fetal/early post-natal
stage (Melcangi et al. 1998). 5a-Reductase activity has also been demonstrated in
human and rat adipose tissue (Perel et al. 1986; Zyirek et al. 1987) although it is not
known what isozyme is present in fat.
1.2.1.3 The role of 5a-reductase types 1 and 2
The roles of the 5a-reductases have gained most attention with respect to androgen
physiology. The significant differences in apparent Km values exhibited by the two
isozymes suggested that they may have different physiological functions. The lower
Km of the rat type 2 isozyme indicated that this enzyme played an anabolic role in
steroid hormone metabolism, thus the type 2 isozyme is responsible largely for the
paracrine and autocrine generation of DHT in androgen target tissues. This is
supported by the finding that mutations in the human 5a-reductase type 2 gene
(Andersson et al. 1991) cause developmental abnormalities in DHT-dependent
tissues of the embryo termed male pseudohermaphroditism. In contrast, the higher
substrate Km value of the rat type 1 isozyme suggested a catabolic role in androgen
metabolism, involving the inactivation of testosterone in non-androgen target tissues.
The abundant expression of 5a-reductase type 1 in the rat liver supported this role as
liver enzymes have a known catabolic role in steroid metabolism.
Mutations in the 5cc-reductase type 1 gene have not yet been identified in humans
however an induced mutation in the mouse 5a-reductase type 1 gene produced male
mice indistinguishable from wild-type counterparts. In contrast, female mice that
lack the type 1 enzyme exhibit defects in parturition and fecundity (Mahendroo et al.
1996; Mahendroo et al. 1997). The fecundity defect was caused by an increase in
testosterone being converted into toxic oestrogens by the aromatase enzyme at
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Table 1.2: Summary of properties of 5a-reductase isozymes of rat, mouse and
human.
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critical times in pregnancy in the mutant mice, revealing an unexpected but essential
function of the type 1 isozyme. The parturition defect was traced to a failure of the
uterus to synthesise 5a-reduced androgens in late gestation. The seminal vesicle and
ventral prostate are more dependent on the production of DHT for maintenance and
growth than any other androgen target tissues (George et al. 1991). These tissues
express nearly equal levels of both isozymes, thus 5a-reductase type 1 may serve as
a back-up generator of DHT. The finding that both isozyme mRNAs are induced by
androgens in the regenerating prostate supports this hypothesis. These effects
implicate the type 1 isozyme as playing an essential role in maintaining a balance
between the levels of oestrogens and androgens.
The parturition defects were not worsened if 5a-reductase type 2 was also knocked-
out suggesting that the type 1 enzyme has evolved to play an essential role in the
female (Mahendroo & Russell 1999). The female rat liver also expresses 10-20 fold
more mRNA (Andersson et al. 1989) and activity (Yates et al. 1958) than does male
liver suggesting that 5a-reduction is a more important pathway of hepatic
metabolism in females.
1.2.1.4 Regulation of 5a-Reductase
The expression of steroid 5a-reductase enzyme activity is under hormonal control.
The best-studied tissue is the rat ventral prostate. Castration of male rats causes a
marked regression in the size and weight of the ventral prostate caused by apoptosis
of the lumenal epithelial cells (Raff 1992). Regression can be readily reversed or
prevented by administration of testis extracts.
The induction of 5a-reductase enzyme activity in the ventral prostate of castrated
rats given testosterone is accompanied by a large increase in the mRNA for both the
type 1 and type 2 isozymes (Andersson et al. 1989; Normington & Russell 1992).
When castrated rats were given the 5a-reductase inhibitor finasteride with
testosterone, growth of the prostate gland was blocked and induction of 5a-reductase
activity and 5a-reductase mRNA by testosterone was prevented. This regimen did
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not prevent DHT-mediated increases in either 5a-reductase activity or mRNA
implying that DHT is the active androgen that enhances 5a-reductase type 1 mRNA
and activity in the ventral prostate (George et al. 1991). This so-called feed-forward
regulation is contrary to the usual feedback regulation in which the product of an
enzyme negatively regulates expression of the gene.
In adult rat testis, testosterone has been shown to negatively regulate the expression
of 5a-reductase type 1. This observation was consistent with the hypothesis that a
reduction in testicular testosterone leads to an increase in the metabolism of
testosterone to the more potent metabolite, DHT (Pratis et al. 2003). Thus, when
testicular testosterone levels are low and unable to maintain sperm production,
amplification of the androgenic stimulus via conversion of testosterone to DHT
would enable continued low levels of spermatogenesis. Negative regulation of 5a-
reductase type 1 by testosterone has been demonstrated in other tissues such as liver
(Yates et al. 1958; Lopez-Solache et al. 1996) and adrenal cortex (Lephart et al.
1991). Conversely, positive regulation of 5a-reductase type 1 by testosterone and
dihydrotestosterone has been elucidated in rat liver (Torres & Ortega 2003). Unlike
the 5a-reductase type 1 isozyme, the 5a-reductase type 2 isozyme was not regulated
by testosterone in the rat testis. This is in contrast to the above observation in the
ventral prostate that androgens positively regulate 5a-reductase type 2, suggesting
that the factors that regulate the 5a-reductase isozymes may be isozyme and tissue
specific.
5a-Reductase enzymes appear to be controlled by products of the pituitary gland as
in hypophysectomised female rats, activity of 5a-reductases are dramatically
decreased and steroid hormones no longer influence their activity (Denef 1974;
Gustafsson et al. 1980). On the other hand replacement of an ectopic adult rat
pituitary can restore normal 5a-reductase activity in hypophysectomised female rats
(Denef 1974). The pituitary hormones responsible for maintaining hepatic 5a-
reductase activity in adult female rats remain to be elucidated. Administration of
prolactin to hypophysectomised female rats only produced a slight increase in 5a-
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reductase activity (Lax et al. 1976). Other investigators have reported that luteinising
hormone (LH) and follicle-stimulating hormone (FSH) do not influence 5a-reductase
activity although the literature is controversial. In rat testis, some studies showed a
positive effect of FSH on 5a-reductase type 1 activity (Nayfey et al. 1975; Welsh &
Wiebe 1976) whereas others did not (Dorrington & Fritz 1975; Murono & Payne
1979). In a more recent study, Pratis et al showed that FSH positively regulates 5a-
reductase type 1 and type 2 in rat testis (Pratis et al. 2003). Growth hormone (GH)
has also been shown to increase 5a-reductase activity in intact and
hypophysectomised male rats and in hypophysectomised-gonadectomised male and
female rats, (Rumbaugh & Colby 1980; Mode et al. 1981)and in isolated hepatocytes
(Miller & Colas 1982). In genital skin fibroblasts that exclusively express 5a-
reductase type 2, 5a-reductase activity has been shown to be regulated by DHT and
insulin-like growth factor-1 (Horton et al. 1993), transforming growth factor-(3l and
-(32 (Wahe et al. 1993) and activin A (Antonipillai et al. 1995).
1.2.2 5(3-Reductase and 3a-Hydroxysteroid Dehydrogenase
The enzymes 5(3-reductase and 3a-hydroxysteroid dehydrogenase (3a-HSD) are
members of the aldo-keto reductase superfamily. The aldo-keto reductases (AKRs)
are an enzyme superfamily of NAD(P)(H)-dependent oxidoreductases with a broad
spectrum of physiological roles. Typically, members of the superfamily are
monomeric (a/(3)s-barrel proteins, about 320 amino acids in length, which use
NAD(P)(H) to metabolise a range of substrates at an active site containing a catalytic
tetrad of a tyrosine, a lysine, an aspartate and a histidine (Jez et al. 1997).
The aldo and keto groups of substrates are not involved chemically in the reaction
catalysed by 5(3-reductase, however the enzyme shares a relatively high homology
(approximately 50%) with other members of the AKR superfamily. 5(3-Reductase
catalyses the reduction of all steroid hormones carrying a 4-ene-3-keto group
(Berseus 1967). The presence of the 3-keto group is essential, structurally for the 5(3-
reductase activity. The enzyme is most abundant in liver and is localised in the
cytosol (Onishi et al. 1991). The best known activity of 5(3-reductase is the formation
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of biliary acids, namely cholic and chenodeoxycholic acids (Berseus et al. 1965).
There is a limited amount of literature on this enzyme with respect to glucocorticoid
metabolism, however 5(3-reduced glucocorticoids have been shown to be decreased
in essential hypertension (Iki et al. 1994) and in the Syndrome of Apparent
Mineralocorticoid Excess (Monder et al. 1986). Altered 5P-reduction of
glucocorticoids has also been implicated in obesity (Andrew et al. 1998).
3a-HSDs work in concert with the 5a- and 5P-reductases to generate the 3a/5a and
3a/5(3-tetrahydrosteroids. In this manner they catalyse the second step in the
metabolism of all steroid hormones that contain a A4-3-ketosteroid functionality and
serve to protect against circulating steroid hormone excess (Penning et al. 1986). The
most extensively characterised mammalian 3a-HSD is the enzyme from rat liver.
The rat appears to express only one known 3a-HSD isoform whereas at least four
human isoforms exist (Khanna et al. 1995). Hepatic 3a-HSD also plays a critical
step in the synthesis of bile acids and is responsible for the production of 5P-
cholestane-3a, 7a-diol, which is a committed precursor of bile acids (Danielsson &
Sjovall 1975). In steroid target tissues, the production of 3a/5a and 3a/5P-
tetrahydrosteroids is not without consequence. In the human prostate, 3a-HSD can
regulate the occupancy of the androgen receptor by androgen. It catalyses the
interconversion of the potent androgen 5a-DHT to 3a-androstanediol, a weak
androgen (Liao et al. 1973) and can therefore regulate androgen-dependent growth of
this gland (Taurog et al. 1975). Evidence exists in the dog prostate that 3a-HSD may
work in concert with 5a-reductase to maintain high levels of DHT (Jacobi et al.
1977). In brain, 3a-HSD can regulate the occupancy of the GABAa receptor by
converting 5a-dihydroprogesterone into allopregnanolone, a potent allosteric agonist
of the GABAa receptor. In this way, 3a-HSD can control chloride conductance and
regulate the anxiolytic and anaesthetic actions of 3a-hydroxysteroids. Thus, 3a-
HSDs can regulate the occupancy of both a nuclear receptor and a membrane bound
ion-gated channel and may have profound effects on receptor function (Majewska et
al. 1986). Glucocorticoids have been shown to increase the transcription of the rat
3a-HSD gene. This effect is mediated by glucocorticoids binding to the occupied GR
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which can mediate its effects at both a distal and proximal glucocorticoid response
element (GRE) on the 5' flanking region of the 3a-HSD gene (Hou et al. 1998). The
ability of glucocorticoids to up-regulate 3a-HSD gene expression implies that these
steroids can regulate their own metabolism.
1.2.3 1ip-hydroxysteroid dehydrogenase type 1
liP-hydroxysteroid dehydrogenase type 1(11P-HSD 1) is a low affinity NADP(H)-
dependent enzyme and is expressed in a wide range of tissues including the liver,
lung, adipose tissue, gonads and the CNS (Krozowski et al. 1990). In vitro, hepatic
llp-HSD 1 activity is bi-directional, functioning as both a reductase and a
dehydrogenase (Monder & Lakshmi 1989). However, in primary hepatocyte cultures
and isolated purfused rat liver reductase activity predominates, suggesting that 11P-
HSD 1 reactivates intracellular glucocorticoids in intact tissues (Jamieson et al.
1995; Jamieson et al. 2000). This is supported by observations from 11P-HSD 1
deficient transgenic mice, which cannot metabolise corticosterone from implanted
pellets of 11-dehydrocorticosterone following adrenalectomy (Kotelevtsev et al.
1997). Therefore, alterations in hepatic 11P-HSD 1 may play an important role in
regulating glucocorticoid-mediated effects. Indeed, transgenic deficiency of 11P-
HSD 1 attenuates activation of glucocorticoid induction of gluconeogenic enzymes
in fasting animals (Kotelevtsev et al. 1997), and inhibition of lip-HSD 1 with
carbenoxolone improves whole body insulin sensitivity in man (Walker et al. 1995).
llp-HSD 1 is also expressed in adipose tissue where it functions predominantly as a
reductase (Napolitano et al. 1998).(Bujalska et al. 1999)1 lP-HSD 1 activity is higher
in omental fat compared with subcutaneous fat and can be enhanced by exposure to
both glucocorticoids and insulin. It has been suggested that 11P-HSD 1 plays a role
in the development of central obesity in situations of glucocorticoid excess (Bujalska
et al. 1999). Indeed, adipose tissue from obese humans has increased llp-HSD 1
activity (Rask et al. 2002). Also, transgenic mice over-expressing 11P-HSD 1
selectively in adipose tissue develop central obesity which is exaggerated on a high
fat-diet (Masuzaki et al. 2001).
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The brain is a key glucocorticoid target and glucocorticoids regulate developmental,
metabolic and neurotransmitter functions in the brain via both glucocorticoid and
mineralocorticoid receptors (McEwen et al. 1986). Glucocorticoids bind to
mineralocorticoid receptors under normal circumstances but when glucocorticoid
levels increase e.g. during stress or at the diumal peak they will bind to classical
glucocorticoid receptors (Reul & De Kloet 1985). 11(3-HSD 1 is highly expressed in
hippocampal neurones and other regions of the CNS (Moisan et al. 1992; Sakai et al.
1992) where it acts as a reductase to amplify glucocorticoid action (Rajan et al.
1995). Studies in 11(3-HSD deficient mice support the notion that 11(3-HSD 1 in the
brain has deleterious effects on cognitive function (Yau et al. 2001) and may
influence negative feedback regulation of the HPA axis by glucocorticoids
(Kotelevtsev et al. 1997; Harris et al. 2001). Impaired activity of llfl-HSD 1 in the
periphery could also have an effect on the HPA axis by increasing the metabolic
clearance rate of active glucocorticoid and thus increasing drive to the HPA
(Phillipou et al. 1996).
The expression of 11(3-HSD 1 is sexually dimorphic at least in the rat, with males
having higher hepatic and renal enzyme activity than females (Lax et al. 1978; Smith
& Funder 1991). This sexual dimorphism is due to differences in growth hormone
secretion patterns which are regulated by oestradiol (Low et al. 1994a). Studies of
urinary steroid metabolites in man have not been conclusive with increased, normal
and decreased 11(3-HSD activity reported in women compared with men (Andrew et
al. 1998; Stewart et al. 1999; Finken et al. 1999).
Glucocorticoids increase 11(3-HSD 1 expression and activity in both human
fibroblast cell cultures and rat vascular smooth muscle cells and hepatocytes in vitro
(Hammami & Siiteri 1991; Takeda et al. 1994; Jamieson et al. 1995) In vivo,
glucocorticoids induce llp-HSD 1 in liver and hippocampus, whist adrenalectomy
decreases hepatic 11(3-HSD 1 mRNA and activity (Walker et al. 1994; Low et al.
1994b).
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1.3 The role of glucocorticoids in obesity
The impetus for most studies of glucocorticoids and obesity is the similarities
between hypercortisolemic states (e.g Cushing's syndrome) and patients with
idiopathic obesity. Idiopathic obesity is associated with elevated urinary free Cortisol
excretion (Marin et al. 1992), impaired suppression of plasma Cortisol by
dexamethasone (Ljung et al. 1996) and enhanced sensitivity of plasma Cortisol to
exogenous ACTH (Hautanen & Adlercreutz 1993). These abnormalities of the HPA
axis are more pronounced and prevalent when the fat is distributed in a central or
visceral pattern in both men and women (Pasquali et al. 1993). The mechanism of
activation of the HPA-axis has not been established. Despite an increase in
glucocorticoid excretion rate indicated by an increase in urinary glucocorticoid
metabolites (Gray et al. 1956; Migeon et al. 1963), plasma Cortisol levels in obese
humans tend to be normal or even low (Migeon et al. 1963; Ljung et al. 1996;
Rosmond et al. 1998) implying that the rate of removal of Cortisol from the
circulation must be increased. This has been confirmed by in vitro tracer studies
(Strain et al. 1980).(Lottenberg et al. 1998)
Several studies in man have looked at the levels of specific urinary metabolites in
obesity. These showed that 5a-reductase activity may be enhanced in obesity,
(Andrew et al. 1998; Fraser et al. 1999) and that liP-hydroxysteroid dehydrogenase
activity is altered with impaired regeneration of Cortisol from cortisone (Stewart et
al. 1999; Rask et al. 2001). The combination of increased Cortisol inactivation and
impaired liver regeneration of Cortisol may lead to a compensatory activation of the
HPA axis via loss of the negative feedback signal, to maintain circulating Cortisol
levels.
Evidence for linking glucocorticoids and obesity has also come from animal studies
as several models of obesity have been characterised by increased secretion of
glucocorticoids e.g. the ob/ob mouse and the Zucker rat. The obese Zucker rat (fa/fa)
has frequently been used as an animal model of obesity since its description in the
early 1960s (Zucker & Zucker 1961). The phenotypic expression of obesity in the
obese Zucker rat is inherited as an autosomal recessive mutation in the leptin
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receptor gene (Chua et al. 1996). The result of this mutation includes numerous
metabolic and endocrine abnormalities (Bray et al. 1979) and obese Zucker rats are
hyperphagic (Bray & York 1972) and have adrenal hypertrophy (Bestetti et al. 1990;
Walker et al. 1992). The obesity in these animal models has been demonstrated to be
glucocorticoid dependent because many of the metabolic and endocrine impairments
are normalised or attenuated after adrenalectomy (Freedman et al. 1986) or
administration of the glucocorticoid receptor antagonist RU486 (Langley & York
1990). Corticosterone replacement reverses the effects of adrenalectomy
(Castonguay et al. 1986; Freedman et al. 1986; Fletcher 1986).
Conflicting results have been reported on the sensitivity of the HPA-axis to the
elevated circulating glucocorticoids in obese Zucker rats with reports of normal
(Guillaume-Gentil et al. 1990), increased (Bestetti et al. 1990; Plotsky et al. 1992)
and decreased (Castonguay et al. 1986; Routh et al. 1990) sensitivity of the
CRH/ACTH secretory system.
It is evident that the nature of and mechanisms underlying the abnormalities of the
HPA axis in obesity are unclear and therefore recent studies have focused on factors
that control tissue glucocorticoid concentrations.
Access of glucocorticoids to receptors is controlled at a tissue level by the 11(3-
hydroxysteroid dehydrogenases, which interconvert active and inactive
glucocorticoids. Tissue-specific alterations in 11(3-HSD1 have been reported in
obesity. llp-HSDl activity is higher in human visceral compared with subcutaneous
adipose tissues (Bujalska et al. 1997), and reactivation of Cortisol from cortisone is
increased selectively in adipose tissue (Rask et al. 2001) and decreased in liver of
obese humans (Stewart et al. 1999; Rask et al. 2001). Similar tissue-specific
differences were reported in obese Zucker rats (Livingstone et al. 2000).
Altered glucocorticoid metabolism by the ll(3-hydroxysteroid dehydrogenases in
obesity will therefore influence local tissue concentrations of active glucocorticoids
independently of circulating glucocorticoid levels.
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It is not known if 5a-reductase activity in specific tissues is altered in obesity nor if
alterations in 5oc-reductase activity can change glucocorticoid availability and
receptor activation within tissues. 5a-reductase type-1 and -2 are both capable of
metabolising glucocorticoids (Normington & Russell 1992). It is unclear whether one
or both of these isozymes are responsible for glucocorticoid metabolism in vivo as
previous studies investigating glucocorticoid metabolism often report on urinary
steroid metabolites and do not identify the isozyme or tissue involved. 5a-Reductase
is also expressed in adipose tissue and thus this tissue may be of increased
importance as a metabolic site in obesity (Perel et al. 1986; Zyirek et al. 1987).
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1.4 Aims of this thesis
The primary aim of this thesis was to study glucocorticoid metabolism by A-ring
reductases in relation to glucocorticoid receptor activation and obesity. The
following list of aims was addressed:
• To study localisation and activity of A-ring reductases in glucocorticoid target
tissues, necessitating establishment of new methodology.
• To assess whether glucocorticoid receptor binding of A-ring reduced
glucocorticoids influences glucocorticoid receptor activation.
• To quantify A-ring reductase expression and activity in glucocorticoid target
tissues in obese Zucker rats.
• To determine whether glucocorticoid receptor binding of corticosterone and its






Unless otherwise stated all chemicals, reagents and drugs were purchased from
Sigma, Poole, UK. All HPLC grade solvents were purchased from Rathburn
Chemicals, Walkerburn, UK. All epi-steroid standards were from Steraloids,
Newport, USA. All enzymes for molecular biology were purchased from Promega,
Southampton, UK. All radioactively labelled steroids and radioactive isotopes were
purchased from Amersham, Little Chalfont, UK. Sources other than these are
indicated.
2.2 Buffers and Solutions
Alkaline SDS solution: 0.2M NaOH, 1% w/v SDS
Borate Buffer: 8.25g boric acid, 2.7g NaOH, 3.5ml conc. HC1 and 5g BSA made up
to 1 litre with distilled water, pH 7.4. Stored at -20°C and thawed at room
temperature immediately before use.
Box Buffer: 20ml 20xSSC (saline sodium citrate) buffer, 50ml deionised formamide
made up to 100ml in DEPC-treated water (see below).
Caesium Chloride/TE solution: lOOg CsCl dissolved in 100ml TE buffer (see
below).
Calcium-free Buffer: Krebs buffer (see below) without CaCl2.
DEPC-treated water: Distilled water mixed with diethylpyrocarbonate (DEPC;
300pl/ 100 ml), shaken and left for 1-24 hours prior to autoclaving.
Deionised formamide: 150ml Formamide mixed with 15g Amberlite ion exchange
resin (MB-6113) (BDH, Lutterworth, UK) for 1 hour, filtered twice to remove
Amberlite and stored at -20°C.
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1Kb DNA ladder: 20p,g 1Kb ladder (Life Technologies, Paisley, UK), in 200jli1
distilled water with 10% (v/v) loading buffer.
0.5M EDTA (pH 8.0): 800ml water was added to 186.lg Na2EDTA.2H20. pH was
adjusted to 8.0 with NaOH and the volume adjusted to 1000ml.
GTE: 50mM glucose, 25mM tris (hydroxymethyl)-aminomethane (tris), lOmM
EDTA, pH8.0
Hepatocyte incubation buffer: As Krebs buffer (see below) but with 120mM NaCl
and 5mM glucose, lOmM lactate, 2mM glutamine, ImM pyruvate and BSA (RIA
grade, Fraction V) (2g/100ml buffer). Dialysed overnight with dialysis tubing, size 1-
8/32" (Medicell International Ltd, London, UK) against a large volume (10L) of
Krebs buffer and stored at 4°C.
2xHybridisation buffer: 1.2M NaCl, 20mM Tris-HCl, 2x Denhardts, 2mM K2-
EDTA, 0.2mg salmon sperm DNA, 0.2mg yeast tRNA and 2g dextran sulphate made
up to 10ml in DEPC-treated water, stored at -20°C.
Krebs'-Ringer Bicarbonate (KRB) Buffer: 118mM NaCl, 3.8mM KC1, 1.19mM
KH2P04, 2.54mM CaCl2, 1.19mM MgS04, 25mM NalTCCL in distilled water, pH
7.4. Stored at 4°C and supplemented with 0.2% w/v glucose immediately before use.
LB agar: Luria-Bertoni broth with 15g agar per litre broth added before autoclaving.
Loading buffer: 40% sucrose w/ v, 0.25% bromophenol blue (w/v) in distilled
water.
Luria-Bertoni broth: lOg bactotryptone, 5g bacto yeast extract, 5g NaCl made up to
1 litre with distilled water and autoclaved immediately.
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Luciferase assay buffer: 40mM Tricine, 67mM DTT, 0.2mM Na2EDTA.2H20,
2mM MgS04, 0,25mM coenzyme A, pH 7.8.
Lysis buffer: 25mm Tris phosphate pH 8.0, 2mM DTT, 1% Triton X-100, 10%
glycerol.
Molybdate Buffer: lOmM Tris-HCl, 2mM DTT, 1.5mM EDTA, 0.1M sodium
molybdate, 10% glycerol, pH 7.2. Stored at 4°C.
lOx MOPS buffer: 0.2M 3-(N-morpholino) propanesulfonic acid, 50mM Na acetate,
5mM EDTA, pH 7.0.Autoclaved before use.
4% Paraformaldehyde in 0.1M phosphate buffer: 20mM NalEPCE, 80mM
Na2HP04 in 11 DEPC-treated water, heated to 80°C prior to addition of 40g
paraformaldehyde. Stirred for 1 hour to dissolve and stored at 4°C.
Phosphate Buffer: 0.2M NaH2P04 0.6M Na2HP04; 5mM EDTA. Autoclaved before
use.
Phosphate buffered Saline (PBS): 0.1M phosphate buffer with 137mM NaCl,
2.7mM KC1 in distilled water, pH 7.4, autoclaved before use.
5M Potassium Acetate: 60ml of 5M potassium acetate, 11.5ml glacial acetic acid,
28.5ml water.
2xPre-hybridisation buffer: 1.2M NaCl, 20mM Tris-HCl, 2x Denhardt's, 2mM K2-
EDTA, lOmg salmon sperm DNA, 0.2mg yeast tRNA made up to 10ml in DEPC-
treated water, stored at -20°C.
lx Restriction Digest buffer: 500mM NaCl, 500mm Tris-HCl pH 8.0, llOmM
MgCh, 60mM (3-mercaptoethanol, lmg/ml bovine serum albumin.
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lOx Reverse Transcription buffer: 0.1M Tris-HCl, 0.5M KC1, 1% Triton X (ready
mixed from Promega).
RNase Buffer: 0.5M NaCl, lOmM Tris-HCl, ImM K2-EDTA in 10ml distilled
water.
2Ox Saline Sodium Citrate buffer (SSC): 3M NaCl, 0.3M Na citrate in 11 DEPC-
treated water, pH 7.0, autoclaved before use.
Sodium Phosphate Buffer: 40mM NalTPO^ 0.32M sucrose, ImM DTT.
Sucrose buffer: 250mM sucrose, lOmM Hepes, pH7.5.
T4 DNA ligase buffer (lx): 30mM Tris-HCl (pH 7.8), lOmM MgCl2 10mM DTT,
ImM ATP (ready mixed from Promega).
IOxTBE buffer: 0.9M TRIZMA base, 0.9M Boric acid, 20mM K2-EDTA in
distilled water.
TE buffer: lOmM Tris-HCl, ImM EDTA, pH 7.5, autoclaved before use.
Thermophilic DNA polymerase lOx reaction buffer: 500mM KC1, lOOmM Tris-
HCl and 1% Triton X (ready mixed from Promega).
5xTranscription optimised buffer: 200mM Tris-HCl, 50mM NaCl, 30mM MgCl2,
and lOmM spermidine (ready mixed from Promega).
Wash Buffer One: lx SSC buffer, 0.1% sodium dodecyl sulphate (SDS) made with
DEPC-treated water.
Wash Buffer Two: 0.3x SSC buffer, 0.1% SDS made with DEPC treated water.
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2.3 Animal Maintenance
Male lean and obese Zucker rats (Harlan Orlac, Bicester, UK) and male Wistar rats
(Charles River, Kent, UK) were obtained at 4-6 weeks of age. Animals were
maintained under controlled conditions of light (lights on 0800 h - 2000 h) and
temperature (21-22°C), and allowed free access to standard chow (Special Diet
Services, Witham, UK) and drinking water.
2.3.1 Surgery
The surgical procedures were carried out by Dr. CJ Kenyon of the Molecular
Medicine Centre, Western General Hospital. Six week-old lean and obese Zucker
rats were anaesthetised with 4% halothane and either bilaterally adrenalectomised
(ADX) or sham-operated through dorsal incisions and the incisions closed with
staples. All rats were maintained on 0.9% saline as drinking water to allow the ADX
rats to maintain their electrolyte balance.
2.4 Maintenance of cell lines
HeLa (a human cervical cancer cell line) and H4IIE, 2S-FAZA (rat hepatoma cell
lines) and HepG2 (a human hepatoma cell line) cells were maintained at 37°C with
5% CO2, 95% O2 in Dulbecco's minimal essential medium (DMEM) supplemented
with 10% heat-inactivated foetal calf serum, penicillin /streptomycin (100pg/ml) and
L-glutamine (2mM). A summary table of cell lines used is detailed in Table 2.1.
Cells were routinely split 1:4 when confluent. To harvest and split cells, they were
washed with serum-free DMEM (8ml), then treated with trypsin/EDTA in HBSS
(1.5ml) for l-2min to release the cells from the flask surface, then resuspended in
DMEM (6.5ml) with serum. Cells were then diluted as appropriate in DMEM with
serum.
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Cell line Animal Cell type Reference
H4UE Rat Hepatoma (Pitot et al.
1964)
2S-FAZA Rat Hepatoma (Voice et al.
1996)




(Gey et al. 1952)
Table 2.1: Cell lines summary table.
2.5 Enzymology
2.5.1 Preparation of tissue homogenates
Tissues were frozen routinely on dry ice directly after dissection from the animal and
stored at -80°C until use. Tissues were roughly dissected while frozen and 0.5-lg of
tissue was homogenised in sucrose buffer (4-5ml) with an Ystral mechanical
homogeniser (Scientific Instruments Centre, Liverpool, UK). Homogenates were
centrifuged at lOOOg at 4°C for lOmin to allow any small amounts of unhomogenised
tissue to sink to the bottom and the supernatant was removed.
2.5.2 Sub-cellular fractionation of liver
Sub-cellular fractions of liver were prepared by differential and sucrose gradient
centrifugation of the homogenate as described by Fleischer and Kervina (Fleischer &
Kervina 1974). Briefly, rat liver was homogenised in 5 volumes of sucrose buffer.
The homogenate was then centrifuged at lOOOg x 10 min and the resulting pellet
contained the nuclear fraction and plasma membrane. The supernatant was filtered
through several layers of cheesecloth and centrifuged at 25000g x 10 min in a
Beckman J20 centrifuge. The residue from this second spin is enriched in
mitochondria. The supernatant was once again decanted and centifuged at 34000g x
30 min in a Beckman J20 centrifuge. The pellet containing heavy microsomes was
resuspended in 0.25M sucrose (2ml) and the supernatant centrifuged at 124000g x 60
min in a Beckman Optima TLX ultracentrifuge . The resulting supernatant was kept
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as cytosol and the microsomal pellet resuspended in 0.25M sucrose (2ml). The
fractionation process is summarised in Figure 2.1.
2.5.3 Protein Estimation
The protein concentration of tissues and sub-cellular fractions were determined
colorimetrically using a Bio-Rad protein assay kit (Bio-Rad, Hemel Hempstead,
UK). A range of protein standards (0.1-1.2mg/ml) was prepared in duplicate in
distilled water from the provided protein standard (bovine serum albumin). Protein
assay dye reagent was diluted 1:4 in distilled water and filtered through Whatman
No. 1 filter paper prior to use. Diluted protein assay dye reagent (1.96 ml) was added
to protein standard (40pi) or appropriately diluted tissue homogenate in a
borosilicate glass tube, vortexed to mix and left at room temperature for 15 min-1
hour to allow colour development. Absorbance of samples at A595nm was measured
using a Shimadzu UV/ visible recording spectrophotometer and the concentration of
protein in each sample was estimated from the standard curve. An example of a
standard curve is shown in Figure 2.4.
2.5.4 In vitro assay of 5a-reductase activity
The assay conditions to measure the bioactivity of 5a-reductase, 5(3-reductase and
3a-hydroxysteroid dehydrogenase were determined. The starting point for the
development of the assay was an assay used previously to measure 5a-reduction of
testosterone and androstenedione in tissues and cells (Mahendroo et al. 2001;
Reichert et al. 2001).
In our assay, we attempted to quantify the enzymes in liver by measuring the
conversion of [3H]4-corticosterone to [3H]4-5a-dihydro- and tetrahydro-
corticosterone and [3H]4-5(3-dihydro- and tetrahydro-corticosterone. Initially liver
homogenates were incubated in duplicate at 37°C in sodium phosphate buffer with
NADPH (2mM) and [3H]4-corticosterone (50nM) in a total volume of 250pl for 4h.
The reaction was stopped with 10 volumes of HPLC grade ethyl acetate. The organic
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Figure 2.1 : Flow diagram for the subcellular fractionation of rat liver
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nitrogen at 50°C. Steroid extracts were-re-suspended in the mobile phase described
above and injected into the HPLC system under the optimised conditions described
in chapter 2.5.6.
Under these conditions no stable 5a-reductase activity could be detected therefore a
series of different tissue preparations were investigated.
Firstly, isolated hepatocytses (2 million cells /ml) were prepared as described in
2.11.1.3 and incubated with NADPH (2mM) and [3H]4-corticosterone(100mM) at
37°C in sodium phospate buffer for 1,2,4,6,and 24h. 5a-reductase bioactivity was
observed in these isolated hepatocytes, however this was not very reliable as 5a-
reductase activity could not always be measured in this preparation. On many
occasions, corticosterone was converted solely to 11-dehydrocorticosterone (A)
indicating that the hepatocytes were no longer viable.
5a-Reductase is a microsomal enzyme and therefore we tried the assay under the
same initial conditions in microsomes and different sub-cellular fractions of liver
including the nuclear fraction, mitochondria, heavy microsomes and cytosol. These
were prepared as described in 2.5.2. All assays were carried out with two different
tissue concentrations (20pg and 200pg) and aliquots were removed at
10,30,60,120,240 and 360 minutes. The only activity that was detected in any of
these preparations was 5(3-reductase activity in cytosol which would be expected as it
is a cytosolic enzyme. As a positive control, the assay was performed in prostate
using corticosterone and testosterone as substrates. 5a-Reduction of testosterone but
not corticosterone could be measured in prostate.
This time-course was repeated using Hep-G2, 2S-FAZA, fresh liver, fat and adrenal
but still no 5a-reductase activity could be measured.
To try to preserve 5a-reductase activity, buffers used successfully to synthesise
reduced metabolites of aldosterone were used. The first buffer included soybean
trypsin inhibitor to prevent degradation of the enzyme (Mcdermott et al. 1985) and in
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the second buffer an NADPH generating system was used as a constituent of the
incubation buffer to generate more co-factor for the enzyme (Morris et al. 1982).
These buffers were prepared as follows.
1) Sucrose 0.25M, potassium phosphate buffer pH 7.2 (lOOmM), DTT (5mM)
soybean trypsin inhibitor (50pg/ml)
2) Tris-HCl buffer pH 7.4 (50mM), glucose-6-phosphate (50mM), glucose-6-
phosphate dehydrogenase (25 units per ml), NADPH (500pM), MgCl2 (5mM).
None of these modifications resulted in detection of 5a-reductase metabolism of
corticosterone. A summary of the conditions used is given in Table 2.2.
2.5.5 In vitro assay of 5p-reductase activity
Preliminary studies were carried out in order to determine the protein concentrations
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required to ensure that the percentage conversion of [ H]4-corticosterone to [ H]4-
3a,5(3 tetrahydrocorticosterone by each tissue was between 10 and 40% after 240min
incubation.
Cytosol at the appropriate concentration (40mg/ml protein) was prepared in duplicate
in sodium phosphate buffer, with NADPH (2mM) and [3H]4-corticosterone (50nM)
in a total volume of 250pl. Tissue blanks were prepared in duplicate in sodium
phosphate buffer with NADPH and [3H]4-corticosterone in the absence of cytosol.
Samples not containing co-factor were prepared in duplicate in sodium phosphate
buffer with [3H]4-corticosterone and cytosol in the absence of NADPH to ensure the
reaction monitored was driven by the presence of NADPH. Samples not containing
protein were included to monitor the stability of the substrate under the incubation
conditions. Samples were incubated at 37°C for 240min. Following incubation, the
reaction was stopped by the addition of ethyl acetate (10 volumes) to each tube, and
tubes were vortexed. The organic phase (containing steroids) was removed to a fresh
tube and solvent evaporated under oxygen free nitrogen at 50°C.
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When possible, where results between different groups of animals were to be
compared, incubations were carried out at the same time.
Tissue/Cell Preparation 5a-Reductase 5|3-reductase activity
Frozen liver homogenate X ✓
Fresh liver homogenate X ✓
Fresh liver slices X V









Nuclear Fraction X X
Mitochondria X X
Heavy Microsomes X X
Isolated Hepatocytes V X
HEP-G2 cells X X
2S-FAZA cells X X
H4IIE cells ✓ V
Kidney X X
Fat X X
Prostate with testosterone ✓ X
Prostate with corticosterone X X
Table 2.2: Determination of 5a-reductase and 5(3-reductase bioactivity





Figure 2.2: Protein Assay Standard Curve
A Bio-Rad protein assay kit was used to colorimetrically determine the protein
concentration of tissue homogenates. Absorbance of protein standards of known
concentrations (0.1-1.2mg/ ml) at X595nm was measured using a Shimadzu UV/
visible recording spectrophotometer. A standard curve was produced allowing
subsequent estimation of protein concentrations in each tissue homogenate. Samples
were prepared in a dilution allowing estimation in the middle range of the curve.
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2.5.6 High - Performance Liquid Chromatography
2.5.6.1 Preliminary work
An existing protocol for the measurement of A-ring reductase activity in rat liver
using corticosterone as a substrate was not established in our laboratory. In order to
measure metabolites of corticosterone by HPLC, separation conditions had to be
optimised.
The high-performance liquid chromatography (HPLC) system comprised an auto-
sampler and mobile phase pump (Waters, UK), a Symmetry Shield C8 column
(15cm diameter, 3.5pM pore size, (Waters, UK), a radioactivity monitor linked to a
scintillation fluid pump (Berthold, UK), a dual wavelength absorbance UV detector
(Waters, UK) and a column heater/chiller (CIL, France). The system was controlled
by the Winflow computer programme (JMBS Developments, France).
Chromatography is a separation technique where component molecules in a sample
mixture are transported by a mobile phase through a column of stationary phase
material. In our HPLC system, the mobile phase is a liquid solvent system consisting
of different percentages of water, acetonitrile and methanol. The solution properties
of the liquid mobile phase compete with the retention forces of the column to
determine the distribution ratio and hence retention time of the molecules in a
sample. The rate of migration of component molecules through the column depends
on the distribution of the molecules between the mobile phase and the column. The
factors that influence the distribution and therefore retention times are composition
of the mobile phase, type and properties of the stationary phase, column temperature
and the hydrophobicity/ hydrophilicity of the analyte. Analytes eluting from the
column are then detected by a number of characteristics, in this thesis by ultra-violet
(UV) and radiochemical detection.
Non-radioactive standards were employed to optimise resolution conditions with an
on-line dual wavelength absorbance UV detector. The wavelength of UV detection
was determined by the structural characteristics of the analytes. Corticosterone, 11-
dehydrocorticosterone and other metabolites with an ene-one moiety in the A-ring of
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their steroid structure absorb UV light maximally at around 240-244nm. However
this feature is not present in the tetrahydro-metabolites leaving only C-0 bonds
absorbing at 195nm. This made it necessary to ensure that the composition of the
mobile phase was comprised of low UV cut-off solvents. When selecting the solvents
for a HPLC mobile phase, the overall solvent strength is adjusted to give a suitable
retention by mixing together one weakly eluting solvent with one or more strongly
eluting solvents. In reversed-phase HPLC, the weakest solvent and therefore the most
commonly used is water. The other solvents are usually chosen from methanol,
acetonitrile or tetrahydrofuran. All three of these solvents have low viscosity, a
reasonably low toxicity level and a low UV cut-off. Acetonitrile has the lowest UV
cut-off all of these, however still has a strong absorbance at this short wavelength
and therefore adds to the level of background detected.
Various mobile phases containing different percentages of HPLC grade water,
acetonitrile and methanol at different flow rates and column temperatures were
investigated to aid resolution of the reduced metabolites.
Our aim was to separate all of the steroids in Table 2.1. Our initial chromatography
conditions were as follows based on an existing protocol to separate corticosterone
and 11-dehydrocorticosterone only.
• Mobile Phase : water (65%), acetonitrile (10%), methanol (25%)
• Flow rate : 1.5ml/min
• Column temperature : 30°C
These conditions successfully separated most of the steroids, however the most
important 5a - and 5(3-isomers were not separated. These steroids are stereoisomers
and are very similar structurally to each other. The 5a-reduced glucocorticoids are







11-dehydrocorticosterone (A) 21.98 y
6a-hydroxycorticosterone 3.17 y




















Table 2.3: Initial retention times for separation of corticosterone and
its metabolites.
Table shows retention times of corticosterone and its metabolites under
the following chromatographic conditions : mobile phase : water (65%),
acetonitrile (10%), methanol (25%), flow rate 1.5ml/min, column
temperature 30°C.
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A mobile phase consisting of water (65%), acetonitrile (20%) and methanol (15%) at
a flow rate of 0.7ml/min and a column temperature of 40°C allowed resolution of the
dihydro-metabolites (Figure 2.3).
A mobile phase of water (60%), acetonitrile (15%) and methanol (25%) at a flow rate
of 1.2ml/min and a column temperature of 40°C separated the tetrahydro-metabolites
from corticosterone but the retention times for 5a- and 5(3-THB were exactly the
same as each other (Figure 2.4. (a)). To try to increase the resolution of the
tetrahydro-metabolites the flow-rate of the mobile phase was slowed to 0.7ml/min
and the column temperature decreased to 10°C. Decreasing the column temperature
increases the mobile phase viscosity giving a decreased rate of mass transfer and
decreased solubility of the metabolites. The tetrahydo-metabolites maintain their
shape and become more rigid exacerbating the small differences in their structures
resulting in increased separation with only a 25% overlap between the two
stereoisomers, however the run-times were very long (Figure 2.4 (d)).
A mobile-phase modifier, (3-cyclodextrin was then added to the mobile phase as
previous literature recommended its usefulness in the separation of mixtures of chiral
compounds at low temperatures. Cyclodextrins are cyclic chiral carbohydrates
composed of six, seven or eight glucopyranose units. The monomers are configured
such that the cyclodextrin resembles a hollow truncated cone or barrel-like cavity.
The internal lining is essentially hydrophilic composed of methylene and oxygens of
the 1,4-glycosidic bonds. When used with reverse phase solvents these chiral-cavity
media act by allowing selective occlusion or intercalation of one stereoisomer into
chiral cavities in the matrix of the phase, therefore exaggerating the tiny differences
between the steroid structures. Addition of (3-cyclodextrin to a final concentration of
2mM separated 5a- and 5(3-THB by 10 minutes and halved the run-time however the
retention time for corticosterone was exactly the same as 5aTHB. Repetition of the
same run but with a final concentration of ImM (3-cyclodextrin in the mobile phase
resulted in complete separation of the peaks with at least three minutes between each
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Figure 2.3: Separation of 5a- and 5p-dihydro-metabolites of corticosterone
by HPLC
Figure shows separation of 5a- and 5(3-dihydro-metabolites of corticosterone by
HPLC under the following chromatographic conditions: mobile phase water














Figure 2.4: Separation of 5a and 5(3--tetrahydro-metabolites of
corticosterone by HPLC
Figure shows chromatograms of increased separation of 5a-reduced steroids
with decreasing temperature and flow rate. The mobile phase for each
chromatogram was water; 60%, acetonitrile; 15%, methanol; 25%. Panel (a)
flow rate = 1.2ml/min, temp = 40°C. Panel (b) flow rate = 0.7ml/min, temp =
25°C. Panel (c) flow rate = 0.7ml/min, temp = 15°C. Panel (d) flow rate =
























Figure 2.5: Separation of 5a- and 50- tetrahydro metabolites of
corticosterone with 0-cycIodextrin
Figure shows chromatogram of separated 5aTHB, 50THB and corticosterone
UV standards by HPLC upon addition of 0-cyclodextrin (ImM) to the mobile
phase (water 60%: acetonitrile 15%: methanol 25%), 0.7ml/min, 10°C
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2.5.6.2 HPLC conditions for in vitro 5(3-reductase assay
Steroid extracts from single time point experiments were re-suspended in mobile
phase 200pl (60% water, 15% acetonitrile, 25% methanol) containing (Tcyclodextrin
(ImM). An aliquot (200pl) of each sample was injected into the HPLC system. The
flow rate of the mobile phase was 0.7ml/ min and the flow rate of the scintillant
(Quicksafe Flow 2; Zinsser, UK) was 1.4ml/ min to achieve optimal mixing and
counting efficiency. The column temperature was maintained at 10°C to improve
chromatography and maintain stability of retention times. Non-radioactive standards
were injected at the start of each batch of samples to confirm peak identity by UV
detection (k 195nm). The approximate retention times for [3H]4-corticosterone and
[3H]4-3a,5|3- tetrahydrocorticosterone were 46min and 42min respectively, with
greater than lmin between the two peaks. Peaks were less than lmin 30s wide and
peak height was at least 50x background.
Following chromatography, the area under each peak was integrated using the
"3
Winflow software to quantify the percentage conversion of [ H]4-corticosterone to
[3H]4-3a,5P-tetrahydrocorticosterone. Peaks were accepted for quantification if they
had areas greater than 2x the background. The percentage conversion in each tissue
sample was corrected for the "apparent conversion" occurring in tissue blanks
included in each experiment, which was always <4%.
2.6 Gas chromatography / mass spectrometry
2.6.1 Extraction of steroids
2.6.1.1 Extraction from cell medium
Medium was retained at -20°C from H4IIE cells cultured as described in 2.5.
Steroids in medium were recovered by solid-phase extraction. Sep-pak CI8
cartridges (Water, Herts, UK) were activated using methanol (5ml) followed by
water (5ml). Medium was loaded on to the column and the eluant discarded. The
column was washed with water (5ml) and steroids eluted in methanol (2ml). The
eluant was dried under a stream of oxygen free nitrogen at 60°C and resuspended in
54
ethyl acetate (2ml) and water (200(0.1). The organic layer was separated and dried
before derivatisation to form methoxime-trimethylsilyl derivatives as described
previously (Best & Walker 1997).
2.6.1.2 Extraction from tissues
A solution of methanol containing acetic acid (1%) (10 volumes, w/v) was added
together with Wistar rat liver (2g). The sample was then sonicated in an ultrasonic
bath for 5 min, left overnight at room temperature and centrifuged at 3000 x g for 5
min. the organic phase was collected and the rest of the extract residue washed again
with methanol (20ml) containing acetic acid (1%) and centrifuged. The two organic
phases were pooled and evaporated to dryness under a stream of oxygen free
nitrogen at 60°C, taken up in 1ml of methanol:water (40:60,v/v) and sonicated for
5min. A clean-up step was performed by solid-phase extraction with Sep-pak C18
cartridges as described in 2.6.1.1. The unconjugated steroid fraction was eluted with
5ml methanokwater (85:15, v/v), filtered through a Millipore PFTE membrane
(0.45pm) and dried. The dried samples were then hydrolysed and derivatised as
described previously (Best & Walker 1997).
2.6.2 Gas chromatography / mass spectrometry
Gas chromatographic mass spectrometric analysis was performed in electron impact
mode using a Polaris Q ion-trap GCMS (Thermofinnigan, UK) as described
(Livingstone et al. 2000). The identities of steroids were confirmed using analytical
standards obtained from Steraloids (Newport, USA). The level of detection for
steroids was < InM. All solvents were HPLC distilled grade (Rathburn, Walkerburn,
UK) and reagents were obtained from Sigma (Poole, UK).
2.7 RT-PCR
RT-PCR allows the detection and amplification of specific mRNA species from
isolated total RNA. Using 01igo(dT)i5 primers, the reverse transcriptase enzyme
transcribes mRNA into double stranded cDNA - the necessary template for Taq
polymerase. Subsequent PCR amplification consists of a number of cycles, during
which the cDNA template is repeatedly denatured, annealed with target-specific
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primers and replicated using Taq polymerase. Following 20-40 cycles the amplified
DNA can be analysed for size and quantity using gel electrophoresis.
Only RNase free, sterile solutions and equipment were used for RT-PCR in order to
prevent degradation of target RNA by exogenous RNases and contamination of




Liver and prostate were frozen routinely on dry ice immediately after dissection from
the animal. Cultures of cell lines at third passage were removed from the culture
flask directly into Trizol (7.5ml) and frozen on dry ice. Tissues were stored at -80°C
until required.
2.7.2 RNA Extraction
RNA extraction was carried out using TRIzol Reagent (Gibco, UK) - a mono-phasic
solution containing phenol and guanidine isothiocyanate. This reagent maintains
RNA integrity whilst disrupting cells and dissolving cell components.
2.7.2.1 Homogenization
TRIzol was added per 50-100mg tissue or powdered tissue whilst frozen and samples
were homogenized on wet ice using an Ystral mechanical homogeniser (Scientific
Instruments Centre, UK). Samples were centrifuged at 12,000 x g at 4°C for lOmin
to remove insoluble material and small amounts of unhomogenized tissue. The
resulting supernatant was removed to a fresh sterile eppendorf.
2.7.2.2 Phase Separation
Following homogenisation, samples were allowed to equilibrate to room temperature
(estimated 20°C) then left for 5 minutes to allow complete dissociation of the
nucleoprotein complexes. For cell experiments, 1ml aliquots were removed from the
56
original 7.5ml and the protocol followed as for homogenised tissue. Chloroform
(0.2ml per ml TRIzol used in original homogenisation) was added to each sample.
Samples were shaken vigorously by hand for 15 seconds then incubated at room
temperature for 3 minutes. Samples were centrifuged at 12,000 x g at 4°C for 15min
resulting in a lower red phenol-containing phase (containing proteins), an interphase
(containing DNA and denatured proteins) and an upper aqueous phase containing
RNA.
2.7.2.3 RNA Precipitation
The upper aqueous phase from each sample was transferred into a fresh eppendorf
and the RNA was precipitated by addition of isopropanol (500pl per ml TRIzol in
original homogenisation). Following addition of isopropanol, samples were
incubated at room temperature for lOmin prior to centrifugation at 12,000 x g at 4°C
for lOmin. The RNA precipitate forms a visible gel-like pellet on the side of the
tube.
2.7.2.4 RNA Wash
Following centrifugation the supernatant was removed and the RNA pellet was
washed with ethanol (75% 1ml/ ml TRIzol in original homogenisation). Pellets were
vortexed and centrifuged at 7,500 x g at 4°C for 5min.
2.7.2.5 RNA Resuspension
Following the RNA wash, the ethanol was removed and the pellets were briefly air-
dried for 5min, being careful not to completely dry out the RNA, which greatly
reduces solubility. RNA pellets were dissolved in DEPC-treated water (10-50pl
depending on pellet size) by pipeting followed by incubation at 60°C for lOmin. For
cell experiments all of the pellets from the original 7.5ml were pooled together and
then resuspended in DEPC-treated water (20pl). RNA was stored at -80°C until
required.
2.7.2.6 RNA Quantification
Before use, RNA was quantified using a GeneQuant RNA/ DNA Calculator
(Pharmacia Biotech, Sweden). RNA was diluted 1:25-1:100 in DEPC-treated water
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and the optical density at X260nm (wavelength for RNA) and )t280nm (wavelength
for DNA) was determined to assess concentration and purity. RNA was only used
with a A260/A280 of between 1.5 and 1.8.
2.7.3 Reverse Transcriptase Reaction
First strand cDNA synthesis was performed using the Reverse Transcription System
(Promega, UK). Total RNA (1 pg) was reverse transcribed in a reaction mixture
containing MgCU (5mM), lx reverse transcription buffer, dATP, dCTP, dGTP and
dTTP (ImM), Rnasin (20U), 01igo(dT)]5 primers (0.5pg) and AMV-reverse
transcriptase (15U) made up to 20pl in DEPC-treated water. Samples were
incubated at 42°C for 45min followed by 5min at 95°C then 5min on ice to inactivate
enzymes and prevent binding to complementary DNA.
Negative control reactions for each RNA sample were performed in parallel (made
up as above but in the absence of AMV-reverse transcriptase) in order to determine
genomic DNA contamination. Additionally, a negative control reaction containing
water instead of RNA was performed to determine RNA contamination of the
Reverse Transcriptase System reagents.
2.7.4 PCR Reactions
cDNA template (5|il) was used in each PCR reaction containing lx Thermophilic
DNA polymerase Reaction Buffer, MgCb (1.5mM), dATP, dCTP, dGTP and dTTP
(200pM), upstream primer (40pmol), and downstream primer (40pmol) made up to
50pl in DEPC-treated water. One TaqBead (1.25U) was added to each reaction tube
before starting the required PCR programme. A negative control reaction containing
DEPC-treated water rather than cDNA was prepared in parallel to determine
contamination of PCR reagents.
PCRs were carried out on an Eppendorf Mastercycler Gradient (Eppendorf,
Germany) with a heated lid. Samples were heated to 95°C for 3min for initial
denaturation, then underwent 35 cycles of PCR amplification (denaturation at 95°C
for 45s, primer annealing at primer-specific temperature for 30s and elongation at
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72°C for lmin 30s). Upon completion of the PCR programme, samples were
incubated at 72°C for a further 5min to ensure elongation of products to full length
and chilled to 4°C prior to gel electrophoresis. The 5a-Reductase type 1, 2 and lb
primers were gifts from Dr Dawn Livingstone. The 3a-HSD primers have been
described previously (Lin et al. 1999). To confirm authenticity of PCR products,
primers and templates were fully sequenced by Miss Alison Condie (Genetics Core,
Wellcome Trust Clinical Research Facility, Edinburgh) using the ABI PRISM®
sequencing kit (Applied Biosystems).
Specific primer sequences and PCR conditions are detailed in Table 2.4.
2.8 Real-Time PCR
2.8.1 Tissue preparation
Subcutaneous and omental adipose tissue was removed from lean and obese male
Zucker rats at sacrifice and snap frozen.
2.8.2 RNA extraction and Quantification
Total RNA was isolated from frozen subcutaneous and omental adipose tissue by
homogenising fat (250mg) in TRIzol (1ml). RNA was purified using RNA aid RNA
binding matrix (Anachem, Luton, UK), washed three times, and dissociated by
addition of DEPC FLO/DTT/Rnasin. Total RNA was quantified as described above in
2.7.2.6.
2.8.3 Real -Time PCR reactions
RNA (500ng) was reverse transcribed as described in 2.7.3. cDNA was diluted three
times and transcript level quantification for 5a-reductase type 1 was performed with
Real Time PCR primer-probe sets using the 7900MT sequence detection system (PE
Applied Biosystems, Cheshire,UK) with the following primers and probes: 5'-
CTGTTTCCTGACAGGCTTTGC-3'(forward), 5'-GCCTCCCCTGGGTATCTTGT-
3' (reverse), and 5' -6-FAM-CAGACCACATCCTGAGGAATCTGAGAAAACC-
TAMRA-3' (probe). Rat cyclophillin (PE Applied Biosystems, Cheshire, UK)
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primers and probes were included in a singleplex reaction to normalise the transcript
levels. A standard curve for each primer-probe set was generated in triplicate by
serial dilution of cDNA pooled from different animals. Samples for cyclophillin and
5a-reductase type 1 were run in duplicate and the mean values were used to calculate
transcript level. Values were calculated as a relative fold change in mRNA from an
internal control sample using standard curves. RT negative controls and intron
spanning primers were used to examine for genomic DNA and prevent amplification.
2.9 Northern Analysis of mRNA
2.9.1 Extraction of RNA
Total RNA was extracted from liver and H4IIE cells by the TRIzol method as
described above (2.7.2).
2.9.2 RNA electrophoresis and capillary transfer
Total RNA was separated by electrophoresis on an agarose formaldehyde denaturing
gel (1.2 %). A gel (100ml) was prepared by melting of agarose (1.2g) in DEPC-
treated water (88ml), adding formaldehyde (40%) and lOx MOPS buffer (10ml) and
pouring into a gel mould with appropriately sized combs in place. RNA was prepared
for electrophoresis by aliquoting RNA (20(tg), adding DEPC-treated water to bring
the total volume to IOjliI, then adding deionised formamide (10(d), formaldehyde
(2.5|il) and lOx MOPS buffer (2.5(d) to give a total volume of 25(tl. The sample was
mixed and denatured by incubating at 65°C for 15 min. Ethidium bromide was added
to the loading buffer (lpl per 50(ll loading buffer) and 2(0.1 of this mix was added to
each sample of denatured RNA. The RNA was loaded into the wells on the gel and
electrophoresis performed at 80V for 4-6 hours until the front band of the loading
buffer was % of the way down the gel. The gel was photographed under UV light
(254nm) with as little exposure as possible to minimise RNA damage. The gel was
soaked in 20x SSC buffer for 15min before blotting onto a nylon membrane (Zeta-
Probe® GT, (Bio-Rad, Hemel Hempstead, UK). A wick of Whatman 3MM filter
paper was placed over an upturned gel mould in a plastic tray containing 20x SSC
buffer and the gel was placed on top. A piece of nylon membrane cut to the same
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size as the gel and pre-wetted in the 20x SSC was smoothed on top of the gel and this
was covered with 3 layers of 3MM filter paper and approximately 5cm of paper
towels. A glass plate was placed on the top to secure the apparatus and a light weight
balanced on the top. Capillary transfer was allowed to take place overnight at room
temperature.
The next day, the membrane was washed in 20x SSC to remove any gel and the
efficiency of the transfer was checked by photographing the gel and the membrane
under UV light (254nm). The membrane was dried between two sheets of 3MM filter
paper at 80°C for 2 hours and the RNA cross-linked under UV light.
2.9.3 Hybridisation to 32P-labelled cDNA
The nylon membrane was soaked in 20x SSC buffer for 5min, then placed in an
Hybaid hybridisation bottle containing 20% SDS (10ml) and phosphate buffer
(20ml) that had been warmed to 55°C. To this was added denatured salmon testes
DNA (lOmg/ml; lOOpl). The membrane was pre-hybridised in an Hybaid
hybridisation oven at 55°C for at least 2 hours. The 32P-labelled cDNA probe was
added to the pre-hybridisation buffer, and the membrane hybridised with the probe
overnight at 55°C. The probe was then disposed of and the membrane rinsed with
wash buffer one. This was followed by one wash in wash buffer one at room
temperature for 30min, one wash in wash buffer one at 55°C for 30 min and one
wash in wash buffer two at 55°C for 30 min. The membrane was wrapped in cling¬
film and exposed to a Fujifilm imaging screen for 1-48 hours and the level of
hybridised probe quantified using a Fuji FLA2000 fluorescent image analyser. The
membranes were then rehybridised with U1 cDNA in the same way to control for
RNA loading and transfer. The level of expression of the RNA of interest was




























Upstream: 5'-TGA 48 35
TCC ACT ACG TGC
AAA GG -3'
Downstream: 5'-AAC
TTC TCA TGG TAC
CAC TG -3'
Upstream: 5'-AAC 48 35
TTC TCA TGG TAC
CAC TG
Downstream: 5'-AAC
TTC TCA TGG TAC
CAC TG -3'
Upstream: 5'-ATG 48 35
TCC TGC TGG CTC
TCT TC-3'
Downstream: 5'- AGC
AGT TCC TCC ACA
GAA AC-3'
Upstream: 5'-AGG 48 35
TGG CAG AAG GGA
AGG TA -3'
Downstream: 5'-AGC
GAG GTT AGG AGT
TCA TC-3'
Upstream: 5'-CTT 48 35
TGG AGC ACT TTC
CATAGA -3'
Downstream: 5'-GTT







Table 2.4: Specific primers and PCR conditions.
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2.10 Preparation of 32P and 35S labelled cDNA probes
2.10.1 DNA ligation
Fragments recovered from low melting point agarose gels were ligated using T4
DNA ligase (1-5U) in 1 x supplied buffer in a final volume of lOpl. Typically, 2-4pJ
(approximately 50ng) of insert DNA was used and 0.5-lpl (approximately lOOng)
vector DNA. Reactions were incubated at 4°C overnight before transforming into
competent Eschericia. coli.
2.10.2 Bacterial Transformation
Eschericia coli HB101 cells were grown in 100ml of Luria-Bertoni (LB) broth at
37°C in a shaking incubator until they reached mid-log phase (A6oo = 0.3-0.6). They
were then centrifuged at 1000 x g for 5min at 4°C, the pellet re-suspended in cold
calcium chloride (0.1M; 20ml) and left on ice for between lOmin and 2 hours. The
centrifugation step was repeated to re-pellet the cells and the cells were re-suspended
in cold calcium chloride (0.1M; 2ml). The competent cells were stored on ice in the
fridge for up to 3 days before transformation.
Competent cells (200pl) were mixed with plasmid DNA (50ng) and left on ice for
20min. The cells were heat shocked at 42°C for 50s and placed back on ice. The heat
shock and the calcium chloride lead to the incorporation of the plasmid DNA into the
cells. The cells were spread onto LB agar plates containing ampicillin (100p,g/ml),
and the plates incubated overnight at 37°C. Only cells that had incorporated the
plasmid DNA grew on the plates containing ampicillin, as HB101 cells do not have
inherent ampicillin resistance.
2.10.3 Screening of clones
Screening of clones was carried out by small-scale preparation of plasmid DNA
followed by appropriate restriction digests and agarose gel elctrophoresis as
described later in 2.10.5. Following transformation, single colonies were picked and
used to seed 2ml of LB containing ampicillin (100pg/ml). After overnight incubation
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in a rotating incubator at 37°C, cultures were transferred into 1.5ml eppendorf tubes,
centrifuged in a microcentrifuge at 12000 x g for lmin and the pellets resuspended in
GTE (lOOpl). Fresh 0.2M NaOH/1% SDS (w/v) (200|E) was added, the tubes
vortexed and placed on ice for 2 min. 5M potassium acetate (150pl) was then added,
the tubes vortexed and placed on ice for 5min. The tubes were centrifuged in a
microcentrifuge at 12000 x g for 5min and the supernatant transferred to fresh
eppendorf tubes. Chloroform/isoamyl alcohol (24:1) (225pl) and Tris-HCl saturated
phenol (225pl) was added, the tubes vortexed and centrifuged for 2min. The
supernatant was transferred to a fresh eppendorf tube, 2 volumes of absolute ethanol
added and the tubes vortexed prior to incubation at room temperature for 5min. The
tubes were centrifuged at 12000 x g for 5min, the supernantant removed with a glass
pasteur pipette and the pellet left to air-dry for lOmin. The pellet was resuspended in
TE (50|al) containing RNAse A (50ng) and stored at -20°C until needed.
2.10.4 Plasmid DNA preparation
A single transformed bacterial colony was selected from an agar plate and incubated
for 6 hours in LB (2ml) containing ampicillin (100pg/ml). This was then added to
LB (500ml) containing ampicillin (100pg/ml) and incubated overnight at 37°C. The
culture was centrifuged at 3500 x g for 5min at 4°C in a Beckman J14 centrifuge,
and the supernatant discarded. The cell pellet was resuspended in cold GTE buffer
(12ml) and freshly prepared alkaline SDS (24ml). The mixture was shaken
vigorously by hand and left on ice for lOmin. Cold potassium acetate (5M; 16ml)
was added and the mixture left on wet ice for 10 min before being centrifuged at
3500 x g for 5min at 4°C in a Beckman J14 centrifuge. The mixture was filtered
through two layers of sterile gauze to remove the precipitate, isopropanol (32ml) was
added to the filtrate and the mixture was left at room temperature for 30min to
precipitate the DNA. The DNA was pelleted by centrifugation at 7800 x g for 3min
at 4°C in a Beckman J20 centrifuge, and the supernatant discarded. The DNA pellet
was left to dry. The DNA pellet was resuspended in TE buffer (2.2ml), CsCl (2.95g)
added and dissolved and ethidium bromide (lOOpl, lOmg/ml) added. The mixture
was transferred to Beckman Quickseal ultracentrifuge tubes, topped up with CsCl/TE
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solution (lg/ml) and centrifuged at 175 000 x g for 20 hours at 20°C in a Beckman
Optima TLX ultracentrifuge. The DNA was separated into bands that could be
visualised by the pink colour of the ethidium bromide. These DNA bands were
removed using a 21 gauge needle and syringe, transferred to fresh ultracentrifuge
tubes, topped up with CsCl/TE solution (lg/ml) and centrifuged at 356 000 x g for 4
hours at 20°C. The DNA bands were collected as above and the ethidium bromide
was removed by extracting repeatedly with isopropanol until the pink colour
disappeared. The DNA was transferred to dialysis tubing and dialysed against three
changes of TE buffer. The concentration and purity of the DNA was assessed
spectrophotometrically using a GeneQuant RNA/ DNA Calculator (Pharmacia
Biotech, Sweden). RNA was diluted 1:25-1:100 in DEPC-treated water and the
optical density at 7.260nm and A,280nm was determined.
2.10.5 Restriction enzyme digestion of plasmid and purification of
fragment.
Plasmid DNA (10pg) was digested with the appropriate restriction enzyme (10 units)
in lx restriction enzyme buffer in a total volume of 100pl for 2 hours at 37°C.
Digestion of the DNA was confirmed by electrophoresis of 3pl of the digest through
a 1.2% agarose gel (prepared by dissolving agarose (1.2g) in 0.5 x TBE and adding
ethidium bromide (2|il,(10mg/ml)). The digest was compared with uncut plasmid and
a lkB DNA ladder containing fragments ranging from 75bp-12kb under UV light at
254nm. If the plasmid was sufficiently digested, the remaining digest was
electrophoresed in a large single well of a 1.2% low melting point agarose gel (made
as above but using low melting point agarose).
The DNA fragment was visualised under UV light, excised from the gel using a
scalpel and purified from the gel using a DNA Purification kit (Hybaid, Ashford,
Middlesex) and resuspended in DNAase free/RNAase free water (50pl). Recovery of
the DNA fragment was assessed by electrophoresis of l|il of the DNA solution
through a 1.2% agarose gel as described above.
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2.11 35S In Situ Hybridisation
In situ hybridisation allows the visualisation of the exact cellular and/ or structural
location of specific mRNAs (indicating transcription of the corresponding gene) by
hybridisation of a 35S-labelled 'antisense' RNA probe to the mRNA of interest. 35S-
UTP labelled RNA 'sense' probes of similar length, nucleotide content and specific
activity but not complimentary to the gene were included in each experiment in order
to assess the specificity of the hybridisation reaction.
Only RNase free, sterile solutions and equipment were used for in situ hybridisation
experiments in order to prevent degradation of target mRNA by exogenous RNases.
2.11.1 Slide Preparation
Prior to use, glass microscope slides were coated in 3-aminopropyltriethoxysilane in
order to prevent section dehiscence. Slides were racked and washed in the following
series of solutions; HC1 (0.2M) for 3min, DEPC-treated water for 3min, 3-
aminopropyltriethoxysilane in acetone (2%; filtered through NaSCU) for 10s, acetone
for 3min (twice), and finally DEPC-treated water for 3min. Slides were air-dried for
30-60min before baking at 50°C for 4-16 hours. Dried slides were wrapped in
aluminium foil and stored for up to 3 months.
2.11.2 Tissue section preparation
Liver and prostate were routinely frozen on dry ice immediately after dissection from
the animal. Tissues were stored at -80°C until required.
Frozen tissue sections were cut using a Leica cryostat (Leica Microsystems,
Germany). Tissues frozen at -80°C were placed in the cryostat chamber at -20°C and
allowed to equilibrate for approximately 30min. Following equilibration, tissues
were embedded in Cryo-m-bed embedding compound (Brights, UK) and positioned
in the correct orientation for sectioning. 10|am thick sections of liver and prostate
were thaw-mounted onto 3-aminopropyltriethoxysilane-coated slides. Slides with
tissue sections were stored at -80°C until required.
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2.11.3 Fixation protocol
Slides were removed from the -80°C freezer and kept on dry ice until the start of the
fixation procedure. Slides were fixed in ice cold paraformaldehyde (4%) in
phosphate buffer (0.1M) for lOmin, rinsed twice in lx PBS for 5min, acetylated in
triethanolamine (0.1M) with acetic anhydride (0.25%) for lOmin to prevent loss of
signal and rinsed in lx PBS for 3min. Following dehydration through a series of
ethanol solutions (70, 80 and 95% ethanol in DEPC-treated water) slides were air
dried for 30min.
2.11.4 Probe templates for in situ hybridisation
Target specific RNA probes for rat 5a-reductase type 1, 5a-reductase type 2 and 3a-
HSD were produced in vitro using T7 or SP6 phage polymerase systems. The T7/
SP6 promoter sequence flanked linear cDNA templates for 5a-reductase type 1 and
5a-reductase type 2 were gifts from Dr Dawn Livingstone. The T7/ SP6 promoter
sequence flanked cDNA template for 3a-HSD was synthesised as described
previously in 2.9.
2.11.5 Synthesis of 35S-UTP labeled ribo-probes
See Table 2.5 for specific characteristics of probe generation.
Probe RNA polymerase Temp (°C)
5a-reductase 1 s T7 37
5a-reductase 1 as SP6 40
5a-reductase 2s T7 37
5a-reductase 2 as SP6 40
5(3-reductase s T7 37
5P-reductase as SP6 40
3a-HSD s SP6 40
3a-HSD as T7 37
Table 2.5: Characteristics of Probe Generation for In Situ Hybridisation
s = sense, as =antisense
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2.11.6 Pre-hybridisation & hybridisation steps
Following fixation, slides were pre-hybridised with 200pl/ slide of 2x pre-
hybridisation buffer diluted 1:1 with deionised formamide, at 50°C for 2h.
Dampening two layers of Whatman No.3 chromatography paper with box buffer
humidified the slide boxes, hence preventing tissue sections from drying out.
For all probes, linear cDNA template (0.5-1 ng) was transcribed by incubation at the
appropriate temperature for 60-90min with ATP, CTP and GTP (lOmM each), 35S-
UTP (s.a. 800Ci/ mmol), dithiothreitol (DTT, lOmM), RNase inhibitor (0.5p,l), and
appropriate polymerase (lftl) in a total volume of 10(il lx transcription optimised
buffer. Following incubation, DNase 1 (RNase free) (l|ul) was added and reactions
incubated at 37°C for a further 15min to degrade the DNA template, after which
probes were placed on ice for 1-5 min and purified using NICK columns (Pharmacia
Biotech, Sweden) to remove unincorporated radioactivity. The column was prepared
by washing through with TE buffer (3ml). The probe mixture was then applied to
the column. The column was washed with TE buffer (400p,l) and the initial elutant
discarded. Labelled probe was eluted in an additional TE buffer (400pi).
2.11.7 RNase treatment & washes
Following hybridisation, slides were washed three times in 2x SSC for 5min and
carefully wiped dry around the sections with lens tissue. RNase A (200pl, 30mg/ ml
in RNase buffer) were applied to each slide and slides were incubated at 37°C for 1
hour in humidified boxes (1 layer of Whatman No.3 chromatography paper
dampened with RNase buffer) to remove unhybridised probe.
Sense and antisense probes were thawed and added to 2x hybridisation buffer diluted
1:1 in deionised formamide to give a final probe concentration of 20xl0~6 cpm/ml.
Probes were denatured at 90°C for lOmin and placed on ice before addition of DTT
(lOmM). Pre-hybridisation buffer was drained from slides and appropriate probe
(200pl) was applied to slides. Slides were hybridised in sealed, humidified boxes at
50°C for an optimum of 16 hours.
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Following RNase treatment, slides were washed in 2x SSC at room temperature for
30min, then twice in O.lx SSC at 60°C for 60min. After washes, slides were
dehydrated through a series of ethanol solutions containing ammonium acetate
(0.3M) (2min in each of 50, 70 and 90% ethanol) and air-dried.
For each probe, the total activity was estimated by counting lpl of probe in 1ml
PicoFluor 40 scintillant fluid (Canberra Packard, UK) in duplicate in a |3-counter
(minimum activity required 2xl05 cpm/pl). The purity of each probe was determined
by running l-2pl on a urea gel (3.6g urea, 1.32ml acrylamide, 0.1% ammonium
persulphate (v/v), lOjil TEMED in lx TBE) and exposing the gel to Kodak Biomax-
MR film (HA West Ltd, Edinburgh, UK), which should produce a single black band
on the film when developed. Probes were stored at -20°C until required, for a
maximum of 7 days.
2.11.8 Visualisation of Hybridisation
Slides were exposed to Kodak Biomax-MR film for 2-7 days. Afterwards, slides
were individually dipped in NTB-2 photographic emulsion (Kodak, UK, diluted 1:1
with DEPC-treated water at 42°C) and exposed in light-tight boxes for 5 days to 12
weeks at 4°C. Slides were developed in D19 solution (HA West Ltd, UK) diluted
1:1 with water at 15°C, fixed in Amfix solution (HA West Ltd, UK) diluted 1:5 with
water at 15°C, rinsed in water and counterstained with haematoxylin and eosin.
2.12 Glucocorticoid receptor binding assays
2.12.1 Tissue Handling
2.12.1.1 Cytosol preparation
The livers of freshly sacrificed lean male Zucker rats were perfused with saline
(20ml) via the hepatic vein to remove blood and the liver was excised. The liver was
chopped into small pieces in ice-cold molybdate buffer and then disrupted using an
Ystral mechanical homogeniser. Cytosol was prepared by first centrifuging at 20,000
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x g for 20 min. at 4°C and then at 105,000 x g for 60 min. at 4°C. The supernatant
was then stored on ice.
2.12.1.2 Microsome preparation
Microsomes were prepared as for cytosol (2.11.1.1). After the 105,000 x g spin, the
resulting pellet was resuspended in molybdate buffer and stored on ice.
2.12.1.3 Hepatocyte preparation
Rats were anaesthetised with Sagatal (0.3ml) and cannulated via the inferior cava
(for waste drainage) and the hepatic vein. Calcium-free buffer was pumped through
the liver at a flow rate of 25ml/min and then Krebs buffer containing collagenase
type IV was pumped through to break down the contacts between cells. The liver was
then removed and transferred to Krebs buffer (100ml) and broken up mechanically.
The suspension was rinsed through nylon mesh (aperture 0.125mm) with Krebs
Buffer. The remaining cells were centrufuged at 500 x g for 2 min. and then
resuspended in Krebs buffer. This centrifugation step was repeated three times.
Following this, the cells were resuspended in hepatocyte incubation buffer (30ml).
The cell viability was estimated by trypan blue exclusion under light microscope and
counted using a haemocytometer.
2.12.2 Binding assays
■J
For competitive binding experiments the incubation medium consisted of 25pl [ H]4
-dexamethasone (specific activity, 91Ci/mmol, 1.5nM final concentration ), non¬
radioactive dexamethasone or corticosterone (25pl, ranging from OnM to 200pM) or
one of the following corticosterone metabolites 5aDHB, 5aTHB, 5pDHB, 5(3THB,
A, DHA or THA (25pl, ranging from OnM to 200pM), cytosol or microsomes (50pl,
4mg/ml) or hepatocytes (2million cells/ml). The assay wells were incubated at 4°C
for 24h and all reactions were performed in duplicate. The reaction was terminated
by rapid filtration on filtermats pre-soaked in polyethylenimine (0.3% v/v) using a
Combi cell harvester (Skatron Instruments) with ice-cold distilled water. The
filtermats were left to dry and then encapsulated with Meltilex (heated to
approximately 90°C). The radioactivity retained on the filters was counted by a 1450
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Microbeta Plus Liquid Scintillation Counter for 5minutes per sample. Results were
expressed as percentage dexamethasone bound compared to no competitor and the
dissociation constant (Kd) and the total number of binding sites (Bmax) were
determined using the non-linear curve-fitting program Radlig.
2.13 Transient transfection studies
2.13.1 Transient transfections
24h before transfection, HeLa cells were seeded on 60mm dishes, allowing three
dishes per transfection. Cells were harvested by centrifugation at 500 x g for 5min
and resuspended in medium (10ml). Cells were counted using an Improved Neubauer
haemocytometer (Hawksley) and if necessary diluted further to give a cell count of 3
x 10° cells/ml. 1ml of cells was added to each 60m dish containing 3ml of medium
and incubated at 37°C with 5% CO2.
All solutions used were equilibrated to room temperature prior to use. Medium on
cells was replaced with fresh medium (4ml) at least lhr prior to transfection. For
each transfection DNA solutions (300pl total) were set up in triplicate in filter-
sterilised water and contained filter-sterilised CaCl2 (2M; 37pl).
The plasmids used were pGEM3 (inert DNA) (Promega), pCHllO (a (3-galactosidase
expression plasmid which was used as an internal control for transfection efficiency)
(Amersham Pharmacia), pSV2L (firefly luciferase gene driven by a mammalian
SV40 early promoter which was used as a positive control) (de Wet et al. 1987),
pLTR-Luc (full length MMTV LTR driving the expression of a luciferase gene)
(Lefebvre et al. 1991) and pRShGR, a human glucocorticoid receptor gene
(Lefebvre et al. 1991).
Control DNA solutions consisted of (i) pGEM3 (10p,g) and (ii) pSV2L (5pg),
pCHllO (lpig) and pGEM3 (4pg) to give a total of lOpg DNA. pCHllO (lftg),
RShGR (1 jLtg) and LTR-Luc (5pg) was used in each transfection and the amount of
pGEM3 adjusted to give a total of 10pg DNA. DNA solutions were briefly vortexed
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to mix. Before transfection (20-30min), DNA solutions were added dropwise to 2 x
BBS (300pl) with slow agitation and incubated at room temperature for 20min. After
briefly vortexing, the DNA solutions were added slowly to the dishes of cells with
agitation. 24 hr after transfection the medium was replaced on the cells with fresh
medium (4ml) at least lhr prior to steroid treatment. To treat cells with steroid,
steroid (4pl in ethanol) at the appropriate concentration was added to the cells. 24hr
later, cells were harvested for assays. Medium was aspirated, cells were washed with
phosphate-buffered saline (3ml) and lysis buffer (300pl) was added to the dishes.
After incubation at room temperature for 15min, cells were scraped and pipetted into
eppendorf tubes; cell debris was pelleted by centrifugation at 13000 x g for 2min in a
microcentrifuge. All transfections were performed using at least two independently
prepared plasmid DNAs.
2.13.2 Luciferase assays
Since luciferase activity is labile, luciferase assays were performed in duplicate on
the same day that cells were harvested. All solutions were equilibrated to room
temperature. Sample (40jxl) was added to 2x assay buffer (lOOpl) with 0.1M ATP
(5pl) in a 5ml borosilicate glass tube (Starstedt). Luciferase activity was measured
using a Lumat LB9501 luminometer (Berthold) that injected ImM beetle luciferin
(105pl) (Promega, Southampton, UK). Values recorded were the means of the two
duplicates.
2.13.3 p-galactosidase assays
(3-galactosidase activity was asayed using a Galacto-Light Plus (Applied Biosystems,
UK) and all samples were assayed in duplicate. All solutions used equilibrated to
room temperature prior to use. Galacton-Plus substrate was diluted 1:100 with
Reaction Buffer Diluent to make the reaction buffer which was then dispensed in
67pl aliqouts into 5ml borosilicate tubes. Sample (lOpl) was added, left to incubate
at room temperature for 15-60min and then assayed using a Lumat LB9501
luminometer which injected Light Emission Accelerator (105pl). Values recorded
were the means of the two duplicates.
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2.13.4 Data analysis
Data were analysed using a Microsoft Excel spreadsheet. The means of the
background luciferase and p-galactosidase activities (those for transfections with
pGEM3 only) were subtracted from experimental values and luciferase activity
expressed as luciferase activity/(3-galactosidase activity, thus controlling for
differences in cell number and transfection efficiency. The mean value obtained for
empty vector was then set to a value of 1 and mean experimental activities expressed
relative to this value. The value obtained with pSV2 luciferase confirmed successful
transfection; transfections in which pSV2 luciferase activities were not above that of
the empty vector alone were excluded from analysis.
2.14 Examination of glucocorticoid effects on angiogenesis
Aortic rings from 8-10 week old, male C57/B16 wild type mice were embedded on
steroid free Matrigel (Beckton Dickinson, Bedford, UK) and incubated at 37°C in
serum free MCDB 131, with heparin, ascorbic acid, and GA 1000 (all supplied in the
EGM-2 bulletkit, Cambrex Biosciences, Berkshire, UK) in the presence or absence
of corticosterone (600nM) or 5aTHB (lpM) with/without the glucocorticoid
receptor antagonist, RU486 (lpM). Steroids were dissolved in ethanol and
subsequently diluted in aqueous solution. The final ethanol content in all culture
media was 1-3% v/v. media was changed every 48hours. Angiogenesis was
quantified by counting new vessels on day 7 of culture.
2.15 Plasma assays
2.15.1 Adrenocorticotropin (ACTH) radioimmunoassay
The concentrations of ACTH were quantified using a radioimmunoassay kit
(Eurodiagnostica BV, Arnhem, The Netherlands). Plasma samples were diluted 1 in
5 in the supplied buffer before assay. A range of concentrations of ACTH were
prepared (0-1250pg/ml) to allow construction of a standard curve. Samples and
standards were incubated in duplicate in primary sheep anti-rabbit antibody coated
plastic tubes with [I25I] sheep-anti-ACTH (total volume lOOpl) at room temperature
for 4 hours. The tubes were then washed twice with supplied wash buffer (5ml) and
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counted in a y-counter. The radio-iodinated sheep IgG recognises the amino terminal
region of ACTH. The second antibody reacts non-competitively with the C-terminal
region of the ACTH molecule and during incubation both antibodies react with the
molecules of the sample. A sandwich type complex is formed and bound to the tube
wall. The remaining excess of tracer is removed by washing and the radioactivity
measured is directly proportional to the concentration of ACTH in the sample,
estimated by comparison with the standard curve. The inter- and intra-assay
coefficients of variation were <4%.
2.14.2 Corticosterone radioimmunoassay
Plasma samples were diluted 1 in 10 in borate buffer and denatured at 65° C for 30
min to dissociate corticosterone (B) from proteins. A range of concentrations of B
were prepared (0.6-320nM) to allow construction of a standard curve. Samples and
standards were incubated with a mixture of [3H]4-B (10,000cpm per sample) and B
antibody (1 in 10,000 dilution) in borate buffer in a total volume of 70pl for 2h.
Scintillation proximity assay beads (SPA; Amersham, Bucks, UK) were then added
to each sample and the samples were incubated overnight. The SPA beads bind to the
primary antibody and if the primary antibody is bound to [ H]4-B the SPA beads
cause scintillation of the radioactive signal. As the concentration of unlabelled B
increases there is competition between binding of unlabelled and labelled B to the
primary antibody, and the radioactive signal decreases. Samples were counted on a
Wallac Microbeta Plus liquid scintillation counter. The concentration of B in each
sample was estimated from the standard curve. The inter- and intra-assay coefficients
of variation were <10%.
2.15 Statistics
All values are expressed as mean ± standard error. Data were analysed statistically
by Student's t-tests or Analysis of variance followed by post-hoc LSD tests for
parametric data, or Mann-Whitney U tests for non-parametric data.
74
Chapter Three
Localisation of A-ring Reductases
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3.1 Introduction
Two isozymes of 5a-reductase have been cloned (types 1 and 2). The two isozymes
can be distinguished by their pH optima and tissue distribution. The type 1 isozyme
has a broad pH optimum that spans the alkaline range (pH 6-8.5), while the type 2
isozyme has a narrow acidic pH optima centred around pH5.0 (Andersson & Russell
1990; Normington & Russell 1992). In the rat, the type 1 isozyme is expressed
predominantly in the liver, whereas the type 2 form is associated with androgen
sensitive tissues and is primarily responsible for the conversion of testosterone into
the more potent androgen, dihydrotestosterone (Andersson et al. 1991).
5a-reductase type-1 and -2 are both capable of metabolising glucocorticoids
(Normington & Russell 1992). It is unclear whether one or both of these isozymes
are responsible for glucocorticoid metabolism in vivo as previous studies
investigating glucocorticoid metabolism often report on urinary steroid metabolites
and do not identify the isozyme or tissue involved. We anticipate that the liver will
be the major site of inactivation, hence implicating type 1 at least in the rat. 5a-
Reductase is also expressed in adipose tissue and thus this tissue may be of increased
importance as a metabolic site in obesity (Perel et al. 1986; Zyirek et al. 1987). An
elongated version of 5a-reductase type 1 (henceforth termed lb) which differs by 4
amino acids at the N-terminal end has also been reported (Lopez-Solache et al.
1996). The exact role of the additional 4 amino acids is unknown, however in
transfection studies they confer higher affinity for the substrate to the enzyme,
especially for glucocorticoids for which the Km is decreased 7.5-fold (Lopez-Solache
et al. 1996). Therefore this form of the enzyme may be responsible for glucocorticoid
metabolism by 5a-reductase.
The aims of this chapter were to :
1. Establish methodology to quantify the activity and expression of 5a-reductase
type 1 and type 2 in metabolic tissues (i.e liver and adipose) ex vivo.
2. Study the cellular distribution of these enzymes.
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3.2 Methods
3.2.1 A-ring reductase Expression Studies
3.2.1.1 RT-PCR
Expression of 5a-reductase type 1 mRNA and the reported elongated isoform 5a-
reductase type lb, 5(3-reductase and 3a-hydroxysteroid dehydrogenase was
investigated in RNA from liver and omental and subcutaneous adipose tisue of male
lean Zucker rats (n = 6-8) by RT-PCR as described in chapter 2.7.
3.2.1.2 In Situ Hybridisation
Localisation of 5a-reductase type 1 and type 2, 5(5-reductase and 3a-hydroxysteroid
dehydrogenase mRNA expression was investigated in liver from male Wistar rats (n
= 4- 6) using in situ hybridisation as described in chapter 2.11. Rat prostate was used
as a positive control for 5a-reductase type 2.
3.2.2 Bioactivity assays
5P-reductase activity was measured in rat liver cytosol as described in 2.5.5.
3.2.3 5a- and 5p-reductase activity in liver
The presence of 5a and 5P-reduced metabolites was investigated in Wistar rat liver
by GCMS as described in chapter 2.6.
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3.3 Results
3.3.1 Detection of A-ring reductase expression by RT-PCR
Expression of mRNA of 5a-reductase type 1, 5(3-reductase and 3a-hydroxysteroid
dehydrogenase was detected in rat liver (Figure 3.1) and in H4IIE cells (Figure 3.4)
5a-reductase type 2 was not detected in rat liver (Figure 3.2). In omental and
subcutaneous adipose tissue, only 5a-reductase type 1 and 3a-hydroxysteroid
dehydrogenase were detected (Figure 3.3)
In addition, mRNA encoding the reported elongated version of 5a-reductase type 1
was not detected in rat liver (Figure 3.5).
3.3.2 Localisation of A-ring reductase mRNA expression by in situ
hybridisation
5a-Reductase type 1 mRNA expression, but not 5a-reductase type 2 mRNA
expression, was detected throughout the liver (Figure 3.6). 5a-Reductase type 1
mRNA showed marked zonation in a pattern consistent with expression in the
periportal region (Figure 3.7). 5[3-reductase and 3a-hydroxysteroid dehydrogenase
mRNA expression was detected uniformly throughout the liver. Specific
hybridisation was not observed in sections hybridised with sense probes.
3.3.3 5cc-Reductase activity
As described in 2.5.4, 5a-reductase activity could not be detected by bioactivity
assay in rat liver using corticosterone as a substrate (Table 2.2). However in vivo this
reaction does occur, since 5a-reduced metabolites of corticosterone were identified
in Wistar rat liver (Figure 3.8) and in H4IIE cells by GCMS.
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3.3.4 5(3-Reductase activity
5|3-reductase activity was present in rat liver as indicated by conversion of [ H]4-
corticosterone to [3H]4-3a,5p-tetrahydrocorticosterone by liver cytosol (Figure 3.9).
3 "3
Consistently there was no conversion of [ H]4-corticosterone to [ H]4-3oc,5a-
tetrahydrocorticosterone by liver cytosol detected therefore the temperature was
increased from 10°C to 35°C to enable faster run-times. An additional peak was
present in a proportion of the samples. This peak was believed to be the 20(3-
dihydrocorticosterone metabolite of corticosterone, however a synthetic standard of
this steroid was unavailable to allow confirmation of this. To confirm 5(3-reductase
activity in vivo, 5[3-reduced metabolites of corticosterone were identified in Wistar
rat liver (Figure 3.8) by GCMS.
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5a -reductase type 1 5P-reductase 3oHSD
456bp 512 bp 315bp
H20 -RT +RT Hp -RT +RT HP -RT +RT
Figure 3.1: Expression of 5a-reductase type 1, 5(3-reductase and 3a-HSD
mRNA in rat liver
lpg of total RNA isolated from lean male Zucker liver was used in RT-PCR
with specific primers to detect expression of 5a-reductase type 1, 5P-reductase
and 3a-HSD. Negative controls included an RT reaction containing no RNA







Figure 3.2: Absence of Expression of 5a-reductase type 2 in rat liver
lpg of total RNA isolated from liver was used in RT-PCR with specific primers
to detect expression of 5a-reductase type 2. Negative controls included an RT
reaction containing no RNA (H20) and a reaction carried out in the absence of
the RT enzyme for each RNA (-RT). Prostate was used a positive control.
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5a-reductase type 1 5P-reductase 3a-HSD 5a-reductase type 2
456bp 512bp 315bp 567bp
liver OM SC liver OM SC liver OM SC prostate OM SC
HoO-RT+RT-RT +RT-RT+RT H2O-RT+RT-RT +RT-RT+RT H20-RT+RT-RT +RT-RT+RT H2O-RT+RT-RT +RT-RT+RT
Figure 3.3: Expression of 5a-reductase type 1 and 3a-HSD mRNA in omental
and subcutaneous adipose tissue.
lpg of total RNA isolated from lean male Zucker omental (OM) and subcutaneous
(SC) adipose tissue was used in RT-PCR with specific primers to detect expression of
5a-reductase type 1 and type 2, 5(3-reductase and 3a-HSD. Negative controls
included an RT reaction containing no RNA (H2O) and a reaction carried out in the
absence of the RT enzyme for each RNA (-RT). Liver and prostate was used as a
positive control.
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5a-reductase 1 5P-reductase 3a-HSD
456bp 512bp 315bp
HeLa H4IIE HeLa H4IIE HeLa H4IIE
H,0-RT +RT -RT +RT -RT+RT-RT +RT -RT +RT -RT +RT
Figure 3.4: Expression of 5a-reductase type 1, 5(3-reductase and
3a-hydroxysteroid dehydrogenase in H4IIE cells but not in HeLa
cells.
lpg of total RNA isolated from HeLa and H4UE cells was used in RT-
PCR with specific primers to detect expression of 5a-reductase type 1,
5|3-reductase and 3a-HSD. Negative controls included an RT reaction
containing no RNA (H20) and a reaction carried out in the absence of
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Figure 3.5: Expression of 5a-reductase Type 1 and 5oc-reductase Type
lb mRNA in rat liver
Figure shows the presence of 5cc-reductase Type 1 but not 5a-reductase
Type lb in lean male Zucker rat liver (n=8). lpg of total RNA isolated
from liver was used in RT-PCR with specific primers to detect expression
of 5a-reductase type 1 and 5cc-reductase type lb. Negative controls
included an RT reaction containing no RNA (H2O) and a reaction carried













Figure 3.6: A-ring Reductase mRNA Expression in Rat Liver
Anti-sense 35S-labeled ribo-probes (left hand pictures in each panel) specific
for rat 5a-reductase type 1 and 2, 5p-reductase and 3a-HSD were used to
detect mRNA in 10pm thick sections of liver and prostate from male Wistar
rats by in situ hybridisation. Sense probes (right hand pictures in each panel)
were used to confirm the absence of non-specific hybridisation. Following in





Figure 3.7: Periportal 5a-reductase type 1 distribution
Figure shows representative photomicrograph (original magnification
xlOO) showing in situ mRNA hybridisation to frozen sections of rat liver.
Note higher density of silver grains in the periportal area compared to the
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Figure 3.9: Chromatogram of 5P-reductase activity in liver cytosol
Following assay for 5(3-reductase activity, steroid extracts were re-suspended in
mobile phase consisting of 60% water, 15% acetonitrile, 25% methanol and [3-
cyclodextrin (ImM) and injected into the HPLC system. The flow rate of the mobile
phase was 0.7ml/ min, flow rate of the scintillant was 1.4ml/ min and the column
temperature was set to 35°C. The approximate retention times for [3H]4-
corticosterone and [3H]4-5[3THB were 15.48 min and 23.90 min respectively as




Having optimised the HPLC conditions for separation of A-ring reduced metabolites
of corticosterone, the bio-activity assay conditions remained to be determined. The
starting point for the development of the assay was an assay used previously to
measure 5a-reduction of testosterone and androstenedione in tissues and cells
(Mahendroo et al. 2001; Reichert et al. 2001).
In our assay we attempted to quantify the enzyme in liver homogenates by measuring
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the conversion of [ H]4-corticosterone to [ H]4-5a-dihydro- and tetrahydro-
corticosterone and [3H]4-5(3-dihydro- and tetrahydro-corticosterone as described in
section 3.2.2. An assay for 5P~reductase was successfully developed but
unfortunately, 5a-reduced metabolites were not detected under these assay
conditions. These assay conditions were then repeated using several different time-
courses, protein concentrations and co-factor concentrations but 5a-reductase
activity could not be detected.
Fresh tissue homogenates and fresh liver slices were then used because the initial
assay was carried out with frozen tissue and it was thought that the enzyme might
have been degraded as it is known to be extremely labile (Eicheler et al. 1995).
Again only 5(3-reductase activity could be measured.
5a-Reductase is a microsomal enzyme and therefore we tried the assay in
microsomes and different sub-cellular fractions of liver including the nuclear
fraction, mitochondria, heavy microsomes and cytosol. The only activity that was
detected in any of these preparations was 5P~reductase activity in cytosol which
would be expected as it is a cytosolic enzyme. As a positive control, the assay was
performed in prostate using corticosterone and testosterone as substrates. 5a-
Reduction of testosteronebut not corticosterone could be measured in prostate.
89
To try to preserve 5a-reductase activity, glycerol was added to the tissue sample
after homogenisation, and trypsin and protease inhibitors were used in the buffers to
prevent degradation of the enzyme. Finally, an NADPH generating system was used
as a constituent of the incubation buffer to generate more co-factor for the enzyme,
as this had previously been used in synthesis of aldosterone metabolites (Morris et al.
1982) and had been used successfully in our laboratory in prostate assays. None of
these modifications resulted in detection of 5a-reductase metabolism of
corticosterone.
Isolated hepatocytes have been shown to be a model system for studying steroid
metabolism (Morais & Wagner 1985). 5a-Reductase activity was measured in
isolated hepatocytes, however this preparation was not reliable because on many
occasions, 5a-reductase activity was overwhelmed by llp-HSDl activity converting
corticosterone to 11-dehydrocorticosterone (A). This increased formation of A is
recognised as a sign that the hepatocytes are no longer viable (Jamieson et al. 1995)
and will attenuate 5a-reductase activity because it will have to compete with 11(3-
HSD1 for substrate. To overcome the problem of cell viability we decided to use a
cell-line. After screening several different cell-lines the rat hepatoma H4IIE cell-line
was chosen. 5a-Reductase type 1, 5(3-reductase and 3a-hydroxysteroid
dehydrogenase mRNA were detected in H4IIE cells by RT-PCR. 5a- and 5(3-reduced
tetrahydro- metabolites of corticosterone could not be detected by UV detection due
to low concentrations but were detected by GCMS in H4IIE cells after overnight
incubation with corticosterone.
Therefore, we have managed to establish optimal conditions for measuring 5(3-
reduction of corticosterone in rat liver cytosol using fresh or frozen tissue. In all of
our assays, only the tetra-hydro metabolites were detected because 3a-HSD reduces
the dihydro-metabolites to tetrahyro-metabolites very rapidly. However, 5a-
reductase activity could not be measured in this way. Many studies with 5a-
reductase have been hampered previously because of the extreme insolubility of the
protein (Moore & Wilson 1972) and its very strong membrane association (Houston
et al. 1985; Enderle-Scmitt et al. 1989). The fact that 5a-reductase activity could be
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identified by GCMS and not by UV detection confirms previous reports that 5a-
reductase is expressed in low levels because GCMS is a much more sensitive tool
than UV-detection.
3.4.2 Isozyme expression
RT-PCR and in situ hybridisation studies have confirmed the previously reported
differences in tissue distribution between the different isozymes of 5a-reductase
(Normington & Russell 1992). Only the type 1 isozyme was expressed in liver. The
expression of the alternative, elongated isoform of 5a-reductase type 1 in rat liver
could not be detected by RT-PCR. This alternative isozyme has only been reported
once in rat liver (Lopez-Solache et al. 1996) therefore it was not possible to include a
positive control for the expression of this transcript. It is thought that the reported
elongation is an inverted repeat of another part of the sequence and was induced
experimentally.
5a-Reduction of steroids has also been identified in adipose tissue however it was
not known which isozyme was responsible. Here we confirm that 5a-reductase type
1 and 3a-hydroxysteroid dehydrogenase were expresed in omental and subcutaneous
adipose tissue but 5a-reductase type 2 and 5P-reductase were not.
Having determined the presence of 5a-reductase, 5P-reductase and 3a-HSD in rat
liver, it was important to confirm the specific cellular localisation of these enzymes.
In situ hybridisation was used to investigate expression of A-ring reductases in the
liver at the level of gene transcription. The expression of 5a-reductase showed
marked zonation with high expression in the periportal zone of the liver. The
expression of many hepatic proteins is dependent on their relative position within the
liver acinus. While hepatocytes in different parts of the liver acinus appear similar,
cells located in the periportal region have a functional capacity different from those
surrounding the central vein, leading to "metabolic zonation" of the liver
(Jungermann & Kietzmann 1996). These differences are due to gradients in
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concentrations of substrates and hormones, related to the passage of blood from the
periportal to the perivenous zone.
Functions of the liver which are zonally distributed include glucose metabolism,
amino acid utilisation, bile formation and xenobiotic metabolism e.g PEPCK is the
rate-limiting enzyme of gluconeogenesis, and is expressed at higher levels in the
periportal than the perivenous zones of the liver (Bartels et al. 1993). Insulin receptor
protein is predominantly located perivenously (Krones et al. 2000) and glucose
uptake and glycolysis occur perivenously (Lindros 1997). The glucocorticoid
receptor has been found to be homogenously (Antakly & Eissen 1984) or periportally
distributed (Nyirenda et al. 1998).
5(3-reductase and 3a-HSD did not show any marked zonation of mRNA expression.
The best known activity of 5(3-reductase is the formation of bile acids (Berseus
1967). 3a-HSD is the major bile acid-binding protein and is involved in the de-novo
synthesis and metabolism of bile acids (Danielsson & Sjovall 1975). Bile acid
processing has been shown to be greater in the pericentral than in the periportal
region of the liver, therefore the uniform expression of 5(3-reductase and 3a-HSD
probably reflects their roles in bile acid synthesis and metabolism in addition to their
role in steroid hormone metabolism.
We have confirmed that 5a-reductase type 1 but not 5a-reductase type 2 is expressed
in liver and adipose tissue. 3a-hydroxysteroid dehygrogenase is also expressed in
these tissues. We have shown that 5a-reductase type 1, 5(3-reductase and 3a-
hydroxysteroid dehygrogenase can work in vivo as measured by GCMS. However,








The rate-limiting step in glucocorticoid inactivation is the reduction of the A4 5 double
bond in the A-ring of the steroid structure. This can be carried out by either 5a- or
5(3-reductase. The resultant dihydro-metabolites are then reduced further by 3a-
hydroxysteroid dehydrogenase (3a-HSD) to form tetrahydro-metabolites. As
discussed in chapter 1, two genes encoding 5a-reductase have been identified in rats
(Normington & Russell 1992) and these isozymes are referred to as 5a-reductase
Type 1 and Type 2. 5a-reductase Type 1 predominates in androgen independent
tissues such as the liver and skin, whereas 5a-reductase Type 2 is the predominant
isozyme in reproductive tissues (Andersson et al. 1991).
5a-reduction of glucocorticoids has been accepted as a pathway of irreversible
inactivation. However, 5a-reduced metabolites of other steroids have been shown to
be more potent in activity than their parent hormone. 5a-Reductase Type 2 catalyses
the conversion of testosterone to dihydrotestosterone (DHT) which is a more potent
androgen than testosterone and can bind preferentially to androgen receptors and
activate them (Siiteri & Wilson 1974). Aldosterone metabolism also results in active
metabolites. Aldosterone is converted to 5a-dihydroaldosterone and this is
subsequently converted to 3a, 5a-tetrahydroaldosterone. Experiments with rat
kidney has demonstrated that these metabolites possess mineralocorticoid activity
(Kenyon et al. 1985; Gorsline et al. 1986). The progesterone metabolites, 5a-
dihydroprogesterone and allopregnanolone are also active and allopregnanolone
binds to the non-nuclear GABAa receptor (Rapkin et al. 1997).
Rat liver contains two distinct types of glucocorticoid binding sites; 1) the high
affinity glucocorticoid receptor (GR) which is located in the cytosol and in the cell
nucleus (Antakly & Eissen 1984) and 2) the low affinity glucocorticoid binding sites
(LAGS) which are present in the microsomal fraction (Ambellan et al. 1981) and in
the nuclear envelope (Kaufmann & Shaper 1984; Roszak et al. 1990).
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The aims of this chapter were to:
1) determine whether 5a- and 5(3- reduced metabolites of corticosterone can bind to
GR.
2) determine whether 5a- and 5(3- reduced metabolites of corticosterone can
activate GR in vitro, ex vivo and in vivo.
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4.2 Methods
4.2.1 Assay of glucocorticoid receptor binding activity
The binding affinities of the A-ring reduced metabolites of corticosterone for the
glucocorticoid receptor were determined by competition binding experiments as
described in chapter 2.12. The ability of the A-ring reduced metabolites of
corticosterone to displace tritiated dexamethasone from binding sites in isolated
hepatocytes, microsomes and cytosol from lean male Zucker rats was determined by
incubation with increasing concentrations of the potential competing steroids.
4.2.2 Glucocorticoid receptor activation in cell lines
HeLa or H4IIE cells were cultured as described in section 2.4.
a) For assessment of glucocorticoid receptor activation, HeLA cells were
transfected with human GR and a luciferase reporter gene linked to the mouse
mammary tumour virus long terminal repeat (MMTV-LTR) which contains several
GREs by calcium phosphate coprecipitation as described in chapter 2.13. Three
different transfection experiments were carried out as follows:
1) To determine whether A-ring reduced metabolites could activate GR, transfected
HeLa cells were incubated with lpM steroid.
2) To examine the dose-response relationships of corticosterone and 5aTHB,
transfected HeLa cells were incubated with increasing concentrations of steroid
(0-1pM).
3) To determine whether 5ccTHB was a full or partial agonist, transfected HeLa
cells were incubated with 5aTHB alone or in combination with corticosterone
(50nM).
b) Induction of tyrosine aminotransferase (TAT) - (a gene whose transcription is
induced by activated GR, (Granner & Hargrove 1983)) mRNA, was investigated in
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H4IIE cells. Cells were treated overnight with steroid (lpM) with/without the
glucocorticoid receptor antagonist RU486 (lpM). Total RNA was prepared using the
TRIzol® method as described in chapter 2.7.2 and separated on a 1.2% agarose
formaldehyde denaturing gel and mRNA was quantified by Northern blot as
described in chapter 2.9.
4.2.3 Metabolic transformation of steroids
Metabolism of steroids by HeLa and H4IE cells was examined by GCMS as
described in chapter 2.6.
4.2.4 Ex vivo glucocorticoid activity of 5aTHB
The ability of 5aTHB to suppress angiogenesis in C57/B16 mouse aortic rings was
examined ex vivo as described in chapter 2.14.
4.2.5 In vivo glucocorticoid activity of 5aTHB
An experiment was carried out to assess in vivo glucocorticoid activity of 5aTHB. In
this experiment 1) suppression of ACTH was measured and 2) hepatic TAT and
PEPCK mRNA expression was measured.
Groups of six, 6-8 week old male lean Zucker rats were bilaterally adrenalectomised
through dorsal incisions under halothane anaesthesia and maintained on 0.9% saline
drinking water for one week before steroid treatment. Corticosterone, 5aTHB
(5mg/kg body weight) or vehicle (saline with 10% ethanol and 10% DMSO) were
administered by i.p. injection at 0900h.
1) Blood samples were taken on ice by tail-tip at 0,60 and 120 min post-injection
and plasma separated immediately and stored at -80°C. Plasma ACTH and
corticosterone concentrations were determined by radioimmunosassay as
described in chapter 2.15.
2) Rats were sacrificed 6h post-injection and livers removed, snap-frozen and stored
at -80°C. Total RNA was prepared using the TRIzol® method as described in
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chapter 2.7.2 and separated on a 1.2% agarose formaldehyde denaturing gel and
mRNA was quantified by Northern blot as described in chapter 2.9.
4.2.6 Statistics
All data are expressed as mean ± standard error and data were statistically analysed
by Analysis of Variance followed by LSD post-hoc tests, n=6 for all groups.
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4.3 Results
4.3.1 Glucocorticoid receptor binding in isolated hepatocytes
In isolated hepatocytes from male lean Zucker rats, the 5a-reduced metabolites, 5a-
DHB and 5a-THB displaced tritiated dexamethasone with a similar affinity as
corticosterone. The Kd value for 5a-THB (258 ± 78nM) was not significantly
different from that of corticosterone (158 ± 43nM) (Table 4.1 & Figures 4.1 and 4.2).
The 5(3-reduced metabolites were ineffective in displacing dexamethasone at these
concentrations (50-DHB, Kd 7798 ± 1901nM, 5(3-THB, Kd 3590 ± 802nM). 11-
Dehydrocorticosterone and its 5a-reduced metabolites, 5a-DHA and 5a-THA did
not displace dexamethasone from its binding sites.
4.3.2 Glucocorticoid receptor binding in cytosol
In cytosol, 5aDHB (Kd, 133 ± 77.5 nM) bound with a similar affinity as
corticosterone (Kd, 161 ± 109 nM) (Table 4.1 & Figure 4.2), however the Kd value
for 5aTHB was much higher than for binding in hepatocytes and was significantly
different from that of corticosterone (5aTHB; Kd, 8580±4230nM). The 5(3-reduced
metabolite, 5J3DHB (Kd, 384 ± 174 nM) also displaced tritiated dexamethasone with
a similar affinity as corticosterone but 5(3THB was again ineffective at these
concentrations (Kd, 5628. ± 2019 nM).
4.3.3 Glucocorticoid receptor binding in microsomes
In the microsomal fraction, 5aDHB displaced tritiated dexamethasone (Kd, 205 ±
12nM) with a greater affinity than corticosterone (5aDHB; Kd, 153 ± 16. nM vs
corticosterone; Kd, 246 ± 29 nM) and 5a-THB displaced tritiated dexamethasone
with a similar affinity as corticosterone. The Kd value for 5a-THB (154 ± 43nM)
was not significantly different from that of corticosterone (Table 4.1 & Figure 4.2).
The 5(3-reduced metabolites were again ineffective at these concentrations (5(3DHB;
Kd, 5740 ± 1900 nM, 5(3THB; Kd, 8275 ± 4058 nM).
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4.3.4 Activation of Glucocorticoid Receptors in Transfected HeLa cells.
In HeLa cells, transiently transfected with human GR and a luciferase reporter
construct linked to the MMTV-LTR, both corticosterone and 5a-reduced
corticosterone metabolites stimulated luciferase activity. The 5(3-reduced metabolites
of corticosterone did not stimulate luciferase activity (Figure 4.3). None of the
steroids induced luciferase activity in the absence of transfected GR (Figure 4.3).
The dose response curves for 5aTHB and corticosterone were different at low
concentrations with 5aTHB eliciting a lesser response at lower concentrations than
corticosterone (Figure 4.4). At lp.M concentrations, the responses of the two steroids
were not different although it was not possible to measure maximal activation since
cell death was observed at higher concentrations (>2pM) of active steroids.
To test whether 5aTHB was a full or partial agonist at glucocorticoid receptors,
5aTHB was added to the incubation medium with corticosterone. The resulting
luciferase activity was not different from the sum of the activities when each steroid
was added on its own, indicating full agonist activity (Figure 4.5).
4.3.5 Induction of tyrosine aminotransferase mRNA in H4IIE cells.
To confirm that 5a-reduced glucocorticoids activate GR and to test the effect on
endogenous gene expression, the amount of mRNA encoding the liver-specific
glucocorticoid-inducible gene, TAT was quantified in liver-derived H4IIE cells after
16h of incubation with steroids. TAT mRNA expression was induced by 5otDHB and
5aTHB albeit to a lesser extent than by corticosterone (29% and 46% response of
corticosterone at maximum respectively) (Figure 4.6). Incubation of H4IIE cells with
the GR antagonist RU486 had no effect alone and prevented TAT induction by
5aTHB (Figure 4.7).
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4.3.6 Metabolic transformation of steroids
By GCMS, corticosterone was not detected in the medium from HeLa or H4IIE cells
to which 5aTHB had been added and in HeLa cells 5aTHB was not detected in the
medium to which corticosterone had been added. The level of detection for steroids
was < InM.
4.3.7 Inhibition of angiogenesis ex vivo
Both corticosterone and 5aTHB inhibited angiogenesis (Figure 4.8 and 4.9). The
glucocorticoid receptor antagonist RU486 did not significantly affect angiogenesis
on its own, but eliminated the angiostatic effects of both corticosterone and 5aTHB
(Figure 4.8)
4.3.8 Suppression of plasma ACTH in vivo
Basal plasma ACTH levels were not different between groups and were high,
consistent with prior adrenalectomy (Figure 4.10 (a)). Within one hour following
administration of steroid, plasma ACTH levels had been significantly suppressed in
B-treated animals compared to a small spontaneous reduction in vehicle treated
animals. 5a-THB also suppressed ACTH levels although this was of similar
magnitude as suppression by corticosterone, it was not apparent until 2 hours after
steroid treatment by which time, ACTH in vehicle treated animals had fallen from
baseline.
Plasma corticosterone levels were significantly increased in the corticosterone-
treated animals by 1 hour post-injection and remained elevated by 2 hours post-
injection. At 6 hours, plasma corticosterone levels in these animals had returned to
baseline. Plasma corticosterone levels in vehicle and 5aTHB-treated animals
remained low and constant throughout the experiment (Figure 4.10 (b)).
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4.3.9 Effect of 5aTHB on hepatic TAT and PEPCK in vivo
Injection of corticosterone or 5aTHB did not alter hepatic PEPCK (corticosterone;
p=0.77, 5aTHB; p=0.6) (Figure 4.11) and TAT (corticosterone; p=0.35, 5ocTHB;



































Figure 4.1: Glucocorticoid receptor binding in isolated hepatocytes from male
lean Zucker rats
Figures depict displacement of tritiated dexamethasone in isolated hepatocytes by
increasing concentrations of competitor steroids. Curves were fitted by Graphpad
Prism. Data are mean ± SEM, n=6.
(a) Displacement of tritiated dexamethasone in isolated hepatocytes by increasing
concentrations of dexamethasone, corticosterone, 5aDHB and 5aTHB.
(b) Displacement of tritiated Dexamethasone in isolated hepatocytes by increasing
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Figure 4.2: Glucocorticoid binding in isolated hepatocytes, cytosol and
microsomes from liver of male lean Zucker rats
Figure shows binding affinities of glucocorticoids in isolated hepatocytes,
cytosol and microsomes from liver of lean Zucker rats. Data are mean ±SEM,
n=6, *p < 0.02 vs B, #p < 0.005 vs B
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Steroid Hepatocytes Cytosol Microsomes
Kd (nM) p vs B Kd (nM) p vs B Kd (nM) p vs B
Dex 37±8 0.002 5.48±0.64 0.18 205111.8 0.22
B 153±79 - 1611109 - 246129.4 -
5cxTHB 268±78 0.33 858014230 0.0005 154142.9 0.107
5txDHB 336±42 0.02 133177.5 0.84 153116.4 0.019
50THB 4484±1313 0.001 562812019 0.015 827514060 0.004
5f3DHB 9656±3230 0.001 3841174 0.29 574011900 0.016
Table 4.1: Binding affinities of glucocorticoids in isolated rat hepatocytes,
cytosol and microsomes.
Data are mean 1 SEM, n=6. p vs B indicates whether the Kd for the steroid is
significantly different from that of the parent hormone corticosterone.
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Figure 4.3: Effects of corticosterone metabolites in HeLa cells
transfected with human GR and a luciferase reporter linked to the
MMTV-LTR.
Effects of individual steroids, showing fold-increases in luciferase activity
compared with basal luciferase activity (vehicle). Steroids were incubated at
l|iM of B, 5ocTHB, 5a-DHB, 5(3DHB or 5PTHB. Data shown in open bars
represents responses observed in the absence of transfected GR. Data are
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Figure 4.4: Effects of corticosterone metabolites in HeLa cells transfected
with human GR and a luciferase reporter linked to the MMTV-LTR.
Figure shows dose response curve for B and 5aTHB. Corticosterone (B) and 5a-
tetrahydrocorticosterone (5aTHB) were incubated alone at the final























Fold increase in luciferase
Figure 4.5: Effects of corticosterone metabolites in HeLa cells transfected
with human GR and a luciferase reporter linked to the MMTV-LTR.
Additive effect of corticosterone (B) and 5aTHB showing fold-increases in
luciferase activity compared with basal luciferase activity (vehicle). All cells were
transfected with both the MMTV-luciferase and the GR constructs. B and 5a-
THB were incubated alone or in combination at the concentrations shown. For
combined steroids, striped bars indicate the predicted luciferase induction,
calculated by adding the responses for each steroid when incubate alone. Filled
bars indicate the observed actual luciferase induction. There was no difference
between predicted and observed induction, consistent with full rather than partial
agonist activity of each steroid. *p<0.05 vs no added steroid. Data are mean ±
SEM, n=6.
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Vehicle Dex B 5ccDHB 5aTHB
Vehicle Dex B 5aDHB 5aTHB
Figure 4.6: Induction of tyrosine aminotransferase (TAT) mRNA by
corticosterone metabolites in H4IIE liver-derived cell line
Figure shows TAT mRNA expression was measured by Northern blot in H4IIE
cells after 16h incubation with lpM steroid: corticosterone (B), 5aTHB or 5a-
DHB. Values are corrected for loading with Ul. A representative blot from one
experiment is shown. Data are mean ±SEM, n=6 *p<0.05 vs vehicle.
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Vehicle RU486 B B & RU486 5ccTHB 5aTHB&
vehicle RU486 B B & 5aTHB 5aTHB
RU486 &
RU486
Figure 4.7: Induction of tyrosine aminotransferase (TAT) mRNA by
corticosterone metabolites in H4IIE liver-derived cell line
Figure shows the effect of the glucocorticoid receptor antagonist RU486 on TAT
mRNA induction by B and 5aTHB. A representative blot from one experiment is
shown. Data are mean ± SEM, n=6. *p<0.05 vs vehicle, #p<0.01 vs steroid alone.
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Vehicle B B +
RU486
Vehicle 5ocTHB 5aTHB+ RU486
RU486
Figure 4.8: Inhibition of angiogenesis by corticosterone and 5aTHB
Vessels were counted after 7 days of incubation with steroids at the concentrations
indicated. Data are mean ± SEM, n=6 for the number of vessels indicated in each






Figure 4.9 Inhibition of angiogenesis by 5aTHB
Figure shows aortic ring (original magnification x 50) after 7 days
in culture (a) without 5aTHB and (b) with 5aTHB (l|j.M). Note






Figure 4.10: Suppression of plasma ACTH by B and 5ocTHB in vivo
Panel (a). Plasma ACTH was measured in lean male Zucker rats treated with
vehicle or 5mg/kg B or 5aTHB by i.p injection. Data are mean ± SEM,
*p<0.001 vs vehicle, n=6 in each group.
Panel (b). plasma corticosterone (B) was measured in lean male Zucker rats
treated with vehicle or 5mg/kg corticosterone or 5aTHB by i.p injection. Data





Figure 4.11: Absence of induction of phosphoenolpyruvate
carboxykinase (PEPCK) mRNA by corticosterone and 5aTHB in rat
liver
Figure shows PEPCK mRNA expression measured by Northern blot in lean
male Zucker rats treated with vehicle or 5mg/kg B or 5aTHB by i.p
injection. Values are corrected for loading with U1 Data are mean ±SEM,




Figure 4.12: Absence of induction of tyrosine aminotransferase (TAT)
mRNA by corticosterone and 5aTHB in rat liver
Figure shows TAT mRNA expression measured by Northern blot in lean
male Zucker rats treated with vehicle or 5mg/kg B or 5aTHB by i.p injection.




Our studies demonstrate that 5a-reduced glucocorticoids are able to compete with
dexamethasone for its binding sites in hepatocytes with affinity similar to that of
corticosterone. In two cell models we have shown that this binding is associated with
the induction of transcription mediated by GR activation. Further 5aTHB acts as a
glucocorticoid ex vivo and in vivo, as judged by its ability to inhibit angiogenesis and
to suppress the hypothalamic-pituitary adrenal axis. This study is the first to report
the agonist properties of 5aTHB at GR although previous studies have been carried
out to investigate the 5a-dihydro products of Cortisol (Baxter & Tomkins 1971;
Carlstedt-Duke et al. 1977).
Our initial receptor binding studies in isolated hepatocytes demonstrated that 5a-
reduced glucocorticoids bind to the dexamethasone binding sites with a Kd of similar
magnitude to that of corticosterone. The affinity of 5aTHB was greater than that of
the 5a-dihydrometabolite and in contrast 5p-reduced metabolites show limited
binding. The ability of 5a- but not 5P- reduced metabolites to bind to GR is due
probably to differences in stereochemistry around the A/B ring junction. Previous
studies of dexamethasone binding in cytosol, nuclear envelopes and plasma
membranes have shown similarly that binding is sensitive to the configuration at the
C5 position (Roszak et al. 1990). The A/B ring junction of the 5P stereoisomers is
"cis" and therefore skewed relative to the plane through rings B, C and D, whereas
the 5a orientation is "trans" and hence has a structure akin to corticosterone. Similar
stereospecificity in favour of 5a- rather than 5p- metabolites has been observed for
binding to the androgen receptor (Lefebvre & Morante 1982).
Glucocorticoids can bind to a site other than the cytosolic GR in hepatocytes. Low
affinity glucocorticoid binding sites ("LAGS") have been demonstrated in the
microsomal fraction (Ambellan et al. 1981) and nuclear envelope (Roszak et al.
1990). Melville et al have shown that LAGS have a preference for 5a-rather than 5p-
reduced steroids (Melville et al. 1998) however, the nature and function of LAGS is
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uncertain. Therefore the following experiments were designed to separate the
classical cytosolic GR and microsomal LAGS.
Firstly we investigated steroid binding in the cytosolic fraction. The presence of the
classical GR was confirmed by a decreased Kd for dexamethasone in this fraction
compared to the Kd obtained for dexamethasone in the isolated hepatocytes.
However, compared to the isolated hepatocytes 5aTHB did not bind whereas both
5ccDHB and 5(3DHB displaced dexamethasone with similar Kd values as
corticosterone. This implies that in the cytosol, the binding site is not sensitive to the
configuration at the C5 position and that the 3a-position is more important in
determining binding affinity.
Secondly we investigated steroid binding in the microsomal fraction. The expected
binding pattern was observed with dexamethasone with higher Kd values observed in
the microsomes compared to cytosol. The affinities of LAGS for dexamethasone and
corticosterone were in accordance with previous publications (Melville et al. 1998)
confirming that our system was working. We observed the same stereo-specificity in
microsomes as in the hepatocytes with both of the 5a-reduced metabolites displacing
dexamethasone with the same affinity as corticosterone. However, in this fraction
5aTHB binding was greater than 5ccDHB.
Therefore we have shown that 5aDHB binds to the cytosolic GR whereas 5aTHB
binds with the same affinity as corticosterone in the microsomal fraction but not in
the cytosol. This suggested that 5aTHB was actually binding to microsomal LAGS
and not the classical cytosolic GR. It was therefore surprising that in further
experiments 5aTHB was more potent than 5aDHB in activating cytosolic GR.
In a transient transfection system, luciferase expression was placed under control of
the mouse-mammary tumour virus long terminal repeat (MMTV-LTR) promoter
linked to a glucocorticoid response element (GRE). In order to induce translation of
luciferase, ligand-activated GR must dimerise and associate with the GRE. The
results obtained indicate that the 5a-reduced metabolites were able to induce
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hGRrsha-mediated luciferase activity and that this response was dependent
completely on the presence of GR. However 5aDHB did not stimulate luciferase
activity to the same extent as 5aTHB.
In a second model, H4IIE cells, activation of endogenous GR was measured by
induction of endogenous TAT mRNA expression. Expression of TAT mRNA is
controlled by numerous factors, including an upstream positive GRE (Grange et al.
2001). Transcriptional up-regulation of TAT was observed in the presence of 5aTHB
and this was prevented by the addition of the GR antagonist, RU486. 5ccDHB did not
induce TAT mRNA expression significantly above basal levels.
Taken together with the results from the binding experiments, these data suggest that
5aTHB binding to microsomal LAGS can activate cytosolic GR. This binding can
mediate transcription of target genes in the same way as steroid binding to the
cytosolic GR, although to date, LAGS has only been associated with non-genomic
effects of steroid hormones (Falkenstein et al. 2000). To further examine if steroid
binding to microsomal LAGS can activate cytosolic GR, it would be advantageous to
carry out a time-course experiment with our transfection system as it would be
predicted that this pathway would take longer than the traditional mechanism of
nuclear translocation. In addition it would be interesting to carry out the hepatocyte
binding experiments with female rats as they do not have LAGS (Omrani et al. 1983)
and therefore it would be predicted that 5aTHB would not bind in these cells.
A determinant for the reduced receptor-binding activity of 5aTHB for the
glucocorticoid receptor in cytosol could be the redox status of the cytosol
preparation. In the absence of added reducing agents, glucocorticoid receptors are
maintained in their reduced, steroid binding form by an NADPH-dependent and
thioredoxin-dependent thiol-disulphide exchange system (Grippo et al. 1983). All
cytosol solutions contain some free thiol (-SH) groups, a condition that favours the
formation of an intramolecular disulphide bond between a vicinally spaced pair of
cysteine -SH groups which blocks the steroid binding domain of the receptor (Miller
et al, 1988). The ability of thiol modifications to block steroid binding depends on
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the structure of the steroid but is independent of the biological activity of the steroid
(Zakula & Moudgil 1991). However addition of the reducing agent, DTT and
molybdate, which stabilises the complex between hsp90 and the 16-kDa fragment of
the hormone binding domain containing the thiols (Simons et al. 1989) to the buffer
used should have prevented disulphide bonds forming.
Another reason for the reduced binding of 5aTHB in the cytosol could be that 3a-
hydroxysteroid dehydrogenase which converts 5odDHB into 5aTHB is freely
reversible and its direction is driven by prevailing steroid and co-factor
concentrations. At physiological pH, the oxidation reaction is favoured by 3-fold
(Penning et al. 1997) and it has been reported that 3a-hydroxysteroid dehydrogenase
acts in the reverse direction when the cell is disrupted. (Hardy et al. 2000). In our
binding experiments the experimental conditions favour the reverse reaction as the
pH is 7.2, 5aTHB is added in excess and the cell is disrupted. Therefore in
experiments where the cells were incubated with 5aTHB, 5aTHB may have been
converted back into 5aDHB and the apparent low binding capacity observed here in
cytosol with 5aTHB could actually reflect 5aDHB binding.
In our transfection system, the dose-response curves for corticosterone and 5aTHB
were different with an apparent shift to the right for 5aTHB indicating that 5aTHB
is a weaker agonist. At a concentration of lpM, corticosterone and 5aTHB produced
the same induction in luciferase activity and the effects of 5aTHB were additive with
those of corticosterone, suggesting that 5aTHB is a full agonist. A full agonist can
produce maximal effects and has high efficacy, which is the ability once bound to
initiate changes which lead to effects. It was not possible to compare maximal
activation of 5aTHB to that of corticosterone in this system since cell death was
observed at the higher concentrations of glucocorticoids that would have been
necessary (>2pM). However a concentration of lpM is 20-100 times higher than
reported Kd values and therefore all glucocorticoids should saturate GR and produce
a maximal effect (Chen et al. 1994).
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In this study, compared to corticosterone, the magnitude of the response observed
with 5aTHB in H4IIE cells was smaller than that observed in the transfected HeLa
cells. In studying different glucocorticoids, Jaffuel et al, 2001 showed that trans -
activation of a luciferase reporter gene in HeLa cells correlated well with trans-
activation of tyrosine aminotransferase in rat hepatoma (HTC) cells. However, trans-
activation potencies and relative binding affinities were not always interrelated
(Jaffuel et al. 2001). It is not uncommon for a given steroid to afford different dose-
response curves in different cells, possibly due to unequal amounts of metabolism,
serum binding proteins and non-specific binding to cells. The ratio of co-activator to
co-repressor is now known to be a defining ingredient for the dose-response curve
for agonist steroids (Szapary et al. 1999). Variations in the levels of co-activators and
co-repressors in different cells have been reported, providing an attractive
mechanism for explaining the cellular variations in response to B and 5aTHB (Misiti
et al. 1998).
The binding experiments carried out in this study were performed at 4°C whereas the
gene expression studies were carried out at 37°C, temperature at which cellular
metabolisms must be taken into account. Thus, the observation that 5aTHB does not
induce tyrosine aminotransferase mRNA to the same extent as corticosterone could
be explained by selective inactivation of 5aTHB in H4IIE cells compared to HeLa
cells. We have shown by RT-PCR that H4IIE cells contain 5a - and 5(3-reductase as
well as 3a-HSD and are therefore probably more metabolically active than HeLa
cells as would be expected from a hepatic cell line. We have shown by GCMS that
metabolic transformation of steroids did not occur in HeLa cells but metabolism of
corticosterone to 5aTHB was observed in H4IIE cells. However the reverse reaction
was not observed and therefore the efficacy of 5aTHB was not due to production of
corticosterone.
Glucocorticoids inhibit angiogenesis in chronic inflammatory conditions for example
rheumatoid arthritis (Colville-Nash & Scott 1992) and in models of rat aortic rings,
administration of supraphysiological concentrations of Cortisol inhibit new vessel
formation (Jaggers et al. 1996). Studies in our laboratory have previously shown that
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physiologically relevant concentrations of corticosterone can act via glucocorticoid
receptors to inhibit angiogenesis (Small et al. 2003). Here we show that 5aTHB can
also inhibit angiogenesis to the same extent as corticosterone and that this angiostatic
effect of 5aTHB is mediated via GR as it is blocked by the GR antagonist RU486.
Finally, we showed that 5aTHB adminstration in vivo induced a classical negative
feedback effect on the hypothalamic-pituitary-adrenal axis. It appears that in
suppressing ACTH, 5aTHB has a slower onset of effect than corticosterone. This
could relate in part to different CNS availabilty of 5aTHB compared to
corticosterone. Although 5aTHB is minimally protein-bound in plasma (Murphy et
al. 1963), its access across the blood brain barrier, and susceptibility to export from
the CNS by multidrug resistance P-glycopreoteins is unknown.
Dubrovsky et al showed that 5a -DHB can easily penetrate the blood-brain barrier as
a higher percentage of neurons responded to i.v. injection of 5aDHB compared to
i.v. injection of corticosterone (Dubrovsky et al. 1985). Access of corticosterone to
mouse and human brain is not hampered by MDRl-type P-gp (Karssen et al. 2001)
because corticosterone lacks a 17-hydroxyl group which in addition to an 11-
hydroxyl group has been shown to determine the ability of steroids to be transported
by MDRl-type P-gp (Bourgeois et al. 1993). 5aTHB also lacks a 17-hydroxyl group
and therefore is probably minimally, if at all, transported. Stereoisomerism around
carbon 5 of the steroid ring structure is also important for steroids to be recognised
by MDRl-type P-gp. An investigation to determine the effect of progesterone and its
metabolites on MDRl-type P-gp showed that metabolites in the 5(3-pathway but none
in the 5a-pathway could enhance activity of MDRl-type P-gp in adrenal glands
(Ichikawa-Haraguchi et al. 1993)It is therefore unlikely that 5aTHB is a substrate for
MDRl-type P-gp and will not be pumped out of the brain.
Another explanation for the different time courses is that corticosterone acts through
both mineralocorticoid (MR) and glucocorticoid receptors. The MR contributes more
to early "shut-off' after stress and may account for the rapid effect of corticosterone
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(Ratka et al. 1989). Corticosterone binds to MR with a higher affinity than GR in the
brain (De Kloet et al. 1975). It is not known if 5aTHB can bind to MR, however
5aDHB has been shown not to possess any mineralocorticoid activity (Sekihara et
al. 1978).
A surprising observation is that by 6h post-injection, 5aTHB further suppressed
ACTH secretion whereas suppression by corticosterone had ceased. It appears that
corticosterone is being cleared more rapidly than 5aTHB by hepatic metabolism
although it would be expected that 5aTHB would be cleared more quickly as it is a
stage further in the metabolic pathway. Corticosterone may also be metabolised by
5a-reductase and 3a-HSD in the brain (Melcangi et al. 1993). It may also be that
5aTHB dissociates from its receptor slower then corticosterone.
If endogenously present at high enough concentrations, 5a-reduced glucocorticoids
will contribute to GR activation in sites where 5a-reductases are expressed. Many
hepatic enzymes involved in carbohydrate and fat metabolism are controlled by
glucocorticoids e.g TAT and PEPCK. 5a- Reduction of corticosterone in liver will
increase local concentrations of active glucocorticoids, potentiating glucocorticoid
action regardless of circulating corticosterone levels. In our in vivo experiment
administration of corticosterone or 5aTHB had no effect on the expression of TAT
or PEPCK. TAT gene expression is under composite hormonal control, being
activated by glucocorticoids and glucagon (via cAMP) (Hashimoto et al. 1984) and
repressed by insulin (Moore & Koontz 1989; Ganss et al. 1994). Other groups
carrying out similar studies in Sprague-Dawley rats have found differences in TAT
mRNA expression after injection of glucocorticoid (prednisolone) within three hours
however the dose administered was 10 times higher than the dose used in our study.
The differences in our result may also reflect strain difference between Zucker rat
and Sprague-Dawley rats.
Whether activation of GR by 5a-reduced glucocorticoids are of significant clinical
importance in conditions in which alterations in 5a-reductase activity have been
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implicated such as obesity (Andrew et al, 1998) and polycystic ovary syndrome
(Stewart et al. 1990) remains to be determined (Fassnacht et al. 2003).
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Chapter Five
A-ring Reductases in Obesity
124
5.1 Introduction
Obesity is of increasing prevalence but is poorly understood. There is increasing
evidence of genetic causes of obesity bringing about metabolic changes which
influence weight gain and feeding behaviour however these only account for a small
proportion of cases.
Features of the Metabolic Syndrome (insulin resistance, centripetal obesity,
hypertriglyceridaemia and hypertension) are remarkably similar to those observed in
subjects with Cushing's Syndrome, where the primary defect is excess Cortisol
secretion as a consequence of a tumour (Cushing 1912; Walker & Edwards 1992).
This has led to the hypothesis that subtle abnormalities in glucocorticoid metabolism
and tissue sensitivity to glucocorticoids may contribute to the development of the
Metabolic Syndrome and obesity in the general population. In central obesity, total
glucocorticoid turnover and production are increased and circulating Cortisol levels
are often lower than normal (Marin et al. 1992; Haytanen & Adlercreutz 1993; Ljung
et al. 1996; Walker et al. 2000).
The mechanisms whereby glucocorticoid metabolism is altered in obesity are poorly
understood. One explanation is that peripheral clearance of glucocorticoids is
enhanced, driving activation of the Hypothalamic-Pituitary-Adrenal axis and
subsequent excess glucocorticoid production. It has previously been reported that
excretion of A-ring reduced glucocorticoid metabolites, in particular the 5a-reduced
metabolites, are increased in urine of obese men and women (Andrew et al. 1998;
Fraser et al. 1999; Rask et al. 2001; Rask et al. 2002) and also in obese Zucker rats
(Livingstone et al. 2000). These changes will only affect tissues where the metabolic
enzymes are expressed. Urinary steroid metabolite profiles do not identify which
tissue or isozyme is involved, however we predicted that the liver would be the major
site of metabolism given that this is where most metabolites are synthesised. The
results described in chapter three of this thesis confirm that 5a-reductase type 1 is the
only isozyme of 5a-reductase expressed in rat liver and fat therefore we
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hypothesised that it is this enzyme that is responsible for the increased clearance of
glucocorticoids in obesity.
Hepatic glucocorticoid receptor binding has also been reported to be altered in
obesity with glucocorticoid receptors from obese rats displaying lower binding
affinities for corticosterone than in lean rats (Nelson et al. 1998). This may be a
consequence of abnormal regulation of GR transcription (Jenson et al. 1996) or a
decrease in receptor integrity. In addition, we hypothesised that competition for GR
between corticosterone and 5a-reduced corticosterone may be responsible for the
reduced binding affinity of corticosterone in obesity.
To investigate the activity of 5a-reductase in obesity we used the obese Zucker rat.
Many studies have addressed the question of central and peripheral target tissue
sensitivity to glucocorticoids in genetically obese Zucker rats (Zucker and Zucker,
1961). The primary defect in the obese Zucker rat is a recessive mutation in the
leptin receptor (Chua et al. 1996). Leptin is a hormone that regulates food intake and
energy balance (Zhang et al. 1994). The obesity in these animals has been shown to
be glucocorticoid dependent, as adrenalectomy or treatment with glucocorticoid
receptor antagonists have been shown to normalise weight gain and associated
metabolic abnormalities (Yukimura et al. 1978; Castonguay et al. 1986; Freedman et
al. 1986; Langley & York 1990). Conflicting results have been reported on the
sensitivity of the hypothalamic-pituitary-adrenal axis in obese Zucker rats with data
supporting normal (Guillaume-Gentil et al. 1990), increased (Bestetti et al. 1990;
Plotsky et al. 1992)or decreased (Castonguay et al. 1986; Plotsky et al. 1992)
sensitivity to the inhibitory effects of corticosterone. Similarly there are reports of
increased (Bestetti et al. 1990; Plotsky et al. 1992) and decreased (Nakaishi et al.
1990; Routh et al. 1990; Plotsky et al. 1992) responses to stress in these animals.
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The aims of this chapter were to :
1) determine the expression and activity of A-ring reductases in obesity
2) examine glucocorticoid-receptor binding of A-ring reduced metabolites in lean
and obese Zucker rats.
3) determine if the presence of A-ring reduced metabolites may account for the
changes in GR binding of corticosterone previously reported in obesity.
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5.2 Methods
5.2.1 A-ring reductase Expression Studies
5.2.1.1 RT-PCR
Expression of 5a-reductase type 1 and the reported elongated isoform 5a-reductase
type lb was investigated in liver from male lean and obese Zucker rats (n=8 per
group) by RT-PCR as described in chapter 2.7.
5.2.1.2 Real Time PCR
Expression of 5a-reductase type 1 was investigated in subcutaneous and omental fat
from lean and obese Zucker rats (n=6 per group) by Real Time PCR as described in
chapter 2.8.
5.2.1.3 Northern Blots
5a- and 5(3 -reductase and 3a-HSD mRNA expression was quantified in liver from
male lean and obese Zucker rats (n=6-8 per group) by Northern blot as described in
chapter 2.9.
5.2.1.4 Western Blots1
5a-reductase type 1 protein levels were determined in liver from male lean and obese
Zucker rats (n=6 per group) by Western Blot. Briefly, Liver microsomes were
prepared by repeated centrifugation in 50mM Tris; 5 mM EDTA; 20mM Sodium
TM
Molybdate; 0.25 sucrose with Complete Protease Inhibitor (Roche Diagnostics,
East Sussex, UK). Proteins (30qg) were separated by SDS-polyacrylamide gel
electrophoresis and transferred electrophoretically to ECL nitrocellulose membrane
(Amersham Biosciences, Bucks, UK). Non-specific binding was blocked with 5%
blotting grade non-fat dried milk (Bio-Rad Laboratories, Herts, UK) in 20mM Tris;
137mM NaCl; 0.1% Tween 20 and the membrane hybridised with 5a-reductase type
1 5a-reductase type 1 Western blot was carried out by Dr Dawn Livingstone, Endocrinology Unit,
University of Edinburgh
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1 antibody (Eicheler et al. 1995). Specific binding was visualised using the
Amersham ECL system and quantified by optical densitometry. eQuivalent loading
of protein was confirmed by Ponceau Red staining of the membrane.
5.2.1.5 In Situ Hybridisation
Localisation of 5a-reductase type 1 mRNA expression was investigated in liver from
male lean and obese Zucker rats (n=3) using in situ hybridisation as described in
chapter 2.11.
5.2.2 5|3-Reductase Activity Studies
5(3 -Reductase activity was investigated in liver from male lean and obese Zucker
rats (n = 8 per group). HPLC analysis determined the percentage conversion of [3H]4-
corticosterone to [3H]4-3a,5(3-tetrahydrocorticosterone in cytosol at known protein
concentrations as detailed in chapter 2.5. All animals were aged 9 weeks.
5.2.3 Glucocorticoid Binding Experiments
For glucocorticoid binding experiments, hepatocytes were prepared from six-eight-
week old male lean and obese Zucker rats (n=6 per group) as described in chapter
2.12.1.3. Competition binding experiments were performed as described in chapter
2.12.2
5.2.4 Statistics
All data are expressed as mean ± standard error and data were analysed statistcally
by one-way ANOVA followed by LSD post-hoc tests except the 5(3-reductase




5.3.1 A-ring reductase expression
5cc-Reductase type la but not the reported elongated version of 5a-reductase type 1
was identified by RT-PCR in livers of lean or obese Zucker rats (Figure 5.1). In liver
of obese versus lean animals, 5a-reductase type 1 mRNA and protein was increased
(Northern blot, 0.58 ± 0.12 vs 0.24 ± 0.03 AU, p<0.01, Figure 5.2 (a); Western blot,
0.70 ± 0.05 vs 0.4 ± 0.07 relative optical density, p<0.005, Figure 5.2 (b)). A typical
Western blot run is shown in Figure 5.3.
Qualitatively, the distribution pattern of hepatic expression of 5a-reductase type 1
was not different between lean and obese Zucker rats (Figure 5.4).
In subcutaneous adipose tissue of Zucker rats there was no significant difference in
mRNA expression of 5a-reductase type 1 between lean and obese rats (p=0.71)
(Figure 5.5 (a)). In omental adipose tissue 5a-reductase type 1 mRNA levels were
significantly decreased in obese animals compared to lean (p<0.01) (Figure 5.5 (b)).
By contrast, hepatic 5(3-reductase mRNA expression was not different between lean
and obese animals (Figure 5.6(b)). 3oc-HSD mRNA expression was not different
between lean and obese animals (Figure 5.7).
5.3.2 A-ring reductase activity
5(3-reductase activity was increased in obese rats compared to lean (p<0.05) (Figure
5.6 (a)). Note that 5a-reductase activity could not be measured (see chapter 3.3.3)
5.3.3 Glucocorticoid receptor binding
Corticosterone (p=0.02) and 5a-DHB (p=0.06) were weaker competitors for
dexamethasone in hepatocytes from obese compared with lean rats whereas no
difference was observed with 5a-THB (Figure 5.8 and Table 5.1). Bmax for
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dexamethasone binding was higher in obese versus lean animals (223 ± 47 vs 87 ±
21 fmols/million cells, p=0.03).
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Figure 5.1: Expression of 5a-reductase type 1 and 5a-reductase type lb in
rat liver
lpg of total RNA isolated from lean and obese male Zucker rat liver (n=8 per
group) was used in RT-PCR with specific primers to detect expression of 5a-
reductase type lb. Negative controls included an RT reaction containing no
RNA (H20) and a reaction carried out in the absence of the RT enzyme for each
RNA (-RT) (n = 8 per group).
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Figure 5.2: Hepatic 5a-reductase type 1 mRNA and protein
expression
Figure shows a) 5a-reductase type 1 mRNA measured by Northern blot
in liver from lean and obese Zucker rats. Values are corrected for loading
with Ul, *p<0.005. b) 5a-Reductase type 1 protein levels measured by
Western Blot in liver from lean and obese Zucker rats, *p=0.008. Data





Figure 5.3: Western blot analysis of liver microsomes from lean
and obese Zucker rats.
Position of molecular weight markers are shown on the left hand side.
In lean and obese Zucker rat liver microsomes, a protein with an
apparent molecular weight of 26Kda is detected.
lean obese lean obese lean obese lean obese





Figure 5.3: 5a-Reductase mRNA Expression in Lean and Obese
Zucker Rat Liver
Anti-sense 35S-labeled ribo-probes (top pictures in each panel) specific
for rat 5a-reductase type were used to detect mRNA in 10pm thick
sections of liver from male lean and obese Zucker rats by in situ
hybridisation. Sense probes (bottom pictures in each panel) were used as
a control for non-specific hybridisation. Following in situ hybridisation,










Figure 5.5: 5a-Reductase type 1 mRNA expression in lean and
obese Zucker rat subcutaneous and omental adipose tissue
Figure shows relative fold change in 5a-Reductase type 1 mRNA
expression measured by Real Time PCR in (a) subcutaneous and (b)
omental adipose tissue from lean and obese Zucker rats. Data are mean































Figure 5.6: 5|3-reductase (a) activity and (b) mRNA expression
Figure shows 5P~reductase activity and mRNA expression in liver
from lean and obese Zucker rats. mRNA values are corrected for
loading with Ul. Data are mean ± SEM, *p<0.05, n=6 per group.
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Figure 5.7: 3a-HSD mRNA expression
Figure shows 3a-HSD mRNA expression measured by Northern blot
in liver from lean and obese Zucker rats. Values are corrected for
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Figure 5.8: Binding coefficients of glucocorticoids in isolated hepatocytes
Figure shows Kd values of glucocorticoids in isolated hepatocytes from lean
versus obese Zucker rats. Data are mean ± SEM. #p<0.06 lean vs obese, n=6
per group.
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Glucocorticoid Lean Obese p value
Dexamethasone 37±8 67116 0.02
B 153±79 6981263 0.005
5a-THB 268±78 312184 0.44
5a-DHB 336±42 11801377 0.06
5p-THB 4484±1313 507211436 0.26
5p-DHB 965613230 1133314101 0.33
Table 5.1 Binding coefficients (Kd, nM) of glucocorticoids in hepatocytes from
lean and obese Zucker rats.
Data are mean ± SEM, n=8-10 per group.
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5.4 Discussion
These data demonstrate that the previously observed increased urinary excretion of
A-ring reduced metabolites of corticosterone in obese Zucker rats is associated with
increased expression of hepatic but not adipose A-ring reductases. In particular, both
5a-reductase type 1 mRNA and protein levels were increased in liver of obese
animals. In addition hepatic 5(3-reductase activity was increased in obese rats
compared to lean although the mRNA was not. Increased hepatic A-ring reductase
expression and activity predicts and explains an increase in the metabolic clearance
of corticosterone, which may contribute to HPA activation and adrenocortical
hypertrophy in obesity. In this situation, the HPA axis may behave differently under
certain conditions, e.g to stress and diurnal variation, parameters that are altered in
obese animals and humans.
It is likely that this up-regulation of hepatic 5a-reductase type 1 explains the
increased excretion of 5a-reduced glucocorticoids in obese Zucker rats and that
similar mechanisms operate in human obesity. The contribution of the 5a-reductase
type 2 isozyme cannot be ruled out in obesity as it is expressed in human liver as
well as 5a-reductase type 1. In addition, the observed increases in metabolites of 5a-
and 5(3- reductase are probably not due to increased expression of hepatic 3aHSD as
the mRNA expression for this enzyme was not changed between lean and obese
Zucker rats. Adipose tissues also have the ability to metabolise glucocorticoids by
5a-reductase (Perel et al. 1986). While 5a-reductase type 1 could be detected in fat,
the expression levels were much greater in liver suggesting a more significant role
for this enzyme in hepatic tissue. We have shown by Real Time PCR that 5a-
reductase mRNA levels were unchanged in subcutaneous adipose tissue but
decreased in omental adipose tissue of obese Zucker rats indicating that regulation of
5a-reductase may be tissue specific as has been shown for 1 l(3-hydroxysteroid
dehydrogenase type 1 (Livingstone et al. 2000).
We investigated also the expression of the alternative, elongated isoform of 5a-
reductase type 1 in liver of lean and obese Zucker rats since it was reported to have
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higher affinity for glucocorticoids (Lopez-Solache et al. 1996). It was therefore
possible that this gene product may have been dysregulated in obesity. This isoform
could not be detected in lean or obese liver by RT-PCR and therefore cannot explain
the up-regulation of 5a-reduction in obesity. Since this clone has only been
expressed by one group it was not possible to include a positive control for the
expression of this transcript.
In addition to its role in the metabolic clearance of glucocorticoids, 5(3-reductase
plays a major role in cholesterol homeostasis by catalysing the catabolism of
cholesterol to bile acids. Thus, dysregulation of 5(3-reductase may contribute to
altered lipid and bile acid metabolism in obesity.
Metabolism of glucocorticoids by 5P~reductase was also increased in obese Zucker
rats as observed by bioactivity assay. This is consistent with increased excretion of
5P-reduced glucocorticoid metabolites in rodent (Livingstone et al. 2000) and human
(Stewart et al. 1999; Fraser et al. 1999; Rask et al. 2001; Rask et al. 2002) obesity.
The increase in 5P-reductase activity was not reflected in the levels of hepatic
mRNA expression. One explanation could be that a second isoform of 5P-reductase
may exist; however, such a gene has not been identified to date (Kondo et al. 1994).
Alternatively, the mRNA of 5P-reductase may be degraded more rapidly than its
protein. 5P-Reductase is a unique member of the aldo-keto reductase family in that it
has a very long 3' non-coding region containing AT-rich sequences and frequent
ATTTA motifs. It is well known that these motifs are present in mRNA species that
are degraded rapidly and diurnally regulated (Shaw & Kamen 1986).
The enhanced metabolism of glucocorticoids by hepatic 5a- reductase may also have
a more direct effect on glucocorticoid target tissues. The data presented in chapter 4
of this thesis has shown that 5a-reduced glucocorticoids can activate glucocorticoid
receptor mediated transcription of genes involved in gluconeogenesis, proteolysis
and lipolysis. This may explain why in obese Zucker rats, in the face of decreased
hepatic liP-hydroxysteroid dehydrogenase type 1 activity (Livingstone et al, 2000),
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an enzyme that regenerates corticosterone in the liver, symptoms of glucocorticoid
excess e.g impaired fasting glucose and lipid profile are still apparent.
In chapter 3, data was presented that 5oc-reductase type 1 was present in greater
abundance in the periportal zone of the liver. Therefore 5a-reduced steroids would be
expected to exert their greatest effects on processes mediated in this area of the liver.
This pattern of expression may allow 5a-reduced steroids to exert a greater effect on
GR as the hepatic distribution of GR has been reported to be also periportal (Nyirenda
et al. 1998).
There have been several reports in the literature suggesting that binding of
corticosterone to GR is impaired in the liver in obesity (Langley & York 1992;
Nelson et al. 1998). This again presents a paradox of impaired efficacy of
corticosterone in the face of evidence of increased glucocorticoid-receptor mediated
effects.
Interestingly, unlike dexamethasone, corticosterone and 5ccDHB the binding of
5aTHB was not impaired in obesity. Therefore up-regulation of 5a-reductase activity
will generate increased amounts of competing steroid which could contribute to the
higher Kd values observed with corticosterone in obesity.
5a-Reductase type 1 in the liver but not in fat is upregulated in obesity generating
increased quantities of active glucocorticoid. The liver is protected from the adverse
effects of glucocorticoids in obesity to some degree by decreased GR expression and
binding capacity and also by decreased ll(3-hydroxysteroid dehydrogenase type 1
activity. However the ability of 5aTHB to bind is not impaired in obesity, thus in the
face of decreased concentrations of local corticosterone, 5a-reduced glucocorticoids
may stimulate GR -mediated events. It is not clear what factors cause this up-
regulation of 5a-Reductase type 1 in obesity but after carrying out some very
preliminary studies it appears that 5a-Reductase type 1 may be regulated by
corticosterone via the glucocorticoid receptor. This is a similar finding to previous
work in mice that has shown that transcriptional control of 5a-reductase is regulated
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by dihydrotestosterone binding to the androgen receptor in the male brain and by
progesterone binding to the progesterone receptor in the female brain via a
progesterone and androgen regulatory element (m5a-R2 PRE/ARE) (Matsui et al.
2002). It is therefore possible that 5a-reductase type 1 may contain a glucocorticoid
response element (GRE) recognisable by the glucocorticoid receptor. Further studies






6.1 5a-reduced glucocorticoids and the glucocorticoid receptor
5a-reduction of glucocorticoids had been accepted as a pathway of irreversible
inactivation however data presented in this thesis show that 5a-reduced
glucocorticoids are GR agonists. When activation of glucocorticoid receptors by
these steroids was assessed 5aTHB was more potent than 5aDHB suggesting that
5aTHB can activate classical cytosolic GR and can mediate GR-dependent gene
transcription.
6.2 A-ring reductases in obesity
Preliminary evidence suggested that A-ring reduction of glucocorticoids was
increased in obesity however the tissues and isozymes involved were not known. In
obese versus lean Zucker rats, hepatic 5a-reductase type 1 mRNA expression and
protein levels were increased. They also had increased activity of hepatic 5(3-
reductase. By contrast, 3a-hydroxysteroid dehydrogenase mRNA expression was
unchanged in obesity. Conversely, 5a-reductase type 1 mRNA expression was
decreased in omental adipose tissue and unchanged in subcutaneous fat. These data
demonstrate that the previously observed increased urinary excretion of A-ring
reduced metabolites of corticosterone in obese Zucker rats is associated with
increased expression of hepatic but not adipose A-ring reductases.
Binding of corticosterone was impaired in obesity whereas 5aTHB binding was
unaltered suggesting that 5aTHB may modulate GR activation disproportionately in
obesity. The differences in glucocorticoid binding observed in obese Zucker rats may
reflect differences in distribution of LAGS between cytosol and microsomal
fractions. This again brings into question the importance of LAGS in GR induced
processes in the liver as to date it is not known to what extent microsomal binding
contributes to glucocorticoid tone in normal physiological conditions or in
pathophysiology.
146
6.3 Physiological relevance of alterations in 5a-reductase
The data from this thesis suggest that 5a-reductase could play an important role in
maintaining glucocorticoid "tone" in the face of low corticosterone levels. It is
apparent that ll(3-hydroxysteroid dehydrogenase type 1 and 5a-reductase type 1 may
be reciprocally regulated and it is therefore possible that under normal physiological
conditions they are maintained in a state of equilibrium with each other. In
pathophysiological conditions such as obesity, it appears that the balance is tipped in
favour of 5a-reductase at least in the liver. Corticosterone levels are decreased in the
liver of obese Zucker rats due to impaired lip-hydroxysteroid dehydrogenase type 1
activity, therefore an increase in 5a-reductase activity will act to preserve
glucocorticoid action in several ways (Figure 6.1).
Firstly, an increase in 5a-reductase activity would be predicted to enhance peripheral
glucocorticoid clearance rate, lower plasma glucocorticoid levels and induce
compensatory activation of the HPA axis resulting in subsequent corticosterone
production. Secondly, increased 5a-reductase activity will increase production of
5aTHB which activates transcription of glucocorticoid-regulated genes via binding
to GR. 5aTHB may therefore act to maintain glucocorticoid action when
corticosterone levels are low.
The regulatory factors that cause this imbalance in enzyme activities in obesity have
not yet been identified and further research is needed to elucidate the underlying
mechanisms of dysregulation.
6.4 Future Studies
The work presented in this thesis has provided a basis for future work aimed at
confirming the role of 5a-reductase in obesity.
The H4IIE hepatoma cell-line has proved a useful tool in this thesis for the study of
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glucocorticoid-mediated transcription of genes and also for study of the regulation
of 5a-reductase type 1. This cell-line could be used further to study the role and
regulation of 5oc-reductase by incubating the cells with finasteride or by
manipulating insulin/IGF-1 concentrations.
The characterisation of a functional green-fluorescent protein (GFP) - glucocorticoid
receptor (Hager et al. 2000) will also allow further study of 5aTHB binding to GR.
The unliganded GFP-GR is found completely in the cytoplasm whereas the hormone
activated receptor is located almost exclusively in the nucleus. Nuclear translocation
of this intrinsically fluorescent receptor is dramatic and easily monitored in real-time
in vitro therefore transfection of this receptor into cells with subsequent 5aTHB
treatment would reveal whether 5aTHB can bind to the traditional cytosolic
glucocorticoid receptor and cause nuclear translocation.
5a-Reductase activity is sexually dimorphic with activity levels in female rats 3-10
times greater than in male rats (Colby 1980). All of the experiments in this thesis
have been carried out in male rats therefore repetition of the experiments in female
rats or in gonadectomised male rats may reveal the role of the sex hormones in
regulation of 5a-reductase. Another reason for carrying out experiments in female
rats is that female rats do not contain microsomal LAGS (Omrani et al. 1983).
Therefore repetition of the competition binding experiments in female rats would
confirm whether 5aTHB is having its effect via binding to microsomal LAGS as





Adverse impact on carbohydrate and lipid metabolism
Obesity
Figure 6.1: Proposed mechanism for the role of 5a-reductase in obesity
5a-reductase and ll(3-hydroxysteroid dehydrogenase type 1 are regulated in
opposite directions in glucocorticoid target tissues so that when one is decreased
the other is increased. This will have important implications for activation of the
HPA-axis and subsequent corticosterone production and also on the activation
of GR-mediated transcription of genes.
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Pharmacological manipulation would also be advantageous. However, to date a
specific 5a-reductase type 1 inhibitor does not exist although a dual 5a-reductase
type 1 and type 2 inhibitor is being developed. The advent of a specific liver targeted
inhibitor would probably be of most use and may have therapeutic potential in the
treatment of obesity as inhibiting 5a-reductase will result in corticosterone being
metabolised by 5|3-reductase to the inactive 5(3-reduced metabolites.
The use of transgenic knock-out and over-expressor models will prove particularly
useful tools in identifying regulators of 5a-reductase. The 1 l(3-hydroxysteroid
dehydrogenase type 1 knockout mouse (Koteletsev et al. 1997) and the 5a-reductase
type 1 knock-out mouse (Mahendroo et al. 2001) will enable confirmation of the
reciprocal relationship between 11 (3-hydroxysteroid dehydrogenase type 1 and 5a-
reductase type 1. Similarly, transgenic mice over- expressing 11(3-HSD 1 in adipose
tissue have been created (Masuzaki et al. 2001) which could be used to determine if
5a-reductase type 1 is down-regulated when 1 l(3-hydroxysteroid dehydrogenase type
1 is up-regulated.
6.5 Summary
We conclude that hepatic A-ring reduction is enhanced in the obese Zucker rat
producing increased concentrations of 5aTHB which can bind and activate
glucocorticoid receptors. Transcription of glucocorticoid regulated genes in tissues
which express 5a-reductases will thus be influenced by intracellular levels of both
corticosterone and its 5a-reduced metabolites. Manipulation of this enzyme may
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